<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0095">
    <title>77 Susceptibility Test Methods: Fastidious Bacteria</title>
    <sect1 id="ch0095s0001">
      <title>77 Susceptibility Test Methods: Fastidious Bacteria</title>
      <anchor id="ch0095s000001a0001"/>
      <anchor id="ch0095s000000a0001"/>
      <para role="chapterAuthor"><phrase role="center">ROMNEY M. HUMPHRIES AND JENNIFER DIEN BARD</phrase>
      </para>
      <para id="ch0095s000000p0001">Most fastidious bacteria do not grow satisfactorily in standard<emphasis>in vitro</emphasis> susceptibility test systems that use unsupplemented media. For certain fastidious species that are more frequently encountered, such as <emphasis>Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitidis, Streptococcus pneumoniae</emphasis>, and other <emphasis>Streptococcus</emphasis> spp., the Clinical and Laboratory Standards Institute (CLSI) and Eureopean Committee on Antimicrobial Susceptibility Testing (EUCAST) recommend slight modifications to the most commonly used broth microdilution method, which is described in International Organization on Standardization (ISO) document 20776-1 (<link linkend="ch0095s000000li0001">1</link>–<link linkend="ch0095s000000li0003">3</link>). CLSI and EUCAST also recommend disk diffusion testing methods that vary from those used for most other bacteria (<link linkend="ch0095s000000li0002">2</link>, <link linkend="ch0095s000000li0004">4</link>) (<anchor id="ch0095s000000a0002"/><link linkend="ch0095s000000a0006">Table 1</link>). The modifications generally involve the use of a test medium with added nutrients and sometimes extended incubation times and/or incubation in an atmosphere with increased levels of CO<subscript>2</subscript> (<link linkend="ch0095s000000a0006">Table 1</link>). Specific zone diameter and MIC interpretive criteria (breakpoints) have been developed by CLSI and/or EUCAST for these bacteria, as have acceptable ranges for recommended quality control (QC) strains (<link linkend="ch0095s000000li0005">5</link>). The CLSI also publishes an approved guideline for testing infrequently isolated and less common fastidious bacteria, which are listed in <anchor id="ch0095s000000a0003"/><link linkend="ch0095s000000a0017">Tables 2</link> and <anchor id="ch0095s000000a0004"/><link linkend="ch0095s000000a0033">3</link>, including methods for testing potential agents of bioterrorism (<link linkend="ch0095s000000a0017">Table 2</link>) (<link linkend="ch0095s000000li0006">6</link>). Interpretive criteria for infrequently isolated and less common fastidious bacteria were primarily adapted from those for nonfastidious and more frequently encountered fastidious bacteria included in CLSI or EUCAST standards, taking into consideration information in the literature, microbiological data (i.e., MIC distributions), and the experiences of the committees. This contrasts with the extensive microbiological, clinical, and pharmacodynamic data normally used for development of interpretive criteria for nonfastidious and more frequently encountered fastidious organisms that appear in CLSI or EUCAST antimicrobial susceptibility testing standards. For this reason, the CLSI M45 document is classified as a guideline rather than a standard. A summary of the testing conditions for infrequently isolated and less common fastidious bacteria appears in <link linkend="ch0095s000000a0033">Table 3</link>.</para>
      <anchor id="ch0095s000000a0005"/>
      <beginpage pagenum="1492"/>
      <para id="ch0095s000000p0002">There are no specific recommendations for many fastidious bacteria, such as<emphasis>Bordetella pertussis</emphasis> and <emphasis>Legionella</emphasis> spp. This is because in part (i) infections caused by these bacteria usually respond to drugs of choice, (ii) isolates are infrequently recovered from patients infected with these organisms, and (iii) isolates are often difficult to grow and special media and test conditions are required.</para>
      <para id="ch0095s000000p0003">In addition to conventional MIC test methods (e.g., agar dilution or broth dilution methods), gradient diffusion methods have been used to test many types of infrequently isolated and less common fastidious bacteria. The gradient diffusion approach allows placement of strips on special media and the use of various incubation conditions. The limitations of this method include lack of gradient strips with regulatory clearance for testing many infrequently isolated and less commonly encountered fastidious bacteria. The United States Food and Drug Administration (FDA) does not recognize many of the CLSI M45-A3 breakpoints, leaving no pathway to achieve FDA clearance of tests for these organisms. FDA clearance status for a given organism-antimicrobial agent combination for gradient strips should be determined. If FDA clearance has not been granted, laboratories should perform a validation study to meet the requirements of the Clinical Laboratory Improvement Amendments (CLIA) to allow use of this test for organisms off-label, and the results should be qualified on the patient report. However, for organisms not included in M100 (<link linkend="ch0095s000000li0005">5</link>), M45 (<link linkend="ch0095s000000li0006">6</link>), or EUCAST clinical breakpoint tables (<link linkend="ch0095s000000li0002">2</link>), the use of gradient diffusion tests is complicated by the absence of a defined method for result comparison, and of clinical breakpoints to interpret results. Laboratories may consider exchanging isolates with a reputable laboratory to perform a validation study, and may refer to EUCAST guidance on how to interpret MIC results for organisms without breakpoints (<link linkend="ch0095s000000li0007">7</link>).</para>
      <para id="ch0095s000000p0004">This chapter summarizes the standard methods recommended by CLSI and EUCAST for antimicrobial susceptibility testing of<emphasis>Streptococcus</emphasis> spp. (including <emphasis>S. pneumoniae</emphasis>), <emphasis>H. influenzae, N. gonorrhoeae</emphasis>, and <emphasis>N. meningitidis.</emphasis> Methods for testing the infrequently isolated or fastidious bacteria included in CLSI guideline M45-A3 and/or EUCAST clinical breakpoint tables are summarized. Test methods and indications for testing and the reporting of results are provided. Where differences between CLSI and EUCAST guidance exist, these are outlined.</para>
      <table id="ch0095s000000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0095s000000a0006"/><link linkend="ch0095s000000a0002">TABLE 1</link></phrase></emphasis> CLSI and EUCAST disk diffusion and MIC testing conditions and recommended QC strains for more common fastidious bacteria
</title>
        
        <tgroup cols="6">
          <tbody>
            <row>
              <entry><phrase role="center">Organism(s)</phrase>
              </entry>
              <entry><phrase role="center">Method</phrase>
              </entry>
              <entry><phrase role="center">Medium<superscript><emphasis><anchor id="ch0095s000000a0007"/><link linkend="ch0095s000000a0011">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Incubation atmosphere<superscript><emphasis><anchor id="ch0095s000000a0008"/><link linkend="ch0095s000000a0012">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Incubation length (h)</phrase>
              </entry>
              <entry><phrase role="center">Recommended quality control strain(s)</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis><superscript><emphasis><anchor id="ch0095s000000a0009"/><link linkend="ch0095s000000a0013">c</link></emphasis></superscript> and <emphasis>Streptococcus</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Disk diffusion (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">MHA + 5% sheep blood</phrase>
              </entry>
              <entry><phrase role="left">5–7% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">18 ± 2 h</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Broth microdilution (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2 h</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>H. influenzae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Disk diffusion (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">HTM agar</phrase>
              </entry>
              <entry><phrase role="left">5–7% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">16–18</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>H. influenzae</emphasis> ATCC 49247, <emphasis>H. influenzae</emphasis> ATCC 49766<superscript><emphasis><anchor id="ch0095s000000a0010"/><link linkend="ch0095s000000a0014">d</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">18 ± 2 h</phrase>
              </entry>
              <entry><para id="ch0095s000000p0005"><phrase role="left"><emphasis>H. influenzae</emphasis> ATCC 49766</phrase>
                </para>
                <para id="ch0095s000000p0006"><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213 for β-lactam/β-lactam inhibitor combinations</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">HTM broth</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>H. influenzae</emphasis> ATCC 49247, <emphasis>H. influenzae</emphasis> ATCC 49766<superscript><emphasis><link linkend="ch0095s000000a0014">d</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Broth microdilution (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2 h</phrase>
              </entry>
              <entry><para id="ch0095s000000p0007"><phrase role="left"><emphasis>H. influenzae</emphasis> ATCC 49766</phrase>
                </para>
                <para id="ch0095s000000p0008"><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213 for β-lactam/β-lactamase inhibitor combinations</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>N. gonorrhoeae</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Disk diffusion (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">GC agar base + supplement</phrase>
              </entry>
              <entry><phrase role="left">5–7% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>N. gonorrhoeae</emphasis> ATCC 49226</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Agar dilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">GC agar base + supplement</phrase>
              </entry>
              <entry><phrase role="left">5–7% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>N. gonorrhoeae</emphasis> ATCC 49226</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>N. meningitidis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Disk diffusion (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">MHA + 5% sheep blood</phrase>
              </entry>
              <entry><phrase role="left">5–7% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">5–7% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Agar dilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">MHA + 5% sheep blood</phrase>
              </entry>
              <entry><phrase role="left">5–7% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0011"/><link linkend="ch0095s000000a0007">a</link></emphasis></superscript>CA-MHB-LHB, cation-adjusted Mueller-Hinton broth plus 2.5–5% lysed horse blood; HTM, <emphasis>Haemophilus</emphasis> test medium; MHA, Mueller-Hinton agar; MH-F, Mueller-Hinton fastidious.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0012"/><link linkend="ch0095s000000a0008">b</link></emphasis></superscript>Incubation temperature, 35°C.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0013"/><link linkend="ch0095s000000a0009">c</link></emphasis></superscript>Note that for <emphasis>S. pneumoniae</emphasis>, EUCAST recommends the inoculum be a 0.5 McFarland from a sheep blood agar plate or 1.0 McFarland from chocolate agar plate. CLSI recommends a 0.5 McFarland from an overnight sheep blood agar plate.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0014"/><link linkend="ch0095s000000a0010">d</link></emphasis></superscript>In addition, <emphasis>H. influenzae</emphasis> ATCC 10211 can be used to assess growth-supporting capabilities of HTM. <emphasis>H. influenzae</emphasis> ATCC 49766 is used for quality control of select cephalosporins (e.g., cefaclor, cefamandole, and cefuroxime).</para>
      <para id="ch0095s000000p0009">In the past, regional and global surveillance studies for antimicrobial resistance among respiratory pathogens including<emphasis>H. influenzae, S. pneumoniae</emphasis>, and <emphasis>Moraxella catarrhalis</emphasis> were conducted regularly. However, the numbers of these studies have declined, and it is somewhat difficult to obtain an accurate global picture of the incidence of resistance in these organisms. Similarly, for more infrequently encountered and fastidious bacteria, surveillance studies are rarely performed, and resistance rates are predominantly reported only in single institutional studies and case series and reports. Nonetheless, the incidence of resistance among contemporary isolates is also provided, as available in the current published literature for organisms described in this chapter.</para>
      <sect2 id="ch0095s0001s0001">
        <title>STREPTOCOCCUS PNEUMONIAE</title>
        <anchor id="ch0095s000001a0002"/>
        <anchor id="ch0095s000000a0015"/>
      </sect2>
    </sect1>
    <sect1 id="ch0095s0002">
      <title>Incidence of Resistance</title>
      <anchor id="ch0095s000002a0001"/>
      <anchor id="ch0095s000000a0016"/>
      <para id="ch0095s000000p0010">Penicillin resistance in pneumococci is caused by alterations to penicillin-binding proteins (PBPs), in particular PBPs 1a, 2b, and 2x, that result in reduced binding affinity for penicillins and other β-lactams (<link linkend="ch0095s000000li0008">8</link>). Altered PBPs are the result of recombination events with homologous genes from related <emphasis>Streptococcus</emphasis> spp. Since first reported in 1967, penicillin resistance in pneumococci has increased worldwide. This trend was interrupted for several years by the introduction of the protein-capsular polysaccharide conjugated 7-valent pneumococcal vaccine (PCV-7) in the United States and other countries that implemented PCV-7 as part of routine immunizations (<link linkend="ch0095s000000li0009">9</link>). Several years after the release of PCV-7, penicillin resistance among pneumococci returned to the pre-PCV-7 trajectory (<link linkend="ch0095s000000li0010">10</link>), as penicillin- and multidrug-resistant, non-vaccine serotypes (e.g., 6C, 15A, 19A, and 23A) emerged (<link linkend="ch0095s000000li0010">10</link>). During this time, the rate of pediatric invasive pneumococcal disease plateaued in the United States. In 2010, the 13-valent conjugate pneumococcal vaccine (PCV-13) was introduced, which included serotype 19A, the serotype that had become most commonly associated with penicillin resistance (<link linkend="ch0095s000000li0010">10</link>, <link linkend="ch0095s000000li0011">11</link>). Three years after implementation of this vaccine, a significant decrease in non-antimicrobial-susceptible invasive pneumococcal disease caused by serotypes included in PCV-13 was noted across all age groups (<link linkend="ch0095s000000li0009">9</link>). More recent data evaluating invasive pneumococci isolated from children ≤3 years of age in the PCV-13 era demonstrated increased incidence of penicillin resistance among non-vaccine serotypes, but a decrease in penicillin resistance overall (<link linkend="ch0095s000000li0012">12</link>).</para>
      <table id="ch0095s000000t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0095s000000a0017"/><link linkend="ch0095s000000a0003">TABLE 2</link></phrase></emphasis> Broth microdilution MIC testing conditions, recommended quality control strains, and drugs recommended for testing potential agents of bioterrorism
</title>
        
        <tgroup cols="7">
          <tbody>
            <row>
              <entry><phrase role="center">Organism(s)</phrase>
              </entry>
              <entry><phrase role="center">Medium<superscript><emphasis><anchor id="ch0095s000000a0018"/><link linkend="ch0095s000000a0025">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Inoculum source<superscript><emphasis><anchor id="ch0095s000000a0019"/><link linkend="ch0095s000000a0026">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Incubation atmosphere<superscript><emphasis><anchor id="ch0095s000000a0020"/><link linkend="ch0095s000000a0027">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Incubation length (h)</phrase>
              </entry>
              <entry><phrase role="center">Recommended quality control strain(s)</phrase>
              </entry>
              <entry><phrase role="center">Drugs recommended for testing</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. anthracis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">CA-MHB</phrase>
              </entry>
              <entry><phrase role="left">16–18-h growth (from sheep blood agar plate)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="center">16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922, <emphasis>S. aureus</emphasis> ATCC 29213</phrase>
              </entry>
              <entry><phrase role="left">Ciprofloxacin, doxycycline, levofloxacin, penicillin</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Brucella</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>Brucella</emphasis> broth, pH adjusted to 7.1 ± 0.1</phrase>
              </entry>
              <entry><phrase role="left">48-h growth (from sheep blood agar plate)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air<superscript><emphasis><anchor id="ch0095s000000a0021"/><link linkend="ch0095s000000a0028">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">48</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922, <emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">Doxycycline, gentamicin, tetracycline, TMP-SMX, streptomycin<superscript><emphasis><anchor id="ch0095s000000a0022"/><link linkend="ch0095s000000a0029">e</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>B. mallei, B. pseudomallei</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">CA-MHB</phrase>
              </entry>
              <entry><phrase role="left">16–18-h growth (from sheep blood agar plate)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="center">16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922, <emphasis>E. coli</emphasis> ATCC 35218<superscript><emphasis><anchor id="ch0095s000000a0023"/><link linkend="ch0095s000000a0030">f</link></emphasis></superscript>, <emphasis>P. aeruginosa</emphasis> ATCC 27853</phrase>
              </entry>
              <entry><phrase role="left">Amoxicillin-clavulanic acid and TMP-SMX (<emphasis>B. pseudomallei</emphasis> only), ceftazidime, doxycycline, imipenem, tetracycline</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>F. tularensis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">CA-MHB with 2% defined growth supplement, pH adjusted to 7.1 ± 0.1</phrase>
              </entry>
              <entry><phrase role="left">24-h growth (from chocolate agar plate)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="center">48</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922, <emphasis>S. aureus</emphasis> ATCC 29213, <emphasis>P. aeruginosa</emphasis> ATCC 27853</phrase>
              </entry>
              <entry><phrase role="left">Chloramphenicol, ciprofloxacin, doxycycline, gentamicin, levofloxacin, streptomycin, tetracycline</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>Y. pestis</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">CA-MHB</phrase>
              </entry>
              <entry><phrase role="left">24-h growth (from sheep blood agar plate)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="center">24<superscript><emphasis><anchor id="ch0095s000000a0024"/><link linkend="ch0095s000000a0031">g</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922</phrase>
              </entry>
              <entry><phrase role="left">Chloramphenicol, ciprofloxacin, doxycycline, gentamicin, levofloxacin, streptomycin, tetracycline, TMP-SMX</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0025"/><link linkend="ch0095s000000a0018">a</link></emphasis></superscript>CA-MHB, cation-adjusted Mueller-Hinton broth.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0026"/><link linkend="ch0095s000000a0019">b</link></emphasis></superscript>Inoculum suspension is in CA-MHB standardized to a 0.5 McFarland standard. Final organism concentration is 5 × 10<superscript>5</superscript> CFU/ml. CHOC, chocolate agar; SBA, sheep blood agar.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0027"/><link linkend="ch0095s000000a0020">c</link></emphasis></superscript>Incubation temperature, 35°C.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0028"/><link linkend="ch0095s000000a0021">d</link></emphasis></superscript>Some isolates may require incubation in 5% CO<subscript>2.</subscript></para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0029"/><link linkend="ch0095s000000a0022">e</link></emphasis></superscript>Different breakpoints when incubating in 5% CO<subscript>2</subscript> versus ambient air.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0030"/><link linkend="ch0095s000000a0023">f</link></emphasis></superscript><emphasis>E. coli</emphasis> ATCC 35218 is used for quality control when testing β-lactam/β-lactamase inhibitor combination drugs.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0031"/><link linkend="ch0095s000000a0024">g</link></emphasis></superscript>If unacceptable growth in the control well, reincubate for an additional 24 h.</para>
      <para id="ch0095s000000p0011">CLSI has defined three sets of penicillin breakpoints for pneumococci: one for meningitis, one for non-meningitis, and one applicable to therapy with oral penicillin G (<link linkend="ch0095s000000li0005">5</link>, <link linkend="ch0095s000000li0013">13</link>). The breakpoints for pneumococcal meningitis are susceptible ≤0.06 μg/ml and resistant ≥0.12 μg/ml, with no intermediate category. For non-meningitis, susceptible, intermediate, and resistant breakpoints are ≤2 μg/ml, 4 μg/ml, and ≥8 μg/ml, respectively. The susceptible, intermediate, and resistant breakpoints for oral penicillin are ≤0.06 μg/ml, 0.12 to 1 μg/ml, and ≥2 μg/ml, respectively (<link linkend="ch0095s000000li0005">5</link>). In contrast, EUCAST has established two sets of breakpoints for the pneumococci. The EUCAST meningitis breakpoints are the same as those of CLSI, but for infections other than meningitis, EUCAST defines susceptible as ≤0.06 μg/ml, and susceptible, increased exposure as 0.12 to 2 μg/ml. EUCAST further provides dosage-based guidance interpreting penicillin MICs for pneumococcal pneumonia: a penicillin MIC of ≤0.5 μg/ml is considered susceptible if a dose of 1.2 g of penicillin intravenously (i.v.) every 6 hours is used; an MIC of ≤1 μg/ml is considered susceptible if a dose of 2.4 g i.v. every 6 hours or 1.2 g i.v. every 4 hours is used; and ≤2 μg/ml is considered susceptible if a dose of 2.4 g i.v. every 4 hours is used (<link linkend="ch0095s000000li0002">2</link>). With this variety of penicillin breakpoints for the pneumococci, interpretation of surveillance susceptibility data is complex. The United States Centers for Disease Control and Prevention (CDC) reports annually on the susceptibility profiles for isolates of <emphasis>S. pneumoniae</emphasis> that cause invasive disease. In 2019, 96.2% of 3,195 isolates tested were reported as penicillin susceptible by CLSI non-meningitis breakpoints, and 80.3% were reported as penicillin susceptible by CLSI meningitis breakpoints (<link linkend="ch0095s000000li0014">14</link>). Penicillin resistance varies by geographical location. A recent summary of a global surveillance program documented penicillin susceptibility as 64.1% in North America, 71.6% in Europe, 55.2% in the Asia-Pacific region, and 70.2% in Latin America by meningitis breakpoints; rates were 99.6%, 95.5%, 89.6%, and 94.8%, respectively, by non-meningitis breakpoints (<link linkend="ch0095s000000li0015">15</link>).</para>
      <anchor id="ch0095s000000a0032"/>
      <beginpage pagenum="1493"/>
      <para id="ch0095s000000p0012">Penicillin-susceptible<emphasis>S. pneumoniae</emphasis> isolates are generally susceptible to other β-lactam agents; however, as penicillin MICs increase, MICs to other β-lactams also increase (<link linkend="ch0095s000000li0016">16</link>). As is the case for penicillin, differences exist between CLSI and EUCAST <emphasis>S. pneumoniae</emphasis> breakpoints for other β-lactams. CLSI has established meningitis breakpoints for cefepime, cefotaxime, and ceftriaxone, whereas EUCAST has published meningitis breakpoints for ampicillin, amoxicillin (i.v.), cefotaxime, ceftriaxone, and meropenem. CLSI and EUCAST ceftaroline breakpoints differ by a single dilution, with CLSI defining susceptible as ≤0.5 μg/ml (no intermediate or resistant category established) and EUCAST defining the susceptible category as ≤0.25 μg/ml and the resistant category as &gt;0.25 μg/ml. Like penicillin, current rates of resistance to the extended-spectrum cephalosporins vary by geographical location (<link linkend="ch0095s000000li0015">15</link>). In the United States, the CDC program documented 98% susceptibility to ceftriaxone among isolates recovered in 2019, by CLSI non-meningitis breakpoints (MIC, ≤1 μg/ml) (<link linkend="ch0095s000000li0014">14</link>). Ceftaroline displays the most potent activity among the β-lactams against <emphasis>S. pneumoniae</emphasis>, with recent data suggesting very rare occurrence of resistance globally, predominantly among isolates from South Korea (<link linkend="ch0095s000000li0015">15</link>). One ceftaroline-nonsusceptible isolate (of serotype 35B) was recently reported which harbored multiple mutations in PBP 2x and alterations in <emphasis>murM</emphasis> (<link linkend="ch0095s000000li0017">17</link>).</para>
      <table id="ch0095s000000t0003"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0095s000000a0033"/><link linkend="ch0095s000000a0004">TABLE 3</link></phrase></emphasis> Disk diffusion and MIC testing conditions, recommended quality control strains, and agents to consider for primary testing for infrequently isolated or less common fastidious bacteria
</title>
        
        <tgroup cols="8">
          <tbody>
            <row>
              <entry><phrase role="center">Organism(s)</phrase>
              </entry>
              <entry><phrase role="center">Method</phrase>
              </entry>
              <entry><phrase role="center">Medium<superscript><emphasis><anchor id="ch0095s000000a0034"/><link linkend="ch0095s000000a0039">a</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Inoculum source<superscript><emphasis><anchor id="ch0095s000000a0035"/><link linkend="ch0095s000000a0040">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Incubation atmosphere<superscript><emphasis><anchor id="ch0095s000000a0036"/><link linkend="ch0095s000000a0041">c</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Incubation length (h)</phrase>
              </entry>
              <entry><phrase role="center">Recommended quality control strain(s)</phrase>
              </entry>
              <entry><phrase role="center">Agents to consider for primary testing</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Abiotrophia</emphasis> spp., <emphasis>Granulicatella</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB<superscript><emphasis><link linkend="ch0095s000000a0041">c</link></emphasis></superscript> + 0.001% pyridoxal HCl</phrase>
              </entry>
              <entry><phrase role="left">20–24-h growth (from CHOC containing cysteine)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">Cefotaxime or ceftriaxone, penicillin, vancomycin</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Aerococcus</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">16–18-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">Penicillin, ceftriaxone, vancomycin</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F agar</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">18 ± 2, or 40–44 if poor growth after 16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><para id="ch0095s000000p0013"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0014"><phrase role="left">(according to ISO standard 20776-1)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2, or 40–44 if poor growth after 16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Aeromonas</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB</phrase>
              </entry>
              <entry><phrase role="left">16–18-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922, <emphasis>E. coli</emphasis> ATCC 35218<superscript><emphasis><anchor id="ch0095s000000a0037"/><link linkend="ch0095s000000a0042">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">3rd or 4th generation cephalosporins, fluoroquinolones, TMP-SMX</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">MHA</phrase>
              </entry>
              <entry><phrase role="left">16–18-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">16–18</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922, <emphasis>E. coli</emphasis> ATCC 35218</phrase>
              </entry>
              <entry><phrase role="left">3rd or 4th generation cephalosporins, fluoroquinolones, TMP-SMX</phrase>
              </entry>
            </row>
            <row>
              <entry><para id="ch0095s000000p0015"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0016"><phrase role="left">(according to ISO standard 20776-1)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>P. aeruginosa</emphasis> ATCC 27853</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F agar</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>P. aeruginosa</emphasis> ATCC 27853</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Bacillus</emphasis> spp. and related genera</phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB</phrase>
              </entry>
              <entry><phrase role="left">16–18-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213</phrase>
              </entry>
              <entry><phrase role="left">Clindamycin, fluoroquinolones, vancomycin</phrase>
              </entry>
            </row>
            <row>
              <entry><para id="ch0095s000000p0017"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0018"><phrase role="left">(according to ISO standard 20776-1)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F agar</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>C. jejuni, C. coli</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">24–48-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">10% CO<subscript>2</subscript>, 5% O<subscript>2</subscript>, 85% N<subscript>2</subscript> (microaerobic)</phrase>
              </entry>
              <entry><phrase role="left">48 at 36°C or 24 at 42°C</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>C. jejuni</emphasis> ATCC 33560</phrase>
              </entry>
              <entry><phrase role="left">Ciprofloxacin, erythromycin, tetracycline</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">MHA + 5% sheep blood</phrase>
              </entry>
              <entry><phrase role="left">24–48-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">10% CO<subscript>2</subscript>, 5% O<subscript>2</subscript>, 85% N<subscript>2</subscript> (microaerobic)</phrase>
              </entry>
              <entry><phrase role="left">24 at 42°C</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 25923</phrase>
              </entry>
              <entry><phrase role="left">Ciprofloxacin, erythromycin, tetracycline</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F agar</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Microaerobic environment, 41 ± 1°C</phrase>
              </entry>
              <entry><phrase role="left">24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>C. jejuni</emphasis> ATCC 33560</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Corynebacterium</emphasis> spp<emphasis>.,</emphasis> coryneforms</phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">24–48-h growth (from SBA or CHOC)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">24–48</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619, <emphasis>E. coli</emphasis> ATCC 25922 for gentamicin</phrase>
              </entry>
              <entry><phrase role="left">Erythromycin, gentamicin, penicillin, vancomycin</phrase>
              </entry>
            </row>
            <row>
              <entry><para id="ch0095s000000p0019"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0020"><phrase role="left">(according to ISO standard 20776-1)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2, or 40–44 if poor growth after 16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F agar</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">18 ± 2, or 40–44 if poor growth after 16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>E. rhusiopathiae</emphasis>
                </phrase>
              </entry>
              <entry><para id="ch0095s000000p0021"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0022"><phrase role="left">(CLSI)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">Penicillin or ampicillin</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Gemella</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">24–48</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">Cefotaxime or ceftriaxone, penicillin, vancomycin</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">HACEK group</phrase>
              </entry>
              <entry><para id="ch0095s000000p0023"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0024"><phrase role="left">(CLSI)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB or HTM or Brucella broth with vitamin K (1 μg/ml), hemin (5 μg/ml), and 5% LHB</phrase>
              </entry>
              <entry><phrase role="left">24–48-h growth (from CHOC)</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">24–48</phrase>
              </entry>
              <entry><para id="ch0095s000000p0025"><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
                </para>
                <para id="ch0095s000000p0026"><phrase role="left"><emphasis>E. coli</emphasis> ATCC 35218 for β-lactam/β-lactamase inhibitor combinations</phrase>
                </para>
              </entry>
              <entry><phrase role="left">Ampicillin, amoxicillin-clavulanic acid, ceftriaxone or cefotaxime, ciprofloxacin or levofloxacin, imipenem, TMP-SMX</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>H. pylori</emphasis>
                </phrase>
              </entry>
              <entry><para id="ch0095s000000p0027"><phrase role="left">Agar dilution</phrase>
                </para>
                <para id="ch0095s000000p0028"><phrase role="left">(CLSI)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">MHA + 5% aged (≥2-week-old) sheep blood</phrase>
              </entry>
              <entry><phrase role="left">72 h growth (from SBA)<superscript><emphasis><link linkend="ch0095s000000a0042">d</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">Microaerobic; produced by gas-generating system for campylobacters</phrase>
              </entry>
              <entry><phrase role="left">~72</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>H. pylori</emphasis> ATCC 43504</phrase>
              </entry>
              <entry><phrase role="left">Clarithromycin</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <table id="ch0095s000000t0004"><title>Table 4 (continued)</title>
        
        <tgroup cols="8">
          <tbody>
            <row>
              <entry><phrase role="left">
                  <emphasis>Kingella kingae</emphasis>
                </phrase>
              </entry>
              <entry><para id="ch0095s000000p0029"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0030"><phrase role="left">(CLSI)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB or HTM or brucella broth with vitamin K (1 μg/ml), hemin (5 μg/ml), and 5% LHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">24–48</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619, <emphasis>E. coli</emphasis> ATCC 35218 for β-lactam/β-lactamase inhibitor combinations</phrase>
              </entry>
              <entry><phrase role="left">Ampicillin, amoxicillin-clavulanate, ceftriaxone or cefotaxime, ciprofloxacin or levofloxacin, imipenem, penicillin, TMP-SMX</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F agar</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">18 ± 2, or 40–44 if poor growth after 16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>H. influenzae</emphasis> ATCC 49766</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Broth microdilution (according to ISO standard 20776-1)</phrase>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2, or 40–44 if poor growth after 16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>H. influenzae</emphasis> ATCC 49766</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Lactobacillus</emphasis> spp.</phrase>
              </entry>
              <entry><para id="ch0095s000000p0031"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0032"><phrase role="left">(CLSI)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">24–48</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619, <emphasis>E. coli</emphasis> ATCC 25922 for gentamicin</phrase>
              </entry>
              <entry><phrase role="left">Penicillin or ampicillin</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Lactococcus</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">Ceftriaxone, clindamycin, erythromycin, penicillin or ampicillin, vancomycin</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Leuconostoc</emphasis> spp.</phrase>
              </entry>
              <entry><para id="ch0095s000000p0033"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0034"><phrase role="left">(CLSI)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619, <emphasis>E. coli</emphasis> ATCC 25922 for gentamicin</phrase>
              </entry>
              <entry><phrase role="left">Penicillin or ampicillin</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>L. monocytogenes</emphasis>
                </phrase>
              </entry>
              <entry><para id="ch0095s000000p0035"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0036"><phrase role="left">(CLSI)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">Penicillin or ampicillin, TMP-SMX</phrase>
              </entry>
            </row>
            <row>
              <entry><para id="ch0095s000000p0037"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0038"><phrase role="left">(according to ISO standard 20776-1)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F agar</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">16–20</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Micrococcus</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Growth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213</phrase>
              </entry>
              <entry><phrase role="left">Penicillin, vancomycin</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>M. catarrhalis</emphasis>
                </phrase>
              </entry>
              <entry><para id="ch0095s000000p0039"><phrase role="left">Broth microdilution</phrase>
                </para>
                <para id="ch0095s000000p0040"><phrase role="left">(CLSI)</phrase>
                </para>
              </entry>
              <entry><phrase role="left">CA-MHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213, <emphasis>E. coli</emphasis> ATCC 35218 for β-lactam/β-lactamase inhibitor combinations</phrase>
              </entry>
              <entry><phrase role="left">Amoxicillin-clavulanic acid, cefaclor or cefuroxime, TMP-SMX</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">MHA</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 25923, <emphasis>E. coli</emphasis> ATCC 35218 for β-lactam/β-lactamase inhibitor combinations</phrase>
              </entry>
              <entry><phrase role="left">Amoxicillin-clavulanic acid, TMP-SMX</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Broth microdilution (according to ISO standard 20776-1)</phrase>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2</phrase>
              </entry>
              <entry><para id="ch0095s000000p0041"><phrase role="left"><emphasis>H. influenzae</emphasis> ATCC 49766,</phrase>
                </para>
                <para id="ch0095s000000p0042"><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213 for β-lactam/β-lactamase inhibitor combinations</phrase>
                </para>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F agar</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">16–20</phrase>
              </entry>
              <entry><para id="ch0095s000000p0043"><phrase role="left"><emphasis>H. influenzae</emphasis> ATCC 49766,</phrase>
                </para>
                <para id="ch0095s000000p0044"><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213 for β-lactam/β-lactamase inhibitor combinations</phrase>
                </para>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <table id="ch0095s000000t0005"><title>Table 5 (continued)</title>
        
        <tgroup cols="8">
          <tbody>
            <row>
              <entry><phrase role="left"><emphasis>Pasteurella</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619, <emphasis>E. coli</emphasis> ATCC 35218 for β-lactam/β-lactamase inhibitor combinations</phrase>
              </entry>
              <entry><phrase role="left">β-Lactam/β-lactamase inhibitor combinations, cephalosporins, fluoroquinolones, macrolides, penicillins, tetracyclines, TMP-SMX</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">MHA with 5% sheep blood</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">16–18</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619, <emphasis>E. coli</emphasis> ATCC 35218, <emphasis>S. aureus</emphasis> ATCC 25923 for amoxicillin-clavulanate</phrase>
              </entry>
              <entry><phrase role="left">β-Lactam/β-lactamase inhibitor combinations, cephalosporins, fluoroquinolones, macrolides, penicillins, tetracyclines, TMP-SMX</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Broth microdilution (according to ISO standard 20776-1)</phrase>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2</phrase>
              </entry>
              <entry><para id="ch0095s000000p0045"><phrase role="left"><emphasis>H. influenzae</emphasis> ATCC 49766,</phrase>
                </para>
                <para id="ch0095s000000p0046"><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213 for β-lactam/β-lactamase inhibitor combinations</phrase>
                </para>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F agar</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">5% CO<subscript>2</subscript></phrase>
              </entry>
              <entry><phrase role="left">16–20</phrase>
              </entry>
              <entry><para id="ch0095s000000p0047"><phrase role="left"><emphasis>H. influenzae</emphasis> ATCC 49766,</phrase>
                </para>
                <para id="ch0095s000000p0048"><phrase role="left"><emphasis>S. aureus</emphasis> ATCC 29213 for β-lactam/β-lactamase inhibitor combinations</phrase>
                </para>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left"><emphasis>Pediococcus</emphasis> spp.</phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">Penicillin or ampicillin</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">
                  <emphasis>Rothia mucilaginosa</emphasis>
                </phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB-LHB</phrase>
              </entry>
              <entry><phrase role="left">18–24-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">20–24</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>S. pneumoniae</emphasis> ATCC 49619</phrase>
              </entry>
              <entry><phrase role="left">Penicillin, vancomycin</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <table id="ch0095s000000t0006"><title>Table 6 (continued)</title>
        
        <tgroup cols="8">
          <tbody>
            <row>
              <entry><phrase role="left"><emphasis>Vibrio</emphasis> spp.<superscript><emphasis><anchor id="ch0095s000000a0038"/><link linkend="ch0095s000000a0043">e</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="left">Broth microdilution (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">CA-MHB</phrase>
              </entry>
              <entry><phrase role="left">16–18-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">16–20</phrase>
              </entry>
              <entry><para id="ch0095s000000p0049"><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922,</phrase>
                </para>
                <para id="ch0095s000000p0050"><phrase role="left"><emphasis>P. aeruginosa</emphasis> ATCC 27853 for carbapenems,</phrase>
                </para>
                <para id="ch0095s000000p0051"><phrase role="left"><emphasis>E. coli</emphasis> ATCC 35218 for β-lactam/β-lactamase inhibitor combinations</phrase>
                </para>
              </entry>
              <entry><para id="ch0095s000000p0052"><phrase role="left">For <emphasis>Vibrio</emphasis> spp. (not <emphasis>V. cholerae</emphasis>): cefotaxime, ceftazidime, tetracycline or doxycycline, fluoroquinolones</phrase>
                </para>
                <para id="ch0095s000000p0053"><phrase role="left">For <emphasis>V. cholerae</emphasis>: ampicillin, azithromycin, chloramphenicol, doxycycline, sulfonamides, tetracycline, TMP-SMX</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (CLSI)</phrase>
              </entry>
              <entry><phrase role="left">MHA</phrase>
              </entry>
              <entry><phrase role="left">16–18-h growth (from SBA)</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">16–18</phrase>
              </entry>
              <entry><para id="ch0095s000000p0054"><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922,</phrase>
                </para>
                <para id="ch0095s000000p0055"><phrase role="left"><emphasis>P. aeruginosa</emphasis> ATCC 27853 for carbapenems,</phrase>
                </para>
                <para id="ch0095s000000p0056"><phrase role="left"><emphasis>E. coli</emphasis> ATCC 35218 for β-lactam/β-lactamase inhibitor combinations</phrase>
                </para>
              </entry>
              <entry><para id="ch0095s000000p0057"><phrase role="left">For <emphasis>Vibrio</emphasis> spp. (not <emphasis>V. cholerae</emphasis>): cefotaxime, ceftazidime, tetracycline or doxycycline, fluoroquinolones</phrase>
                </para>
                <para id="ch0095s000000p0058"><phrase role="left">For <emphasis>V. cholerae</emphasis>: ampicillin, azithromycin, chloramphenicol, doxycycline, sulfonamides, tetracycline, TMP-SMX</phrase>
                </para>
              </entry>
            </row>
            <row>
              <entry/>
              <entry><phrase role="left">Broth microdilution (according to ISO standard 20776-1)</phrase>
              </entry>
              <entry><phrase role="left">MH-F broth</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2</phrase>
              </entry>
              <entry><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922, <emphasis>E. coli</emphasis> ATCC 35218 for β-lactam/β-lactamase inhibitor combinations</phrase>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="left">Disk diffusion (EUCAST)</phrase>
              </entry>
              <entry><phrase role="left">MH-F agar</phrase>
              </entry>
              <entry><phrase role="left">Overnight growth from nonselective media</phrase>
              </entry>
              <entry><phrase role="left">Ambient air</phrase>
              </entry>
              <entry><phrase role="left">18 ± 2</phrase>
              </entry>
              <entry><para id="ch0095s000000p0059"><phrase role="left"><emphasis>E. coli</emphasis> ATCC 25922,</phrase>
                </para>
                <para id="ch0095s000000p0060"><phrase role="left"><emphasis>E. coli</emphasis> ATCC 35218 for β-lactam/β-lactamase inhibitor combinations</phrase>
                </para>
              </entry>
              <entry><phrase role="left">NR</phrase>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0039"/><link linkend="ch0095s000000a0034">a</link></emphasis></superscript>CA-MHB-LHB, cation-adjusted Mueller Hinton broth plus 2.5–5% lysed horse blood; MHA, Mueller-Hinton agar; MH-F, Mueller-Hinton fastidious.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0040"/><link linkend="ch0095s000000a0035">b</link></emphasis></superscript>Suspension is in Mueller-Hinton broth or saline standardized to a 0.5 McFarland standard. For broth dilution, final organism concentration is 5 × 10<superscript>5</superscript> CFU/ml. CHOC, chocolate agar; SBA, sheep blood agar.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0041"/><link linkend="ch0095s000000a0036">c</link></emphasis></superscript>Incubation temperature, 35°C (except for <emphasis>C. jejuni</emphasis> and <emphasis>C. coli</emphasis>).</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0042"/><link linkend="ch0095s000000a0037">d</link></emphasis></superscript>Suspension is in saline standardized to a 2.0 McFarland standard.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0095s000000a0043"/><link linkend="ch0095s000000a0038">e</link></emphasis></superscript>For halophilic species, prepare inoculum in 0.85% NaCl (normal saline).</para>
      <para id="ch0095s000000p0061">Resistance has been described for all other classes of antimicrobial agents that are usually considered for treating pneumococcal infections, except for the glycopeptides. Differences exist between the CLSI and EUCAST breakpoints for most of these antimicrobials. Resistance to macrolides and clindamycin has increased in the United States in the post-PCV era (<link linkend="ch0095s000000li0018">18</link>) and appears to be influenced by macrolide use. The CDC documented that 79.5% of isolates were macrolide susceptible (MIC, ≤0.25 μg/ml) just prior to the introduction of PCV-7, and that macrolide susceptibility declined to 74.9% in 2009 and 69.8% in 2019 (<link linkend="ch0095s000000li0014">14</link>). In some countries, such as China, macrolide resistance is widespread, with recent reports of &gt;90% erythromycin resistance (<link linkend="ch0095s000000li0019">19</link>). In Europe, resistance to macrolides ranges from 10 to 25% (<link linkend="ch0095s000000li0020">20</link>). Erythromycin MICs for pneumococci with macrolide-lincosamide-streptogramin B (MLS)-type resistance (encoded by the <emphasis>ermB</emphasis> gene) are usually ≥64 μg/ml, and clindamycin MICs are ≥8 μg/ml, whereas isolates with the M phenotype (encoded by the <emphasis>mefA</emphasis> gene) have erythromycin MICs of 1 to 32 μg/ml and clindamycin MICs are ≤0.25 μg/ml. The clinical significance of the lower-level macrolide resistance expressed by the M phenotype was once debated; however, treatment failures have been documented with such strains (<link linkend="ch0095s000000li0021">21</link>). Erythromycin resistance but clindamycin susceptibility may also be an indicator of the presence of an inducible <emphasis>ermB</emphasis> gene, which encodes for inducible clindamycin resistance (<link linkend="ch0095s000000li0022">22</link>). There is a theoretical risk of spontaneous conversion from inducible to constitutive resistance in these isolates during extended clindamycin therapy, although this has not specifically been demonstrated in pneumococci. Susceptibility and resistance to azithromycin, clarithromycin, and dirithromycin among <emphasis>S. pneumoniae</emphasis> isolates can be predicted by testing erythromycin (<link linkend="ch0095s000000li0005">5</link>).</para>
      <anchor id="ch0095s000000a0044"/>
      <beginpage pagenum="1494"/>
      <anchor id="ch0095s000000a0045"/>
      <beginpage pagenum="1495"/>
      <anchor id="ch0095s000000a0046"/>
      <beginpage pagenum="1496"/>
      <anchor id="ch0095s000000a0047"/>
      <beginpage pagenum="1497"/>
      <anchor id="ch0095s000000a0048"/>
      <beginpage pagenum="1498"/>
      <anchor id="ch0095s000000a0049"/>
      <beginpage pagenum="1499"/>
      <anchor id="ch0095s000000a0050"/>
      <beginpage pagenum="1500"/>
      <para id="ch0095s000000p0062">Susceptibility rates for trimethoprim-sulfamethoxazole (TMP-SMX) were reported by CDC to be 81.8% in 2019. Resistance rates for fluoroquinolones have remained low at &lt;0.5% (<link linkend="ch0095s000000li0014">14</link>), but resistance is more frequently observed in isolates from elderly patients (<link linkend="ch0095s000000li0023">23</link>, <link linkend="ch0095s000000li0024">24</link>).</para>
      <para id="ch0095s000000p0063">Newer agents for the treatment of pneumococcal pneumonia include lefamulin (a pleuromutilin) and several agents in development (<link linkend="ch0095s000000li0025">25</link>). Clinical breakpoints for lefamulin are available from EUCAST and CLSI, although testing is not widely available and susceptibility rates are high (<link linkend="ch0095s000000li0026">26</link>). Of importance, lefamulin does not cross the blood-brain barrier sufficiently for treatment of meningitis, and this agent should not be reported on isolates recovered from cerebrospinal fluid (<link linkend="ch0095s000000li0027">27</link>).</para>
    </sect1>
    <sect1 id="ch0095s0003">
      <title>Reference Test Methods</title>
      <anchor id="ch0095s000003a0001"/>
      <anchor id="ch0095s000000a0051"/>
      <para id="ch0095s000000p0064">CLSI and EUCAST describe both a broth microdilution (BMD) method and a disk diffusion method for testing pneumococci. Details of these methods (listed in<link linkend="ch0095s000000a0006">Table 1</link>) differ by the testing medium; CLSI endorses use of cation-adjusted Mueller-Hinton broth (CA-MHB) supplemented with 2.5 to 5% lysed horse blood (CA-MHB-LHB) for MIC testing, and either Mueller-Hinton agar (MHA) with 5% sheep blood (BMHA) or Mueller-Hinton fastidious (MH-F) agar for disk diffusion. EUCAST recommends use of MH-F medium for both MIC and disk diffusion tests. MH-F medium consists of Mueller-Hinton agar or broth supplemented with 5% defibrinated horse blood and 20 mg/liter β-NAD.</para>
      <para id="ch0095s000000p0065">BMD may be used to test all the antimicrobial agents recommended by CLSI or EUCAST for pneumococci. With the exception of the 1-μg oxacillin disk screening test, which is used to screen for susceptibility to penicillin (CLSI and EUCAST), ampicillin (EUCAST), and cefaclor (EUCAST), the disk diffusion method does not work reliably for testing β-lactam agents, including the cephalosporins. Guidance provided by CLSI and EUCAST differs on the interpretation of the oxacillin disk diffusion surrogate test. CLSI recommends use of a 1-μg oxacillin disk diffusion zone diameter of ≥20 mm to indicate penicillin susceptibility by the meningitis or oral penicillin breakpoints. Isolates with zone diameters of ≤19 mm cannot be reliably categorized as resistant, and at a minimum, the MICs of penicillin and an extended-spectrum cephalosporin or meropenem should be determined. CLSI indicates that the 1-μg oxacillin disk test should be used only for isolates from patients with non-life-threatening infections. EUCAST guidance indicates that isolates with a 1-μg oxacillin disk zone diameter of ≥20 mm can be reported as susceptible to all β-lactam agents with pneumococcal breakpoints, with the exception of cefaclor, which is to be reported as “susceptible, increased exposure” (I). If the 1-μg oxacillin zone diameter is &lt;20 mm, EUCAST offers a more complex set of instructions for reporting. In this case, benzylpenicillin (meningitis) and phenoxymethylpenicillin (all indications) are considered resistant. Benzylpenicillin for indications other than meningitis must be evaluated by an MIC test prior to reporting the test results. For isolates with a 1-μg oxacillin zone result in the 9- to 19-mm range, ampicillin, amoxicillin, piperacillin (with and without a β-lactamase inhibitor), cefepime, cefotaxime, ceftaroline, ceftobiprole, ceftriaxone, imipenem, and meropenem are reported as susceptible, and specific testing for other β-lactam agents is performed. If the 1-μg oxacillin zone is &lt;9 mm, testing of any β-lactam reported must be performed and interpreted according to that agent’s pneumococcal breakpoints.</para>
      <para id="ch0095s000000p0066">If clindamycin testing is performed, both CLSI and EUCAST stipulate including a screen for inducible clindamycin resistance. This can be accomplished via the D-zone test. A 15-μg erythromycin disk and a 2-μg clindamycin disk are placed 12 mm apart on BMHA or MH-F agar; a flattening of the clindamycin zone of inhibition adjacent to the erythromycin disk is indicative of inducible clindamycin resistance. CLSI also describes a BMD test for inducible clindamycin resistance, using 1 μg/ml of erythromycin and 0.5 μg/ml of clindamycin combined in a single well; growth is indicative of inducible clindamycin resistance (<link linkend="ch0095s000000li0005">5</link>).</para>
      <para id="ch0095s000000p0067">Tetracyclines, in particular doxycycline, are used as alternative agents for the treatment of community-acquired pneumonia in ambulatory and penicillin-allergic patients. In 2013, CLSI revised the<emphasis>S. pneumoniae</emphasis> tetracycline susceptible breakpoint from ≤2 μg/ml to ≤ 1 μg/ml and introduced doxycycline-specific breakpoints; these are the same as EUCAST breakpoints (<link linkend="ch0095s000000li0002">2</link>, <link linkend="ch0095s000000li0005">5</link>). Both CLSI and EUCAST infer minocycline and doxycycline susceptibility from tetracycline results. Isolates resistant to tetracycline should be tested for susceptibility to minocycline and doxycycline individually.</para>
    </sect1>
    <sect1 id="ch0095s0004">
      <title>Commercial Methods for Testing</title>
      <anchor id="ch0095s000004a0001"/>
      <anchor id="ch0095s000000a0052"/>
      <para id="ch0095s000000p0068">Several options are available for determining MICs of various antimicrobial agents with pneumococci. Etest (bioMérieux, Marcy l’Étoile, France) has been extensively evaluated (<link linkend="ch0095s000000li0028">28</link>, <link linkend="ch0095s000000li0029">29</link>) and found to be &gt;90% accurate for most relevant drugs (<link linkend="ch0095s000000li0028">28</link>, <link linkend="ch0095s000000li0029">29</link>). The number of minor errors with penicillin is relatively high, and Etest penicillin MICs are slightly lower than those determined by reference BMD (<link linkend="ch0095s000000li0028">28</link>). Since it is recommended that Etest be incubated in CO<subscript>2</subscript>, the MICs of the macrolides tend to be 1 to 2 dilutions higher than those by the reference broth method, in which incubation is conducted in ambient air. This is because these agents are less active at lower pH, which occurs with CO<subscript>2</subscript> incubation.</para>
      <anchor id="ch0095s000000a0053"/>
      <beginpage pagenum="1501"/>
      <para id="ch0095s000000p0069">Other commercially available FDA-cleared panels or systems specifically designed for testing pneumococci include MicroScan (Beckman Coulter, West Sacramento, CA), Phoenix (BD Diagnostic Systems, Sparks, MD), Sensititre (ThermoFisher, Cleveland, OH), and VITEK 2 (bioMérieux, Inc., Durham, NC). The MicroScan MICroSTREP, Sensititre, VITEK 2, and Phoenix systems have been evaluated and found to produce MICs that are comparable to those obtained with the CLSI BMD reference method (<link linkend="ch0095s000000li0029">29</link>–<link linkend="ch0095s000000li0031">31</link>).</para>
    </sect1>
    <sect1 id="ch0095s0005">
      <title>Strategies for Testing and Reporting of Results</title>
      <anchor id="ch0095s000005a0001"/>
      <anchor id="ch0095s000000a0054"/>
      <para id="ch0095s000000p0070">CLSI suggests that<emphasis>S. pneumoniae</emphasis> isolates from cerebrospinal fluid (CSF) be routinely tested by a reliable MIC method to determine susceptibilities to penicillin and cefotaxime, ceftriaxone, or meropenem. For CSF isolates, as with penicillin, only interpretations using the meningitis breakpoints should be reported for cefotaxime and ceftriaxone; for isolates from other sites, both meningitis and non-meningitis interpretations should be reported. In addition, vancomycin can be tested by either an MIC or a disk diffusion method on isolates from CSF. Along with penicillin, CLSI recommends primary testing and reporting of erythromycin and TMP-SMX for isolates from non-CSF sources. MIC testing of penicillin, cefotaxime or ceftriaxone, and/or meropenem, and MIC or disk diffusion testing of vancomycin, a fluoroquinolone, and tetracycline or doxycycline, would also be appropriate for isolates cultured from non-CSF sources. For isolates that are resistant to erythromycin and susceptible or intermediate to clindamycin, screening for inducible clindamycin resistance should be performed prior to reporting an isolate as clindamycin susceptible (<link linkend="ch0095s000000li0005">5</link>).</para>
      <sect2 id="ch0095s0005s0001">
        <title>STREPTOCOCCI OTHER THAN PNEUMOCOCCI</title>
        <anchor id="ch0095s000005a0002"/>
        <anchor id="ch0095s000000a0055"/>
      </sect2>
    </sect1>
    <sect1 id="ch0095s0006">
      <title>Incidence of Resistance</title>
      <anchor id="ch0095s000006a0001"/>
      <anchor id="ch0095s000000a0056"/>
      <para id="ch0095s000000p0071">Due to significant differences in susceptibility of β-lactam agents between viridans group and beta-hemolytic streptococci, there are separate ampicillin, penicillin, cefotaxime, ceftriaxone, and cefepime interpretive criteria for these organism groups (<link linkend="ch0095s000000li0005">5</link>). Beta-hemolytic streptococci include the large-colony-forming pyogenic strains with group A (<emphasis>Streptococcus pyogenes</emphasis>), C, or G antigens and strains with group B (<emphasis>Streptococcus agalactiae</emphasis>) antigen. The viridans group of streptococci includes the mutans group, salivarius group, bovis group, anginosus group, and mitis group. The anginosus group includes small-colony-forming beta-hemolytic strains with groups A, C, F, or G antigens.</para>
      <para id="ch0095s000000p0072">CLSI has established susceptible-only breakpoints for the beta-hemolytic streptococci with penicillin (≤0.12 μg/ml), ampicillin (≤0.25 μg/ml), cephems (≤0.5 μg/ml), and carbapenems (<link linkend="ch0095s000000li0005">5</link>). The only EUCAST β-lactam breakpoint for this organism group is penicillin (susceptible, ≤0.25 μg/ml) (<link linkend="ch0095s000000li0002">2</link>). CLSI and EUCAST recommend that susceptibilities to other β-lactams should be inferred from penicillin susceptibility. Although beta-hemolytic streptococci have been uniformly susceptible to penicillin, cases of <emphasis>S. agalactiae, S. dysgalactiae</emphasis> subspecies <emphasis>equisimilis</emphasis>, and <emphasis>S. pyogenes</emphasis> with reduced susceptibility to β-lactam antibiotics conferred by the PBP 2x mutation have been reported (<link linkend="ch0095s000000li0032">32</link>–<link linkend="ch0095s000000li0035">35</link>). Introduction of the mutated PBP 2x into penicillin-susceptible strains through allelic exchange resulted in elevated penicillin MICs (<link linkend="ch0095s000000li0036">36</link>). Isolates with reduced penicillin susceptibility also tend to be nonsusceptible to fluoroquinolones and resistant to macrolides compared to penicillin-susceptible isolates (<link linkend="ch0095s000000li0037">37</link>). A French study conducted over an 8-year period reported a rise in fluoroquinolone resistance alongside the emergence of high-level gentamicin resistance in <emphasis>S. agalac</emphasis><emphasis>tiae</emphasis> (<link linkend="ch0095s000000li0038">38</link>).</para>
      <para id="ch0095s000000p0073">MLS-type macrolide resistance due to<emphasis>erm</emphasis> genes in beta-hemolytic streptococci may be either inducible or constitutive. CLSI defines both erythromycin and clindamycin susceptibility as ≤0.25 μg/ml and resistance as ≥1 μg/ml. EUCAST erythromycin susceptible and resistant breakpoints are ≤0.25 μg/ml and &gt;0.5 μg/ml, and clindamycin breakpoints are ≤0.5 μg/ml and &gt;0.5 μg/ml (<link linkend="ch0095s000000li0002">2</link>, <link linkend="ch0095s000000li0005">5</link>). Resistance to erythromycin and clindamycin among 874 beta-hemolytic streptococci isolates from U.S. patients isolated in 2014 was 37.6% and 21.6%, respectively (<link linkend="ch0095s000000li0039">39</link>). A multistate surveillance of 887 isolates obtained from patients with early- and late-onset <emphasis>S. agalactiae</emphasis> disease between 2006 and 2015 reported 44.8% erythromycin resistance and 20.8% clindamycin resistance (<link linkend="ch0095s000000li0040">40</link>). Resistance to erythromycin and clindamycin among <emphasis>S. pyogenes</emphasis> in the United States is also on the rise, from 8.3% in 2011 to 22% in 2017 (<link linkend="ch0095s000000li0041">41</link>). Resistance rates are geographically variable. In Alberta, Canada, susceptibility testing of 1,556 <emphasis>S. agalactiae</emphasis> isolates between 2014 and 2020 revealed increases in erythromycin nonsusceptibility from 36.8% to 50.8% and in clindamycin nonsusceptibility from 21.0% to 45.8% (<link linkend="ch0095s000000li0042">42</link>). In contrast, a study in France between 2007 and 2019 reported stabilized resistance to erythromycin and clindamycin at 32.7% and 26.3%, respectively (<link linkend="ch0095s000000li0043">43</link>). Two patients with vancomycin-resistant <emphasis>S. agalactiae</emphasis> isolates harboring the <emphasis>vanG</emphasis> gene were reported in 2013 (<link linkend="ch0095s000000li0044">44</link>). Resistance rates among beta-hemolytic streptococci vary for tetracyclines and remain low for fluoroquinolones. In several recent large surveillance studies, resistance was not observed for daptomycin or linezolid (<link linkend="ch0095s000000li0039">39</link>, <link linkend="ch0095s000000li0045">45</link>, <link linkend="ch0095s000000li0046">46</link>).</para>
      <para id="ch0095s000000p0074">Penicillin interpretative criteria for viridans group<emphasis>Streptococcus</emphasis> spp. also differ between CLSI and EUCAST. CLSI penicillin and ampicillin susceptible breakpoints are ≤0.12 μg/ml and ≤0.25 μg/ml, respectively (<link linkend="ch0095s000000li0005">5</link>). EUCAST susceptible breakpoints for penicillin (≤0.25 μg/ml) and ampicillin (≤0.5 μg/ml) are 1 dilution higher (<link linkend="ch0095s000000li0002">2</link>). Penicillin resistance in viridans group streptococci has been described, and resistance rates among bloodstream isolates can be &gt;50% (<link linkend="ch0095s000000li0047">47</link>), particularly for <emphasis>Streptococcus mitis, Streptococcus oralis</emphasis>, and <emphasis>Streptococcus sanguinis.</emphasis> Resistance has been described for some viridans group streptococcal isolates for macrolides, lincosamides, and tetracyclines (<link linkend="ch0095s000000li0039">39</link>, <link linkend="ch0095s000000li0047">47</link>, <link linkend="ch0095s000000li0048">48</link>), quinupristin-dalfopristin (<link linkend="ch0095s000000li0047">47</link>, <link linkend="ch0095s000000li0048">48</link>), and fluoroquinolones (<link linkend="ch0095s000000li0039">39</link>, <link linkend="ch0095s000000li0048">48</link>). Single reports of resistance to vancomycin have been noted for <emphasis>Streptococcus gallolyticus</emphasis> (<link linkend="ch0095s000000li0049">49</link>), <emphasis>S. mitis</emphasis> (<link linkend="ch0095s000000li0050">50</link>), <emphasis>S. anginosus</emphasis> (<link linkend="ch0095s000000li0051">51</link>), and <emphasis>Streptococcus suis</emphasis> (<link linkend="ch0095s000000li0052">52</link>). Resistance to linezolid has been reported on rare occasions (<link linkend="ch0095s000000li0053">53</link>). Several reports document single isolates of viridans <emphasis>Streptococcus</emphasis> spp. with daptomycin-nonsusceptible MICs (<link linkend="ch0095s000000li0054">54</link>–<link linkend="ch0095s000000li0056">56</link>). Among a large international collection of bloodstream isolates, all were susceptible to tigecycline (<link linkend="ch0095s000000li0047">47</link>).</para>
      <anchor id="ch0095s000000a0057"/>
      <beginpage pagenum="1502"/>
    </sect1>
    <sect1 id="ch0095s0007">
      <title>Reference Test Methods</title>
      <anchor id="ch0095s000007a0001"/>
      <anchor id="ch0095s000000a0058"/>
      <para id="ch0095s000000p0075">The disk diffusion test may be used to determine the penicillin susceptibility of beta-hemolytic streptococci; however, it is unreliable for viridans group streptococci and should not be used (<link linkend="ch0095s000000li0057">57</link>). That being said, EUCAST does provide zone diameter breakpoints for penicillin as a screening test for β-lactam resistance. For either group, carbapenems, oritavancin, telavancin, and daptomycin should only be tested by an MIC method, whereas other agents may be tested by either an MIC or disk method. Aminoglycoside MICs of &gt;1,000 μg/ml for streptococci have been described (<link linkend="ch0095s000000li0058">58</link>); however, there are no published methods for detecting high-level aminoglycoside resistance in streptococci. The CLSI and EUCAST recommendation for D-zone testing for inducible resistance to clindamycin in beta-hemolytic streptococci is performed in the same manner as the D-zone test described above for <emphasis>S. p</emphasis><emphasis>neumoniae</emphasis>.</para>
    </sect1>
    <sect1 id="ch0095s0008">
      <title>Commercial Test Methods</title>
      <anchor id="ch0095s000008a0001"/>
      <anchor id="ch0095s000000a0059"/>
      <para id="ch0095s000000p0076">The MicroScan, Phoenix, Sensititre, and VITEK 2 systems are cleared by the FDA for the testing of<emphasis>Streptococcus</emphasis> spp. There have been some data to demonstrate that these systems perform reliably for testing of streptococci other than <emphasis>S. pneumoniae</emphasis> (<link linkend="ch0095s000000li0031">31</link>, <link linkend="ch0095s000000li0059">59</link>–<link linkend="ch0095s000000li0062">62</link>). Etest has not been extensively evaluated but does appear to be a possible alternative to the reference methods for testing <emphasis>Streptococcus</emphasis> spp. (<link linkend="ch0095s000000li0063">63</link>, <link linkend="ch0095s000000li0064">64</link>).</para>
    </sect1>
    <sect1 id="ch0095s0009">
      <title>Strategies for Testing and Reporting of Results</title>
      <anchor id="ch0095s000009a0001"/>
      <anchor id="ch0095s000000a0060"/>
      <para id="ch0095s000000p0077">Routine testing of beta-hemolytic streptococci is unnecessary since there have been only sporadic reports of decreased susceptibility to penicillin, primarily in<emphasis>S. agalactiae.</emphasis> However, if erythromycin is being used to treat infections caused by <emphasis>S. pyogenes</emphasis>, and treatment failure is suspected, testing might be considered. Similarly, if clindamycin is being considered for prophylaxis of pregnant women who are highly allergic to penicillin, in an effort to prevent perinatal group B streptococcal disease, testing for clindamycin, including inducible resistance, should be performed. For viridans group streptococci, penicillin MICs should be determined for isolates cultured from blood, especially for patients with infective endocarditis. Certain species within the viridans group streptococci tend to not be susceptible to penicillin, including <emphasis>S. mitis</emphasis> group, <emphasis>S. sanguinis</emphasis> group, and <emphasis>Streptococcus salivarius</emphasis> group. In contrast, the <emphasis>S. anginosis</emphasis> group are often susceptible to penicillin (<link linkend="ch0095s000000li0065">65</link>).</para>
      <sect2 id="ch0095s0009s0001">
        <title>HAEMOPHILUS INFLUENZAE</title>
        <anchor id="ch0095s000009a0002"/>
        <anchor id="ch0095s000000a0061"/>
      </sect2>
    </sect1>
    <sect1 id="ch0095s0010">
      <title>Incidence of Resistance</title>
      <anchor id="ch0095s000010a0001"/>
      <anchor id="ch0095s000000a0062"/>
      <para id="ch0095s000000p0078">Ampicillin resistance in<emphasis>H. influenzae</emphasis> is primarily due to two plasmid-borne β-lactamases, TEM-1 and ROB-1. Globally, TEM-1 is the most common enzyme, and ROB-1 contributes to less than 5% of β-lactamase-producing strains. Susceptibilities to cefaclor and cefprozil are reduced in the presence of ROB-1 as compared to TEM-1 (<link linkend="ch0095s000000li0066">66</link>). Ampicillin resistance can also result from altered penicillin-binding proteins in β-lactamase-negative, ampicillin-resistant (BLNAR) strains. Resistance in BLNAR strains is primarily associated with mutations of the <emphasis>ftsI</emphasis> gene that encodes PBP 3 (<link linkend="ch0095s000000li0067">67</link>). A single N526K mutation has been shown to result in a 2-fold increase in the MIC of ampicillin and a 2- to 8-fold increase in resistance to various cephalosporins. This mutation is relatively common in BLNAR isolates, although other mutations have been described including R517H (<link linkend="ch0095s000000li0068">68</link>, <link linkend="ch0095s000000li0069">69</link>). Isolates of BLNAR <emphasis>H. influenzae</emphasis> express lower levels of resistance to ampicillin, with MICs generally ranging from 0.5 to 8 μg/ml, and are slightly less susceptible to amoxicillin-clavulanic acid and to various cephalosporins such as cefaclor and cefotaxime as compared to isolates with β-lactamase (<link linkend="ch0095s000000li0070">70</link>–<link linkend="ch0095s000000li0072">72</link>). Some strains may possess this β-lactam resistance mechanism and also produce β-lactamase; these strains are referred to as β-lactamase-producing amoxicillin-clavulanic acid-resistant or BLPACR (<link linkend="ch0095s000000li0068">68</link>). Ampicillin MICs for β-lactamase-producing <emphasis>H. influenzae</emphasis> and BLPACR are as high as 512 μg/ml (<link linkend="ch0095s000000li0068">68</link>, <link linkend="ch0095s000000li0069">69</link>).</para>
      <para id="ch0095s000000p0079">A study in the United States showed that 26.2%% of 700 isolates collected in 2016 were β-lactamase positive (<link linkend="ch0095s000000li0073">73</link>). A slightly lower rate of 20% was reported in a study combining 900 clinical isolates from the United States and Europe between 2011 and 2018 (<link linkend="ch0095s000000li0074">74</link>). Similar rates were noted in global surveillance studies that reported 21.7% to 24% β-lactamase-positive isolates (<link linkend="ch0095s000000li0075">75</link>, <link linkend="ch0095s000000li0076">76</link>). The reported incidence of <emphasis>H. influenzae</emphasis> strains that are BLNAR and BLPACR varies considerably. The study of 700 isolates collected in 2016, mentioned above, reported low rates of both BLNAR and BLPACR at 3.1% and 1.9%, respectively (<link linkend="ch0095s000000li0073">73</link>). The rate of BLNAR is globally variable (<link linkend="ch0095s000000li0019">19</link>, <link linkend="ch0095s000000li0071">71</link>, <link linkend="ch0095s000000li0077">77</link>, <link linkend="ch0095s000000li0078">78</link>). For example, a study from Poland that tested 1,481 isolates between 2005 and 2019 reported a rate of 25.6% (<link linkend="ch0095s000000li0079">79</link>), while a study of 474 isolates from Germany in 2016 only reported a rate of 6.5% (<link linkend="ch0095s000000li0080">80</link>).</para>
      <para id="ch0095s000000p0080">Resistance among<emphasis>H. influenzae</emphasis> isolates to broad-spectrum oral cephalosporins (e.g., cefixime and cefpodoxime) and to extended-spectrum cephalosporins (e.g., ceftriaxone and ceftaroline) (<link linkend="ch0095s000000li0081">81</link>–<link linkend="ch0095s000000li0083">83</link>) is rare. Using a CLSI susceptible breakpoint of ≤2 μg/ml, all but 1 of 700 <emphasis>H. influenzae</emphasis> clinical isolates from patients within the United States were susceptible to ceftriaxone. All 700 isolates would be interpreted as susceptible using a EUCAST breakpoint of ≤0.125 μg/ml (<link linkend="ch0095s000000li0073">73</link>). All 487 <emphasis>H. influenzae</emphasis> isolates recovered from pediatric patients in the United States between 2012 and 2014 were susceptible to ceftaroline when using the CLSI susceptible breakpoint of ≤0.5 μg/ml. However, when using the EUCAST breakpoint of ≤0.03 μg/ml, only 98.6% were susceptible (<link linkend="ch0095s000000li0084">84</link>). For 515 <emphasis>H. influenzae</emphasis> isolates from Europe, 100% were ceftaroline susceptible by CLSI and 97.7% by EUCAST breakpoints (<link linkend="ch0095s000000li0081">81</link>). All three studies included at least 25% β-lactamase-producing isolates.</para>
      <para id="ch0095s000000p0081">Globally,<emphasis>H. influenzae</emphasis> susceptibility to TMP-SMX is 68 to 77% (<link linkend="ch0095s000000li0075">75</link>, <link linkend="ch0095s000000li0076">76</link>, <link linkend="ch0095s000000li0082">82</link>), and it may be more prevalent in nontypeable <emphasis>H. influenzae</emphasis> (<link linkend="ch0095s000000li0085">85</link>). Resistance to fluoroquinolones remains rare among <emphasis>H. influenzae</emphasis> (<link linkend="ch0095s000000li0073">73</link>, <link linkend="ch0095s000000li0074">74</link>, <link linkend="ch0095s000000li0076">76</link>, <link linkend="ch0095s000000li0081">81</link>–<link linkend="ch0095s000000li0083">83</link>), but may be higher in some areas of Asia (<link linkend="ch0095s000000li0086">86</link>, <link linkend="ch0095s000000li0087">87</link>). Resistance to newer macrolides is uncommon, with less than 3% of isolates examined in various studies showing resistance to azithromycin (<link linkend="ch0095s000000li0075">75</link>, <link linkend="ch0095s000000li0082">82</link>, <link linkend="ch0095s000000li0083">83</link>).</para>
    </sect1>
    <sect1 id="ch0095s0011">
      <title>Reference Test Methods</title>
      <anchor id="ch0095s000011a0001"/>
      <anchor id="ch0095s000000a0063"/>
      <para id="ch0095s000000p0082">β-Lactamase production in<emphasis>H. influenzae</emphasis> can easily be detected by the chromogenic cephalosporin, acidometric, or iodometric β-lactamase test methods (see <ulink url="ch0092#ch0092s0001">chapter 74</ulink>). EUCAST also recommends a penicillin disk to screen for β-lactamase-producing isolates and isolates with PBP mutations. Isolates with zone size of &lt;12 mm should proceed to a β-lactamase test method (<link linkend="ch0095s000000li0002">2</link>). CLSI has developed BMD MIC and disk diffusion methods for testing <emphasis>H. influenzae</emphasis>, and these methods can be used to test <emphasis>H. parainfluenzae</emphasis> (<link linkend="ch0095s000000a0006">Table 1</link>). Testing of the more unusual <emphasis>Haemophilus</emphasis> spp., including <emphasis>Aggregatibacter aphrophilus</emphasis> (formerly <emphasis>H. aphrophilus</emphasis> and <emphasis>H. paraphrophilus</emphasis>) and <emphasis>Aggregatibacter segnis</emphasis> (formerly <emphasis>H. segnis</emphasis>), is now addressed in the CLSI M45-A3 guideline (<link linkend="ch0095s000000li0006">6</link>). CLSI recommends use of <emphasis>Haemophilus</emphasis> test medium (HTM), which consists of a Mueller-Hinton base, 15 μg of hematin per ml, 15 μg of NAD per ml, and 5 mg of yeast extract per ml. CA-MHB is used with the components listed above for the preparation of HTM broth, which contains 0.2 IU of thymidine phosphorylase per ml when testing sulfonamides or trimethoprim. Although HTM agar is transparent, difficulties in measuring zones and poor growth of some isolates have been noted. BMD tests with HTM generally give clearer endpoints. The problems most often noted with both the disk diffusion and the BMD methods are equivocal endpoints with BLNAR strains with several β-lactams. Because of this, CLSI recommends that BLNAR strains (which are best detected by testing ampicillin) be considered resistant to amoxicillin-clavulanic acid, ampicillin-sulbactam, cefaclor, cefamandole, cefetamet, cefonicid, cefprozil, cefuroxime, loracarbef, and piperacillin-tazobactam (<link linkend="ch0095s000000li0005">5</link>). Some have suggested use of disks with an ampicillin concentration lower (<link linkend="ch0095s000000li0088">88</link>) than the 10 μg recommended by CLSI (<link linkend="ch0095s000000li0005">5</link>); EUCAST recommends an ampicillin disk concentration of 2 μg (<link linkend="ch0095s000000li0002">2</link>). EUCAST also describes methods and interpretive criteria for both MIC and disk diffusion testing of <emphasis>H. influenzae.</emphasis> The methods are nearly identical to the CLSI methods, with the exception of the test media, which are MH-F agar or broth (<link linkend="ch0095s000000li0002">2</link>).</para>
      <anchor id="ch0095s000000a0064"/>
      <beginpage pagenum="1503"/>
    </sect1>
    <sect1 id="ch0095s0012">
      <title>Commercial Test Methods</title>
      <anchor id="ch0095s000012a0001"/>
      <anchor id="ch0095s000000a0065"/>
      <para id="ch0095s000000p0083">Currently, the only FDA-cleared MIC tests for<emphasis>Haemophilus</emphasis> spp. are Sensititre (ThermoFisher) and Etest. Studies have reported that Etest produces considerably higher β-lactam MICs when compared to BMD, which is a particular concern with BLNAR and BLPACR strains (<link linkend="ch0095s000000li0089">89</link>–<link linkend="ch0095s000000li0091">91</link>).</para>
    </sect1>
    <sect1 id="ch0095s0013">
      <title>Strategies for Testing and Reporting of Results</title>
      <anchor id="ch0095s000013a0001"/>
      <anchor id="ch0095s000000a0066"/>
      <para id="ch0095s000000p0084">β-Lactamase testing will detect the most common type of clinically significant resistance in<emphasis>H. influenzae.</emphasis> β-Lactamase-positive isolates are ampicillin and amoxicillin resistant. To detect BLNAR strains, an ampicillin disk diffusion or MIC test is required. To detect BLPACR strains, both a β-lactamase test and amoxicillin-clavulanic disk diffusion or MIC test are required, as these strains are β-lactamase positive and show decreased susceptibility to amoxicillin-clavulanic acid. For laboratories where the incidence of BLNAR is unknown because routine susceptibility tests are not performed, it would be reasonable to test, at a minimum, ampicillin and ceftriaxone for isolates recovered from normally sterile sources. Testing may be considered for TMP-SMX; CLSI suggests routine testing and reporting of this agent (<link linkend="ch0095s000000li0005">5</link>). Other oral agents that might be considered, such as amoxicillin-clavulanic acid, the oral cephalosporins, newer macrolides, and fluoroquinolones, are predictably active against <emphasis>H. influenzae</emphasis> and are often prescribed empirically for respiratory tract infections. Consequently, routine testing of these drugs is generally not necessary.</para>
      <sect2 id="ch0095s0013s0001">
        <title>NEISSERIA GONORRHOEAE</title>
        <anchor id="ch0095s000013a0002"/>
        <anchor id="ch0095s000000a0067"/>
      </sect2>
    </sect1>
    <sect1 id="ch0095s0014">
      <title>Incidence of Resistance</title>
      <anchor id="ch0095s000014a0001"/>
      <anchor id="ch0095s000000a0068"/>
      <para id="ch0095s000000p0085">Antimicrobial resistance among<emphasis>N. gonorrhoeae</emphasis> is a significant concern, and resistance to penicillin, oral cephalosporins, tetracycline, and fluoroquinolones has precluded the use of these drugs as primary agents for the treatment of gonococcal infections. Currently, the CDC recommends treatment of uncomplicated gonorrhea with a single ceftriaxone 500 mg intramuscular dose (<link linkend="ch0095s000000li0092">92</link>); alternatives include ciprofloxacin (if susceptibility is confirmed) or gentamicin plus azithromycin. Globally, combination therapy with ceftriaxone or cefixime plus azithromycin is recommended in European (<link linkend="ch0095s000000li0093">93</link>), Canadian (<link linkend="ch0095s000000li0094">94</link>), Australian (<link linkend="ch0095s000000li0095">95</link>), and World Health Organization (<link linkend="ch0095s000000li0096">96</link>) guidelines for the treatment of gonococcal infections. Limited data demonstrate that the combination of an extended-spectrum cephalosporin plus azithromycin are synergistic against <emphasis>N. gonorrhoeae</emphasis> both <emphasis>in vitro</emphasis> and <emphasis>in vivo</emphasis> (<link linkend="ch0095s000000li0097">97</link>, <link linkend="ch0095s000000li0098">98</link>). The first case of treatment failure for this combination was confirmed in 2018 (<link linkend="ch0095s000000li0099">99</link>), due to an isolate that was resistant to both azithromycin and ceftriaxone.</para>
      <para id="ch0095s000000p0086">Penicillin resistance in<emphasis>N. gonorrhoeae</emphasis> occurs via either the production of a plasmid-associated TEM-1 or TEM-135 β-lactamase (penicillinase-producing <emphasis>N. gonorrhoeae</emphasis> [PPNG]) or multifactorial mutations to the chromosome (chromosomally mediated resistant <emphasis>N. gonorrhoeae</emphasis> [CMRNG]). CMRNG strains arise through stepwise acquisition of mutations to various genes that result in penicillin resistance. These include mutations to the primary penicillin targets, PBP 1 and PBP 2, the membrane porin PorB1b, and the promoter and coding sequence of the transcriptional repressor of the MtrCDE efflux pump, <emphasis>mtrR.</emphasis> While the spectrum of activity for the TEM β-lactamases expressed by PPNG is restricted to the penicillins (<link linkend="ch0095s000000li0100">100</link>), CMRNG may show decreased susceptibility to other β-lactams.</para>
      <para id="ch0095s000000p0087">Strains of<emphasis>N. gonorrhoeae</emphasis> with reduced susceptibility to cephalosporins (e.g., cefixime MIC of ≥0.25 μg/ml and ceftriaxone MIC of ≥0.125 μg/ml) emerged in Japan in 2007 (<link linkend="ch0095s000000li0101">101</link>) and have now spread to many parts of the world (<link linkend="ch0095s000000li0102">102</link>–<link linkend="ch0095s000000li0104">104</link>). Whereas penicillin-resistant CMRNG harbor only four to eight mutations in <emphasis>penA</emphasis>, the gene that encodes PBP 2, isolates with elevated cephalosporin MICs harbor a mosaic <emphasis>penA</emphasis> gene that encodes more than 60 amino acid polymorphisms as compared to the wild-type PBP 2 (<link linkend="ch0095s000000li0105">105</link>). The mosaic <emphasis>penA</emphasis> is thought to have arisen from DNA recombination with the <emphasis>penA</emphasis> genes of multiple saprophytic <emphasis>Neisseria</emphasis> spp. Overexpression of the MtrCDE efflux pump system and mutation of the PorB1b porin result in additional increase in extended-spectrum cephalosporin MICs (<link linkend="ch0095s000000li0105">105</link>). Oral cephalosporin treatment failures have been confirmed in patients infected with these strains (<link linkend="ch0095s000000li0106">106</link>), but injectable ceftriaxone appears to maintain activity. The Gonococcal Isolate Surveillance Program (GISP), which tests urethral isolates from male clients visiting sexually transmitted disease clinics throughout the United States, reported a rapid increase in isolates with decreased susceptibility to cefixime (MIC, ≥0.25 μg/ml), peaking in 2011 at 1.4%. This trend was observed globally, including in the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) (<link linkend="ch0095s000000li0107">107</link>), but has since reversed. Only 0.5% of <emphasis>N. gonorrhoeae</emphasis> tested as part of GISP between 2014 and 2018, and 0.8% of <emphasis>N. gonorrhoeae</emphasis> tested as part of Euro-GASP in 2019 (<link linkend="ch0095s000000li0107">107</link>), displayed a cefixime MIC of ≥0.25 μg/ml (<link linkend="ch0095s000000li0092">92</link>). The notable exception to the reversal trend is data from Hangzhou, China, which show increased prevalence of isolates with a cefixime MIC of ≥0.25 μg/ml from 8% in 2015 to 20% in 2017, with no subsequent decline (<link linkend="ch0095s000000li0108">108</link>). Only 0.21% of isolates tested between 2014 and 2018 in GISP displayed reduced susceptibility to ceftriaxone (MIC, ≥0.125 μg/ml) (<link linkend="ch0095s000000li0092">92</link>), and only two isolates with ceftriaxone resistance were documented in Euro-GASP in 2019 (<link linkend="ch0095s000000li0107">107</link>). Several reports of ceftriaxone treatment failure have been reported for isolates with reduced susceptibility to ceftriaxone in Australia, Sweden, and the United Kingdom (<link linkend="ch0095s000000li0092">92</link>); most of these patients had traveled to Southeast Asia and involved pharyngeal infection.</para>
      <anchor id="ch0095s000000a0069"/>
      <beginpage pagenum="1504"/>
      <para id="ch0095s000000p0088">High-level cefixime (MIC, 8 μg/ml) and ceftriaxone (MIC, 4 μg/ml) -resistant<emphasis>N. gonorrhoeae</emphasis> strains harbor a novel mosaic <emphasis>penA</emphasis> allele, with several unique mutations not previously described in isolates with elevated extended-spectrum cephalosporin MICs (<link linkend="ch0095s000000li0109">109</link>, <link linkend="ch0095s000000li0110">110</link>). In particular, the PBP 2<subscript>A510P</subscript> mutation was found to be an important determinant of ceftriaxone resistance (<link linkend="ch0095s000000li0109">109</link>). The mosaic PBP 2 from one of these strains, when introduced into a wild-type <emphasis>N. gonorrhoeae</emphasis> isolate, resulted in a 500-fold increase in the ceftriaxone MIC (<link linkend="ch0095s000000li0109">109</link>). These strains are the first extensively drug-resistant (XDR) <emphasis>N. gonorrhoeae</emphasis>, as, in addition to ceftriaxone and cefixime resistance, they are resistant to the tetracyclines and fluoroquinolones (<link linkend="ch0095s000000li0109">109</link>). <emphasis>In vitro</emphasis>, ertapenem appears to have activity against these isolates, with MICs ranging from 0.016 to 0.064 μg/ml, although the ertapenem MIC parallels that of ceftriaxone in isolates with mosaic <emphasis>penA</emphasis> alleles other than the ceftriaxone-resistant PBP 2<subscript>A5</subscript><subscript>10P</subscript> (<link linkend="ch0095s000000li0111">111</link>).</para>
      <para id="ch0095s000000p0089">Tetracycline resistance in<emphasis>N. gonorrhoeae</emphasis> can be plasmid or chromosomally mediated, but plasmid-mediated resistance results in higher MICs. Gonococcal fluoroquinolone resistance occurs primarily via spontaneous mutations to the quinolone resistance-determining regions (QRDRs) of <emphasis>gyrA</emphasis> and <emphasis>parC.</emphasis> Efflux-mediated resistance can also occur, again by mutation of <emphasis>mtrR</emphasis>; overexpression of the MtrCDE efflux system is also associated with elevated MICs to tetracyclines and macrolides (including azithromycin). In the United States in 2019, 32.7% of GISP isolates were resistant to tetracycline and 28.4% were resistant to ciprofloxacin (<link linkend="ch0095s000000li0112">112</link>). The Western Pacific and Southeast Asian regions of GASP reported very high rates of fluoroquinolone resistance among <emphasis>N. gonorrhoeae</emphasis> in 2014, including some countries reporting &gt;90% resistance (<link linkend="ch0095s000000li0113">113</link>).</para>
      <para id="ch0095s000000p0090">Azithromycin resistance in<emphasis>N. gonorrhoeae</emphasis> is multifactorial. Alteration of the antimicrobial target by methylation of the 23S rRNA or by mutations in <emphasis>rrl</emphasis> alleles of the 23S rRNA gene is associated with azithromycin MICs of ≥2 μg/ml (<link linkend="ch0095s000000li0114">114</link>). In addition, overexpression of efflux pump systems, such as the multidrug MtrCDE or macrolide MacA-MacB and <emphasis>mefA</emphasis> efflux pumps, plays a role in azithromycin resistance (<link linkend="ch0095s000000li0115">115</link>). Isolates with azithromycin MICs of ≥2 μg/ml (nonsusceptible) are increasing in prevalence in the United States, with GISP reporting 3.25% isolates with reduced susceptibility between 2014 and 2018 (<link linkend="ch0095s000000li0092">92</link>). A significant increase in azithromycin-nonsusceptible <emphasis>N. gonorrhoeae</emphasis> between 2010 and 2013 (1.8% to 22.6%) was reported in Japan, largely due to expansion of azithromycin-resistant sequence type (ST) 6798 clones over this period (<link linkend="ch0095s000000li0116">116</link>). In contrast, in Europe, decrease in susceptibility to azithromycin has been linked to the spread of clone ST1407 (<link linkend="ch0095s000000li0117">117</link>). In 2019, 9.0% of isolates recovered in Europe were azithromycin nonsusceptible (<link linkend="ch0095s000000li0107">107</link>).</para>
    </sect1>
    <sect1 id="ch0095s0015">
      <title>Reference Test Methods</title>
      <anchor id="ch0095s000015a0001"/>
      <anchor id="ch0095s000000a0070"/>
      <para id="ch0095s000000p0091">Routine β-lactamase tests readily detect PPNG and can reliably be performed by either the chromogenic cephalosporin, acidimetric, or iodometric method. CLSI recommends the use of GC agar base for disk diffusion and agar dilution MIC testing, whereas EUCAST recommends an MIC method only. For both CLSI tests, a 1% defined growth supplement must be added. Agar dilution is preferred to BMD for MIC testing because<emphasis>N. gonorrhoeae</emphasis> tends to autolyze in liquid media (<link linkend="ch0095s000000a0006">Table 1</link>). Differences exist between CLSI and EUCAST breakpoints for <emphasis>N. gonorrhoeae.</emphasis> Most relevant are the differences in cephalosporin, fluoroquinolone, and azithromycin breakpoints. EUCAST defines resistance breakpoints for cefixime, cefotaxime, and ceftriaxone (&gt;0.125 mg/liter), whereas CLSI has not established resistance breakpoints for these agents. In contrast, isolates with MICs of &gt;0.25 μg/ml (cefixime), &gt;0.5 μg/ml (cefotaxime), and &gt;0.25 μg/ml (ceftriaxone) are considered nonsusceptible by CLSI standards. Ciprofloxacin susceptibility is defined by an MIC of ≤0.03 mg/liter by EUCAST and ≤0.06 μg/ml by CLSI. EUCAST indicates an epidemiological cutoff for azithromycin of ≤1 mg/liter, which CLSI defines as susceptible (<link linkend="ch0095s000000li0027">27</link>).</para>
    </sect1>
    <sect1 id="ch0095s0016">
      <title>Commercial Test Methods</title>
      <anchor id="ch0095s000016a0001"/>
      <anchor id="ch0095s000000a0071"/>
      <para id="ch0095s000000p0092">The only commercial method currently available for susceptibility testing of<emphasis>N. gonorrhoeae</emphasis> is gradient diffusion, which has been shown to produce results comparable to those of CLSI reference agar dilution methods (<link linkend="ch0095s000000li0118">118</link>, <link linkend="ch0095s000000li0119">119</link>). The CDC recommends use of gradient strips as an acceptable alternative to agar dilution when manufacturer’s instructions and CLSI methods are followed (<link linkend="ch0095s000000li0092">92</link>). Etest has been implemented for testing isolates of <emphasis>N. gonorrhoeae</emphasis> in several United States public health laboratories as part of the Strengthening U.S. Response to Resistant Gonorrhea Project (<link linkend="ch0095s000000li0120">120</link>).</para>
    </sect1>
    <sect1 id="ch0095s0017">
      <title>Strategies for Testing and Reporting Results</title>
      <anchor id="ch0095s000017a0001"/>
      <anchor id="ch0095s000000a0072"/>
      <para id="ch0095s000000p0093">Generally, routine antimicrobial susceptibility testing is not necessary for clinical isolates of<emphasis>N. gonorrhoeae.</emphasis> However, the CDC recommends performing culture and susceptibility testing for <emphasis>N. gonorrhoeae</emphasis> isolated from patients with suspected treatment failures with the recommended combination therapy regimens. Complicating <emphasis>N. gonorrhoeae</emphasis> antimicrobial susceptibility testing is the widespread use of nucleic acid amplification tests (NAATs) for the diagnosis of <emphasis>N. gonorrhoeae</emphasis>; these tests do not yield an isolate for susceptibility testing. Several investigators have evaluated molecular methods by which to detect important resistance determinants, such those that confer resistance to fluoroquinolones, tetracyclines, penicillins, extended-spectrum cephalosporins, and macrolides (<link linkend="ch0095s000000li0121">121</link>, <link linkend="ch0095s000000li0122">122</link>). Due to the multifactorial and ever-evolving nature of antimicrobial resistance in <emphasis>N. gonorrhoeae</emphasis>, these assays unfortunately fall short of the sensitivity and specificity required for their use in guiding treatment of gonococcal infections and do not yet have widespread use. However, detection of the <emphasis>gyrA</emphasis> S91 mutation by molecular methods has been shown in multiple studies as a good predictor of ciprofloxacin susceptibility; this assay is incorporated in CDC treatment guidelines for the use of ciprofloxacin for uncomplicated gonococcal infections (<link linkend="ch0095s000000li0092">92</link>, <link linkend="ch0095s000000li0123">123</link>).</para>
      <para id="ch0095s000000p0094">Laboratories should at minimum identify a reliable reference laboratory for<emphasis>N. gonorrhoeae</emphasis> susceptibility testing in the event that it is requested. Primary agents for testing include ceftriaxone, cefixime, azithromycin, ciprofloxacin, and tetracycline.</para>
      <anchor id="ch0095s000000a0073"/>
      <beginpage pagenum="1505"/>
      <sect2 id="ch0095s0017s0001">
        <title>NEISSERIA MENINGITIDIS</title>
        <anchor id="ch0095s000017a0002"/>
        <anchor id="ch0095s000000a0074"/>
      </sect2>
    </sect1>
    <sect1 id="ch0095s0018">
      <title>Incidence of Resistance</title>
      <anchor id="ch0095s000018a0001"/>
      <anchor id="ch0095s000000a0075"/>
      <para id="ch0095s000000p0095">The modal MIC value for penicillin and<emphasis>N. meningitidis</emphasis> is 0.06 μg/ml. However, <emphasis>N. meningitidis</emphasis> isolates from the United States, Europe, and elsewhere with reduced susceptibility to penicillin (MICs, 0.12 to 1 μg/ml) have been recognized for nearly 2 decades, and the incidence of these strains is increasing (<link linkend="ch0095s000000li0124">124</link>–<link linkend="ch0095s000000li0128">128</link>). A study of 695 meningococcal isolates collected in the United States between 2012 and 2016 reported that 26.3% and 1.3% of isolates were penicillin intermediate and resistant, respectively (<link linkend="ch0095s000000li0129">129</link>). A large study of 4,122 invasive <emphasis>N. meningitidis</emphasis> isolates from England, Wales, and Northern Ireland collected from 2010 to 2019 noted that 34% of isolates were penicillin intermediate (MICs, 0.094 to 0.25 μg/ml); 113 (3%) of isolates in this study were categorized as fully penicillin resistant (MICs, 0.38 to 0.75 μg/ml) (<link linkend="ch0095s000000li0130">130</link>). A study of 866 invasive isolates recovered in Italy over 11 years reported 45% penicillin-intermediate (MIC, 0.094 to 0.25 μg/ml) and no penicillin-resistant isolates (<link linkend="ch0095s000000li0131">131</link>). The increase in penicillin-intermediate strains was likely due to the spread of the hypervirulent strain C-CC11. In contrast, only 2.8% of penicillin-intermediate isolates among 1,447 strains from invasive infections were reported during a similar time frame (2005 to 2008) in South Africa (<link linkend="ch0095s000000li0124">124</link>). Reduced or diminished penicillin and ampicillin susceptibility in meningococci is due to polymorphisms in PBP 2 that result from point mutations of the <emphasis>penA</emphasis> gene (<link linkend="ch0095s000000li0132">132</link>). Further testing on penicillin-intermediate and -resistant isolates from the United States identified mutations in the <emphasis>penA</emphasis> gene in 79% of isolates (<link linkend="ch0095s000000li0129">129</link>). The clinical significance of isolates with elevated penicillin MICs is uncertain, and infections caused by isolates with reduced susceptibility to penicillin have successfully been treated with high doses of penicillin in several cases. Two independent groups examined outcomes in patients infected with isolates with reduced susceptibility to penicillin and concluded that the serogroup, rather than the penicillin MIC, was the microbiological parameter most predictive of mortality (<link linkend="ch0095s000000li0133">133</link>, <link linkend="ch0095s000000li0134">134</link>).</para>
      <para id="ch0095s000000p0096">The extended-spectrum cephalosporins (e.g., ceftriaxone, cefotaxime) remain highly active against isolates with elevated penicillin MICs (<link linkend="ch0095s000000li0127">127</link>, <link linkend="ch0095s000000li0128">128</link>, <link linkend="ch0095s000000li0133">133</link>) and are often used as first-line therapy for meningococcal meningitis in developed countries. However, a report of eight ceftriaxone-resistant serogroup A isolates from India with MICs ranging from 0.25 to 8 μg/ml is of concern (<link linkend="ch0095s000000li0135">135</link>). Emergence of reduced susceptibilities to ceftriaxone and cefotaxime have recently been reported in France, where a 10-fold increase in MICs was noted in 25 invasive <emphasis>N. meningitidis</emphasis> isolates that harbored an altered <emphasis>penA</emphasis> allele (<emphasis>penA327</emphasis>) that was increasingly detected after 2012 (<link linkend="ch0095s000000li0136">136</link>).</para>
      <para id="ch0095s000000p0097">Regarding agents used for prophylaxis, resistance to sulfonamides occurs frequently (<link linkend="ch0095s000000li0124">124</link>, <link linkend="ch0095s000000li0127">127</link>, <link linkend="ch0095s000000li0128">128</link>), and the incidence of resistance to rifampin remains low but has been documented on several occasions following exposure to that agent (<link linkend="ch0095s000000li0125">125</link>–<link linkend="ch0095s000000li0127">127</link>, <link linkend="ch0095s000000li0137">137</link>, <link linkend="ch0095s000000li0138">138</link>). A comprehensive study of 392 isolates from diverse geographic locations collected over 25 years, including 161 isolates with rifampin MICs of &gt;0.25 μg/ml, showed that isolates of <emphasis>N. meningitidis</emphasis> displaying rifampin MICs of &gt;1 μg/ml possess <emphasis>rpoB</emphasis> alleles with mutations that are absent in the alleles found in all isolates with rifampin MICs of ≤1 μg/ml (<link linkend="ch0095s000000li0137">137</link>).</para>
      <para id="ch0095s000000p0098">A great concern is the increasing frequency of diminished fluoroquinolone susceptibility in meningococci from several countries (<link linkend="ch0095s000000li0129">129</link>, <link linkend="ch0095s000000li0139">139</link>). These isolates generally have ciprofloxacin MICs of 0.125 to 0.5 μg/ml, rather than demonstrating high-level resistance. Resistance has been attributed to mutations in the <emphasis>gyrA</emphasis> gene, similar to the situation in gonococci (<link linkend="ch0095s000000li0125">125</link>). Some examples include a case in Venezuela reported to be resistant to both ciprofloxacin and azithromycin (<link linkend="ch0095s000000li0140">140</link>); three meningococcal isolates recovered in Spain that were ciprofloxacin intermediate/resistant and resistant to rifampin (<link linkend="ch0095s000000li0141">141</link>); and three ciprofloxacin- and levofloxacin-resistant isolates from three different states, reported in the United States (<link linkend="ch0095s000000li0129">129</link>). In 2020, a β-lactamase-producing <emphasis>N. meningitidis</emphasis> serogroup Y isolate that was resistant to penicillin and ciprofloxacin was reported in United States-based surveillance of 2,097 isolates; testing revealed that 33 of these isolates contained the ROB-1 β-lactamase gene and the T911 <emphasis>gyrA</emphasis> mutation associated with resistance to penicillin and ciprofloxacin, respectively (<link linkend="ch0095s000000li0142">142</link>).</para>
    </sect1>
    <sect1 id="ch0095s0019">
      <title>Strategies for Testing and Reporting of Results</title>
      <anchor id="ch0095s000019a0001"/>
      <anchor id="ch0095s000000a0076"/>
      <para id="ch0095s000000p0099">CLSI has published standards for MIC testing of<emphasis>N. meningitidis</emphasis> that utilize either the BMD method with CA-MHB-LHB or the agar dilution method with BMHA, both with incubation in 5% CO<subscript>2</subscript> (<link linkend="ch0095s000000li0005">5</link>, <link linkend="ch0095s000000li0143">143</link>). As for <emphasis>N. gonorrhoeae</emphasis>, EUCAST has not yet defined disk diffusion criteria and recommends an MIC method only.</para>
      <para id="ch0095s000000p0100">Interpretive criteria are listed for agents such as penicillin, cefotaxime, and ceftriaxone that might be prescribed for treating meningococcal disease. In addition, interpretive criteria are listed for ciprofloxacin, rifampin, and azithromycin, which might be used for prophylaxis of meningococcal case contacts. For surveillance purposes, isolates with diminished fluoroquinolone susceptibility may best be detected by testing with nalidixic acid by MIC or disk methods (CLSI only) (<link linkend="ch0095s000000li0127">127</link>). CLSI describes a disk diffusion method for testing <emphasis>N. meningitidis</emphasis> that utilizes BMHA and CO<subscript>2</subscript> incubation, and the performance has been reported to be reliable for many agents (<link linkend="ch0095s000000li0127">127</link>). As with MIC tests, interpretive criteria are listed for several therapeutic and prophylactic agents. Unfortunately, these do not include breakpoints for ampicillin and penicillin, as disk testing results obtained with these agents are unreliable (<link linkend="ch0095s000000li0005">5</link>).</para>
      <para id="ch0095s000000p0101">Because of the lack of clinical failures with the drugs of choice for the treatment of meningococcal infections, susceptibility testing is not warranted in most situations. Although Etest has not been cleared by the FDA for testing<emphasis>N. meningitidis</emphasis>, several studies have shown it to be suitable for testing meningococci, and testing is best performed by using BMHA incubated in CO<subscript>2</subscript> (<link linkend="ch0095s000000li0144">144</link>, <link linkend="ch0095s000000li0145">145</link>). Some difficulties in obtaining reliable Etest results with rifampin have been documented (<link linkend="ch0095s000000li0145">145</link>).</para>
      <sect2 id="ch0095s0019s0001">
        <title>POTENTIAL BACTERIAL AGENTS OF BIOTERRORISM</title>
        <anchor id="ch0095s000019a0002"/>
        <anchor id="ch0095s000000a0077"/>
        <para id="ch0095s000000p0102">Several bacterial agents are identified as potential agents of bioterrorism by the CDC (<ulink url="https://www.selectagents.gov/sat/list.htm">https://www.selectagents.gov/sat/list.htm</ulink>). These include <emphasis>Bacillus anthracis, Yersinia pestis, Francisella tularensis, Burkholderia mallei, Burkholderia pseudomallei</emphasis>, and <emphasis>Brucella</emphasis> spp. The antimicrobial susceptibility patterns for most of these organisms are predictable, so susceptibility testing of naturally occurring isolates is often not necessary. However, it is possible for antimicrobial resistance to spontaneously occur among these organisms, and in the case of a bioterrorism event, there is the possibility of engineered resistance. To detect any potential resistance, standardized BMD susceptibility testing methods and interpretive criteria were established and published by the CLSI (<link linkend="ch0095s000000li0006">6</link>) for these organisms. In addition, EUCAST provides MIC and disk diffusion breakpoints for several antimicrobial agents against <emphasis>B. pseudomallei</emphasis> (<link linkend="ch0095s000000li0002">2</link>).</para>
        <anchor id="ch0095s000000a0078"/>
        <beginpage pagenum="1506"/>
        <para id="ch0095s000000p0103">Acquired resistance to antimicrobial agents commonly used for treatment of infections caused by<emphasis>B. anthracis, Y. pestis, F. tularensis, B. mallei</emphasis>, and <emphasis>Brucella</emphasis> spp. is rare. In contrast to other species of <emphasis>Bacillus</emphasis> which produce <emphasis>bla1</emphasis> and <emphasis>bla2</emphasis> β-lactamases that confer resistance to penicillin, most isolates of <emphasis>B. anthracis</emphasis> are susceptible to penicillin. Penicillin-susceptible strains of <emphasis>B. anthracis</emphasis> produce an anti-sigma factor, RsiP, that sequesters the sigma factor required for transcription of the β-lactamase genes. In a naturally occurring penicillin-resistant strain, a single nucleotide deletion in the RsiP gene results in a truncated protein. As a result, sigma factor sequestration does not occur, and the β-lactamase genes are transcribed (<link linkend="ch0095s000000li0146">146</link>). However, amoxicillin is recommended for anthrax prophylaxis only when the isolate has been determined to be susceptible to penicillins, and this recommendation is limited to young children and pregnant women (<link linkend="ch0095s000000li0147">147</link>). Laboratory-generated fluoroquinolone resistance in <emphasis>B. anthracis</emphasis> was described, but fluoroquinolone resistance in clinical isolates has not been reported (<link linkend="ch0095s000000li0148">148</link>, <link linkend="ch0095s000000li0149">149</link>).</para>
        <para id="ch0095s000000p0104">There have been reports of two spontaneously occurring drug-resistant<emphasis>Y. pestis</emphasis> isolates recovered in Madagascar (<link linkend="ch0095s000000li0148">148</link>–<link linkend="ch0095s000000li0151">151</link>). Both isolates acquired conjugative plasmids. In one isolate, the plasmid carried resistant determinants for ampicillin, chloramphenicol, tetracycline, kanamycin, streptomycin, and sulfonamide. In the other isolate, the plasmid conferred resistance to streptomycin. The concern for multidrug resistance encouraged a study of 392 <emphasis>Y. pestis</emphasis> isolates from 17 countries in the Americas, Africa, and Asia. Eight antimicrobial agents used for treatment or prophylaxis of plague were tested and no resistance was reported (<link linkend="ch0095s000000li0152">152</link>). In another study, screening of 713 isolates of <emphasis>Y. pestis</emphasis> from North America failed to demonstrate the backbone plasmids that conferred resistance in the Madagascar strains (<link linkend="ch0095s000000li0153">153</link>).</para>
        <para id="ch0095s000000p0105"><emphasis>B. pseudomallei</emphasis> is intrinsically resistant to many antimicrobial agents, including gentamicin, streptomycin, rifampin, erythromycin, and many β-lactams (<link linkend="ch0095s000000li0154">154</link>). Susceptibility studies of <emphasis>B. pseudomallei</emphasis> and <emphasis>B. mallei</emphasis> indicate that, using CLSI interpretive criteria (<link linkend="ch0095s000000li0006">6</link>), many isolates are susceptible to amoxicillin-clavulanic acid, ceftazidime, imipenem, tetracycline, doxycycline, and TMP-SMX (<link linkend="ch0095s000000li0155">155</link>–<link linkend="ch0095s000000li0157">157</link>). Some isolates of <emphasis>B. pseudomallei</emphasis> have elevated ceftazidime MICs (i.e., MIC, <emphasis role="underline">&gt;</emphasis>8 μg/ml) (<link linkend="ch0095s000000li0156">156</link>–<link linkend="ch0095s000000li0158">158</link>) and elevated amoxicillin-clavulanic acid MICs (i.e., MIC, <emphasis role="underline">&gt;</emphasis>8 μg/ml) (<link linkend="ch0095s000000li0156">156</link>–<link linkend="ch0095s000000li0158">158</link>). Resistance to ceftazidime and amoxicillin-clavulanic acid can be due to a class A PenA β-lactamase (<link linkend="ch0095s000000li0156">156</link>). Resistance to TMP-SMX occurs via overexpression of the BpeEF-OprC drug efflux pump (<link linkend="ch0095s000000li0156">156</link>). TMP-SMX resistance is rare, with one study in Thailand, that evaluated over 6,000 isolates, documenting 0.33% TMP-SMX resistance by Etest (<link linkend="ch0095s000000li0159">159</link>).</para>
        <para id="ch0095s000000p0106">Clinical isolates of<emphasis>Brucella</emphasis> spp. with reduced susceptibility to rifampin and TMP-SMX (<link linkend="ch0095s000000li0160">160</link>–<link linkend="ch0095s000000li0163">163</link>) have been reported. In these publications, the susceptibility testing methods used were either not clearly defined or different from the methods currently recommended by CLSI. A recent study from Iran evaluated 57 isolates of <emphasis>B. melitensis</emphasis> by Etest on unspecified media and reported 35.1% of isolates had reduced susceptibility to rifampin and 3.5% to TMP-SMX (<link linkend="ch0095s000000li0164">164</link>). Also, resistant isolates were not characterized for resistance determinants or mutations. However, mutations in the <emphasis>rpoB</emphasis> gene, the target for rifampin activity, have been observed <emphasis>in vitro</emphasis> in <emphasis>Brucella</emphasis> spp. mutants (<link linkend="ch0095s000000li0165">165</link>, <link linkend="ch0095s000000li0166">166</link>).</para>
        <para id="ch0095s000000p0107">Isolates of<emphasis>F. tularensis</emphasis> demonstrate β-lactamase activity, and they are resistant to β-lactams including cephalosporins and carbapenems (<link linkend="ch0095s000000li0167">167</link>–<link linkend="ch0095s000000li0170">170</link>). Resistance to aminoglycosides, tetracyclines, fluoroquinolones, and chloramphenicol has not been reported.</para>
        <para id="ch0095s000000p0108"><emphasis>B. anthracis, B. mallei, B. pseudomallei</emphasis>, and <emphasis>Y. pestis</emphasis> demonstrate sufficient growth with commonly used BMD MIC testing medium and incubation conditions (<link linkend="ch0095s000000a0017">Table 2</link>). However, the recommended testing medium for <emphasis>F. tularensis</emphasis> is CA-MHB with 2% of a defined growth supplement. This is the same cysteine-containing defined growth supplement that is added to GC agar base for susceptibility testing of <emphasis>N. gonorrhoeae.</emphasis> Some isolates of <emphasis>Brucella</emphasis> spp., particularly isolates of <emphasis>B. abortus</emphasis>, require CO<subscript>2</subscript> incubation. However, incubation in CO<subscript>2</subscript> may increase the MICs of aminoglycosides and decrease the MICs of tetracyclines. The streptomycin susceptibility breakpoint is 1 doubling dilution higher (i.e., increased from 8 μg/ml to 16 μg/ml) when panels are incubated in CO<subscript>2</subscript> (<link linkend="ch0095s000000li0006">6</link>, <link linkend="ch0095s000000li0171">171</link>). For the slower-growing organisms, <emphasis>F. tularensis, Y. pestis</emphasis>, and <emphasis>Brucella</emphasis> spp., 48 h of incubation may be needed to achieve sufficient growth.</para>
        <para id="ch0095s000000p0109">There are few studies comparing alternative susceptibility testing methods to the standard CLSI reference BMD methods. One study compared Etest to BMD for testing<emphasis>B. anthracis</emphasis> (<link linkend="ch0095s000000li0172">172</link>). In this study, Etest MICs were within a single doubling dilution of the BMD MICs for ceftriaxone, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, rifampin, tetracycline, and vancomycin, but not for penicillin. Penicillin MIC values for Etest tended to be lower than those obtained by BMD. A similar trend for penicillin MICs was noted for <emphasis>B. anthracis</emphasis> in a study comparing Etest to agar dilution (<link linkend="ch0095s000000li0173">173</link>). These results suggest that Etest is acceptable for susceptibility testing of <emphasis>B. anthracis</emphasis> with antimicrobial agents other than penicillin. Etest was shown to be reliable for testing 26 diverse strains of <emphasis>Y. pestis</emphasis> with ciprofloxacin, doxycycline, gentamicin, levofloxacin, streptomycin, and tetracycline, but not with chloramphenicol and TMP-SMX (<link linkend="ch0095s000000li0174">174</link>). A recent study conducted by the CDC demonstrated good correlation of amoxicillin-clavulanate, ceftazidime, doxycycline, and imipenem but poor correlation of tetracycline and TMP-SMX between Etest and reference BMD (<link linkend="ch0095s000000li0175">175</link>). In a study that evaluated EUCAST disk diffusion for <emphasis>B. pseudomallei</emphasis>, poor understanding of the EUCAST susceptible, increased exposure (I) breakpoint was noted, as it was misinterpreted to mean not susceptible (<link linkend="ch0095s000000li0176">176</link>).</para>
        <para id="ch0095s000000p0110">Susceptibility testing of potential agents of bioterrorism raises safety concerns for clinical microbiology laboratories. All of the above-mentioned organisms require at least biosafety level (BSL) 2 practices, containment, and facilities. BSL-3 conditions are recommended for activities with a high potential for aerosol production (<link linkend="ch0095s000000li0177">177</link>). Since inoculum preparation for susceptibility testing has the potential for aerosol production, all susceptibility testing procedures must be performed in a BSL-3 facility. Laboratories without BSL-3 facilities should send isolates to an appropriately equipped reference laboratory within the Laboratory Response Network coordinated by the CDC (<ulink url="http://www.selectagents.gov/">http://www.selectagents.gov/</ulink>).</para>
        <anchor id="ch0095s000000a0079"/>
        <beginpage pagenum="1507"/>
      </sect2>
      <sect2 id="ch0095s0019s0002">
        <title>ABIOTROPHIA SPECIES AND GRANULICATELLA SPECIES</title>
        <anchor id="ch0095s000019a0003"/>
        <anchor id="ch0095s000000a0080"/>
        <para id="ch0095s000000p0111">For<emphasis>Abiotrophia</emphasis> spp. and <emphasis>Granulicatella</emphasis> spp., resistance has been reported to agents from several different antimicrobial classes including penicillins, cephalosporins, carbapenems, macrolides, lincosamides, fluoroquinolones, and tetracyclines. CLSI breakpoints for penicillin, ampicillin, cefepime, cefotaxime, ceftriaxone, imipenem, meropenem, vancomycin, erythromycin, clindamycin, ciprofloxacin, levofloxacin, and chloramphenicol are found in the M45-A3 guideline. These breakpoints were adapted from those for viridans group <emphasis>Streptococcus</emphasis> spp. The American Health Association (AHA) endocarditis treatment guidelines recommend that <emphasis>Abiotrophia</emphasis> and <emphasis>Granulicatella</emphasis> spp. be treated with penicillin or ampicillin in combination with gentamicin (<link linkend="ch0095s000000li0178">178</link>). In patients with penicillin intolerance, vancomycin monotherapy or ceftriaxone with gentamicin for susceptible isolates are alternatives. European Society of Cardiology guidance recommends 6 weeks of penicillin, ceftriaxone, or vancomycin in combination with a minimum of 2 weeks of gentamicin (<link linkend="ch0095s000000li0179">179</link>).</para>
        <para id="ch0095s000000p0112">Three recent studies have evaluated susceptibility patterns for<emphasis>Abiotrophia</emphasis> and <emphasis>Granulicatella</emphasis> (<link linkend="ch0095s000000li0180">180</link>–<link linkend="ch0095s000000li0182">182</link>). In these studies, 11 to 24% of <emphasis>Abiotrophia defectiva</emphasis>, 34 to 39% of <emphasis>Granulicatella adiacens</emphasis>, and 80 to 100% of <emphasis>Granulicatella elegans</emphasis> isolates were susceptible to penicillin by CLSI breakpoints. CLSI penicillin breakpoints are ≤0.12 μg/ml, 0.25 to 2 μg/ml, and ≥4 μg/ml for susceptible, intermediate, and resistant.</para>
        <para id="ch0095s000000p0113">Ceftriaxone susceptibility was 92 to 100%, 22 to 47%, and 90 to 100% for<emphasis>A. defectiva, G. adiacens</emphasis>, and <emphasis>G. elegans</emphasis>, respectively (<link linkend="ch0095s000000li0180">180</link>–<link linkend="ch0095s000000li0182">182</link>). Penicillin-susceptible isolates of <emphasis>A. defectiva</emphasis> were generally susceptible to ceftriaxone (95 to 100%), whereas only 21 to 65% of penicillin-susceptible <emphasis>G. adiacens</emphasis> were susceptible to ceftriaxone. Conversely, penicillin-resistant isolates of <emphasis>A. defectiva</emphasis> were often (90 to 97%) susceptible to ceftriaxone, whereas penicillin-resistant isolates of <emphasis>G. adiacens</emphasis> were rarely susceptible to ceftriaxone (5% to 14%) (<link linkend="ch0095s000000li0180">180</link>–<link linkend="ch0095s000000li0182">182</link>). Similar trends were observed for cefotaxime and cefepime (<link linkend="ch0095s000000li0181">181</link>). Generally, isolates of <emphasis>Abiotrophia</emphasis> and <emphasis>Granulicatella</emphasis> spp. are susceptible to meropenem, although nonsusceptible isolates (MICs, ≥1 μg/ml) have been reported. <emphasis>A. defectiva</emphasis> in particular is most likely to be nonsusceptible to meropenem, with the MIC<subscript>90</subscript> reported to be 0.25 to 1 μg/ml (<link linkend="ch0095s000000li0181">181</link>, <link linkend="ch0095s000000li0182">182</link>). Susceptibility to other agents was variable, including 24 to 52% to erythromycin, 77.3 to 100% to clindamycin, and 91.6 to 100% to levofloxacin (<link linkend="ch0095s000000li0180">180</link>–<link linkend="ch0095s000000li0182">182</link>). Resistance to vancomycin has not been reported to date. While clinical breakpoints have not been established, many isolates of <emphasis>G. adiacens</emphasis> and <emphasis>A. defectiva</emphasis> have high MICs to daptomycin, with MIC<subscript>90</subscript>s ranging from 4 to ≥8 μg/ml (<link linkend="ch0095s000000li0180">180</link>–<link linkend="ch0095s000000li0182">182</link>). <emphasis>G. elegans</emphasis> appears to be more susceptible to daptomycin, with MIC<subscript>90</subscript> 0.5 to 2 μg/ml (<link linkend="ch0095s000000li0180">180</link>, <link linkend="ch0095s000000li0182">182</link>). In contrast, the MIC<subscript>90</subscript> for linezolid is 1 to 2 μg/ml for all three species (<link linkend="ch0095s000000li0180">180</link>–<link linkend="ch0095s000000li0182">182</link>).</para>
        <para id="ch0095s000000p0114">Because<emphasis>Abiotrophia</emphasis> spp. and <emphasis>Granulicatella</emphasis> spp. are fastidious, it is recommended that these be tested in CA-MHB-LHB supplemented with 0.001% pyridoxal hydrochloride and incubated in ambient air (<link linkend="ch0095s000000a0033">Table 3</link>) (<link linkend="ch0095s000000li0006">6</link>). Testing of aminoglycosides against <emphasis>Abiotrophia</emphasis> spp. and <emphasis>Granulicatella</emphasis> spp. is not recommended, even though aminoglycosides are commonly used in combination therapy with an agent active against the cell wall, such as penicillin or vancomycin. No commercial tests are currently available for testing <emphasis>Abiotrophia</emphasis> or <emphasis>Granulicatella</emphasis> spp. In a report by Namdari et al., a procedure for adding pyridoxal to an inoculum prepared with the Prompt system and a MicroScan dried Gram-positive panel is described (<link linkend="ch0095s000000li0183">183</link>). Alberti et al. evaluated the performance of penicillin, ceftriaxone, and vancomycin Etest on chocolate MHA, but found very poor agreement with BMD on CA-MHB-LHB and pyridoxal supplementation (<link linkend="ch0095s000000li0184">184</link>).</para>
      </sect2>
      <sect2 id="ch0095s0019s0003">
        <title>AEROCOCCUS</title>
        <anchor id="ch0095s000019a0004"/>
        <anchor id="ch0095s000000a0081"/>
        <para id="ch0095s000000p0115">Both CLSI and EUCAST have established breakpoints for<emphasis>Aerococcus</emphasis> spp. (<link linkend="ch0095s000000li0002">2</link>, <link linkend="ch0095s000000li0005">5</link>), with EUCAST breakpoints being specific to <emphasis>Aerococcus urinae</emphasis> and <emphasis>Aerococcus sanguinicola.</emphasis> CLSI breakpoints were adapted from those for viridans group <emphasis>Streptococcus</emphasis> spp., with the exception of TMP-SMX, which was derived from that of <emphasis>Staphylococcus</emphasis> spp. (<link linkend="ch0095s000000li0006">6</link>). Differences exist between the CLSI and EUCAST breakpoints for every agent (<link linkend="ch0095s000000li0185">185</link>). In addition, the testing methodology differs between CLSI and EUCAST, with CLSI describing a BMD method only, in CA-MHB-LHB and incubation at 35°C in 5% CO<subscript>2</subscript> for 20 to 24 hours. In contrast, EUCAST recommends use of the MH-F for BMD and disk diffusion and incubation 35°C in ambient air for 16 to 20 hours (<link linkend="ch0095s000000a0033">Table 3</link>). Obtaining sufficient growth at 20 hours is problematic, with up to 15% of <emphasis>A. urinae</emphasis> displaying insufficient growth by the BMD method at this time point (<link linkend="ch0095s000000li0185">185</link>, <link linkend="ch0095s000000li0186">186</link>). Isolates with insufficient growth may be reincubated for up to a total of 40 to 44 hours by the EUCAST method, although a pronounced trailing effect may be observed with prolonged incubation (<link linkend="ch0095s000000li0186">186</link>).</para>
        <para id="ch0095s000000p0116">The majority of antimicrobial susceptibility data for<emphasis>Aerococcus</emphasis> spp. are for <emphasis>A. urinae</emphasis> and <emphasis>A. sanguinicola.</emphasis> In general, both species are susceptible to the penicillins (<link linkend="ch0095s000000li0187">187</link>–<link linkend="ch0095s000000li0189">189</link>). Occasional isolates of <emphasis>A. sanguinicola</emphasis> and <emphasis>A. viridans</emphasis> are reported to be penicillin nonsusceptible (<link linkend="ch0095s000000li0190">190</link>, <link linkend="ch0095s000000li0191">191</link>). Data compiled by the CLSI when establishing the <emphasis>Aerococcus</emphasis> breakpoints, which included 70 isolates of <emphasis>A. viridans</emphasis> evaluated at the University of California–Los Angeles (UCLA) and Mayo Clinic, demonstrated that only 64% of isolates were susceptible to penicillin, whereas 95% of 224 isolates of <emphasis>A. sanguinicola</emphasis> were penicillin susceptible (<link linkend="ch0095s000000li0190">190</link>). Similarly, isolates of <emphasis>A. urinae</emphasis> and <emphasis>A. sanguinicola</emphasis> that are susceptible to penicillins but not susceptible to cephems and carbapenems have been reported (<link linkend="ch0095s000000li0187">187</link>, <link linkend="ch0095s000000li0188">188</link>, <link linkend="ch0095s000000li0192">192</link>). The treatment of serious infections, such as endocarditis, caused by <emphasis>Aerococcus</emphasis> spp. is generally with combination therapy of penicillin with an aminoglycoside. <emphasis>In vitro</emphasis>, this combination has been shown to be synergistic and bactericidal against some isolates of <emphasis>A. urinae</emphasis> (<link linkend="ch0095s000000li0193">193</link>–<link linkend="ch0095s000000li0195">195</link>), although high-level aminoglycoside resistance has been documented for <emphasis>A. urinae</emphasis> (<link linkend="ch0095s000000li0194">194</link>).</para>
        <para id="ch0095s000000p0117">Species-specific differences are observed for the fluoroquinolones.<emphasis>A. urinae</emphasis> susceptibility to fluoroquinolones is reported to range from 67 to 84% (<link linkend="ch0095s000000li0188">188</link>, <link linkend="ch0095s000000li0191">191</link>–<link linkend="ch0095s000000li0193">193</link>). In contrast, <emphasis>A. sanguinicola</emphasis> susceptibility rates to the fluoroquinolones are much lower, ranging from 22 to 35% (<link linkend="ch0095s000000li0190">190</link>, <link linkend="ch0095s000000li0191">191</link>). Fluoroquinolone resistance is associated with substitutions in <emphasis>gyrA</emphasis> and/or <emphasis>parC</emphasis> genes (<link linkend="ch0095s000000li0196">196</link>). <emphasis>A. urinae</emphasis> is considered to be resistant to TMP-SMX <emphasis>in vitro</emphasis> when tested on media that contain high concentrations of thymidine, such as those supplemented with sheep blood. However, when tested by the CLSI method using LHB, most isolates of <emphasis>A. urinae</emphasis> will test as susceptible (<link linkend="ch0095s000000li0197">197</link>). This is because LHB contains endogenous thymidine phosphorylase, which converts thymidine to thymine and restores the <emphasis>in vitro</emphasis> activity of TMP-SMX. <emphasis>A. urinae</emphasis>, but not other species of <emphasis>Aerococcus</emphasis>, harbors the <emphasis>folT</emphasis> gene, which is predicted to encode a high-affinity folate transport binding protein, allowing the organism to incorporate exogenous folate and demonstrate resistance to TMP-SMX, akin to what is seen in enterococci. While human urine and blood thymidine levels are typically low, patients with high dietary folate intake may have elevated levels (<link linkend="ch0095s000000li0197">197</link>), and given this, CLSI recommends reporting <emphasis>A. urinae</emphasis> (but not other <emphasis>Aerococcus</emphasis> spp.) as resistant to TMP-SMX, regardless of <emphasis>in vitro</emphasis> susceptibility results (<link linkend="ch0095s000000li0006">6</link>). EUCAST does not provide breakpoints for TMP-SMX and <emphasis>Aerococcus</emphasis> spp. Studies have documented rates of TMP-SMX susceptibility for <emphasis>A. sanguinicola</emphasis> to be ~70% and <emphasis>A. viridans</emphasis> to be 60% (<link linkend="ch0095s000000li0190">190</link>, <link linkend="ch0095s000000li0191">191</link>).</para>
        <anchor id="ch0095s000000a0082"/>
        <beginpage pagenum="1508"/>
        <para id="ch0095s000000p0118">Few data exist for other antimicrobials used to treat urinary tract infections. Though using nonstandardized methods (i.e., Etest on BMHA), Hirzel and colleagues documented 100% susceptibility to nitrofurantoin among 52<emphasis>A. urinae</emphasis> isolates by EUCAST breakpoints and an MIC<subscript>90</subscript> for fosfomycin of 32 μg/ml (<link linkend="ch0095s000000li0192">192</link>). Single cases of vancomycin-resistant <emphasis>A. viridans</emphasis> isolates that harbor the <emphasis>vanA</emphasis> gene have been reported in Korea (<link linkend="ch0095s000000li0198">198</link>) and China (<link linkend="ch0095s000000li0199">199</link>). While no clinical breakpoints exist for daptomycin, bactericidal activity was shown by Hirzel et al. in an evaluation of two clinical isolates by time-kill experiments (<link linkend="ch0095s000000li0194">194</link>).</para>
        <para id="ch0095s000000p0119">No commercial tests are currently available for testing<emphasis>Aerococcus</emphasis> spp. Many studies are conducted using Etest on BMHA, which was shown to perform well compared to the CLSI reference BMD method (<link linkend="ch0095s000000li0185">185</link>, <link linkend="ch0095s000000li0186">186</link>, <link linkend="ch0095s000000li0189">189</link>). Susceptibility testing should be considered for isolates recovered from sterile sites, such as blood or deep tissue specimens. CLSI recommends testing penicillin, ceftriaxone, and vancomycin in these cases. While high-level aminoglycoside resistance has been documented, no standardized test method for this has been developed.</para>
      </sect2>
      <sect2 id="ch0095s0019s0004">
        <title>AEROMONAS</title>
        <anchor id="ch0095s000019a0005"/>
        <anchor id="ch0095s000000a0083"/>
        <para id="ch0095s000000p0120"><emphasis>Aeromonas</emphasis> spp. are typically resistant to ampicillin, show variable results with β-lactam/β-lactamase inhibitor combinations, and are resistant to narrow-spectrum cephalosporins (<link linkend="ch0095s000000li0200">200</link>–<link linkend="ch0095s000000li0203">203</link>). Inducible β-lactamases in <emphasis>Aeromonas</emphasis> spp. have been noted, and resistance may emerge during therapy with a β-lactam agent (<link linkend="ch0095s000000li0204">204</link>). In general, isolates are susceptible to expanded-spectrum cephalosporins, carbapenems, aminoglycosides, and fluoroquinolones. <emphasis>Aeromonas</emphasis> isolates that harbor metallo-β-lactamase genes have been described, including <emphasis>bla</emphasis><subscript>VIM-4</subscript> (<link linkend="ch0095s000000li0205">205</link>), <emphasis>bla</emphasis><subscript>IMP-19</subscript> (<link linkend="ch0095s000000li0206">206</link>), and <emphasis>bla</emphasis><subscript>NDM-1</subscript> (<link linkend="ch0095s000000li0207">207</link>). The metallo-β-lactamase CphA is also frequently found in <emphasis>Aeromonas hydrophila, Aeromonas veronii, Aeromonas jandaei, Aeromonas salmonicida</emphasis>, and <emphasis>Aeromonas dhakensis</emphasis>, but not <emphasis>Aeromonas caviae</emphasis> (<link linkend="ch0095s000000li0208">208</link>, <link linkend="ch0095s000000li0209">209</link>). Detection of carbapenem resistance for isolates with <emphasis>cphA</emphasis> is difficult, and these isolates are often susceptible to carbapenems <emphasis>in vi</emphasis><emphasis>tro</emphasis> (<link linkend="ch0095s000000li0208">208</link>).</para>
        <para id="ch0095s000000p0121">In Taiwan, where infections caused by<emphasis>Aeromonas</emphasis> spp. are frequently encountered, results from 234 isolates in 1996 found species-based differences in overall antimicrobial susceptibility, noting that <emphasis>Aeromonas sobria</emphasis> was more susceptible than was either <emphasis>A. hydrophila</emphasis> or <emphasis>A. caviae</emphasis> (<link linkend="ch0095s000000li0201">201</link>). Similar results were noted by Vila et al. from Spain in 2002 (<link linkend="ch0095s000000li0202">202</link>). In a 2019 study conducted as part of the China Antimicrobial Resistance Surveillance System, 30% of <emphasis>A. hydrophila</emphasis> (<emphasis>n</emphasis> = 745 tested isolates) and <emphasis>A. caviae</emphasis> complex (<emphasis>n</emphasis> = 174) isolates were resistant to ceftriaxone and TMP-SMX compared to &lt;20% of <emphasis>A. veronii</emphasis> complex isolates (<emphasis>n</emphasis> = 190) (<link linkend="ch0095s000000li0210">210</link>). <emphasis>Aeromonas</emphasis> spp. are traditionally considered susceptible to fluoroquinolones (<link linkend="ch0095s000000li0201">201</link>), although resistance to fluoroquinolones appears to be increasing in the Asia-Pacific region, more than doubling from 8% to 17% between the periods of 2003–2006 and 2007–2010 (<link linkend="ch0095s000000li0211">211</link>). Fluoroquinolone resistance in <emphasis>Aeromonas</emphasis> is associated with mutations in the QRDRs of <emphasis>gyrA</emphasis> and <emphasis>parC</emphasis> (<link linkend="ch0095s000000li0212">212</link>, <link linkend="ch0095s000000li0213">213</link>). In the United States, two reports have documented ciprofloxacin-resistant <emphasis>A. hydrophila</emphasis> infections following leech therapy when patients were treated prophylactically with ciprofloxacin (<link linkend="ch0095s000000li0214">214</link>, <link linkend="ch0095s000000li0215">215</link>).</para>
        <para id="ch0095s000000p0122">Although<emphasis>Aeromonas</emphasis> spp. cause diarrheal disease, otherwise healthy individuals with diarrhea caused by <emphasis>Aeromonas</emphasis> spp. usually recover spontaneously without treatment (<link linkend="ch0095s000000li0202">202</link>, <link linkend="ch0095s000000li0216">216</link>) and routine antimicrobial susceptibility testing of isolates from fecal specimens is not recommended (<link linkend="ch0095s000000li0006">6</link>). <emphasis>Aeromonas</emphasis> spp. cause a variety of other infections where treatment may be necessary (<link linkend="ch0095s000000li0201">201</link>, <link linkend="ch0095s000000li0203">203</link>) and isolates from extraintestinal sources may warrant antimicrobial susceptibility testing. <emphasis>Aeromonas</emphasis> spp. share growth characteristics similar to those of the <emphasis>Enterobacterales</emphasis>, and both CLSI and EUCAST recommend use of <emphasis>Enterobacterales</emphasis> disk diffusion or BMD MIC testing methods for <emphasis>Aeromonas.</emphasis> CLSI and EUCAST publish clinical breakpoints for <emphasis>Aeromonas</emphasis> spp., which differ. Specific guidance is given for TMP-SMX disk diffusion by EUCAST, which recommends reading the obvious zone edge for disk diffusion and to disregard haze or growth within the inhibition zone (<link linkend="ch0095s000000li0002">2</link>).</para>
      </sect2>
      <sect2 id="ch0095s0019s0005">
        <title>BACILLUS SPECIES</title>
        <anchor id="ch0095s000019a0006"/>
        <anchor id="ch0095s000000a0084"/>
        <para id="ch0095s000000p0123"><emphasis>Bacillus</emphasis> spp. other than <emphasis>B. anthracis</emphasis> are common contaminants in the clinical laboratory, but in the right circumstances, these bacteria can cause serious disease, including catheter-associated infections, traumatic wound infections, and corneal ulcers. The susceptibility profiles of <emphasis>Bacillus</emphasis> spp. are quite variable, and testing should be considered when <emphasis>Bacillus</emphasis> spp. are isolated from sterile body sites or serious or refractory infections. Isolates of <emphasis>Bacillus</emphasis> spp. can express β-lactamases that confer resistance to penicillins and possibly cephalosporins. <emphasis>Bacillus cereus</emphasis> is the most common species found in clinical specimens, and most isolates are resistant to penicillin and extended-spectrum cephalosporins, but penicillin resistance does not always predict cephalosporin resistance (<link linkend="ch0095s000000li0173">173</link>). Resistance to aminoglycosides, erythromycin, clindamycin, chloramphenicol, tetracycline, fluoroquinolones, TMP-SMX, and even vancomycin has also been reported (<link linkend="ch0095s000000li0173">173</link>, <link linkend="ch0095s000000li0217">217</link>–<link linkend="ch0095s000000li0219">219</link>). When 70 isolates of <emphasis>Bacillus</emphasis> spp. from a variety of clinical specimens were examined, daptomycin had bactericidal activity against vegetative cells but not against spores (<link linkend="ch0095s000000li0217">217</link>). Fatal cases of septicemia and pneumonia in patients treated with meropenem and cefepime, respectively, were reported for carbapenem-resistant <emphasis>B. cereus</emphasis> (<link linkend="ch0095s000000li0220">220</link>, <link linkend="ch0095s000000li0221">221</link>); the resistance mechanism was not determined for either isolate.</para>
        <para id="ch0095s000000p0124">Standard susceptibility testing methods for nonfastidious bacteria can be used for testing<emphasis>Bacillus</emphasis> spp. CLSI provides guidelines for BMD testing (<link linkend="ch0095s000000a0033">Table 3</link>) (<link linkend="ch0095s000000li0006">6</link>). EUCAST provides guidelines for both BMD and disk diffusion testing (<link linkend="ch0095s000000li0002">2</link>). Agar dilution and Etest methods using MHA yielded similar results for several agents including ciprofloxacin, erythromycin, gentamicin, penicillin, tetracycline, and vancomycin (<link linkend="ch0095s000000li0173">173</link>). β-Lactamase testing is not recommended for predicting penicillin susceptibility in <emphasis>Bacillus</emphasis> spp. due to poor performance.</para>
      </sect2>
      <sect2 id="ch0095s0019s0006">
        <title>CAMPYLOBACTER</title>
        <anchor id="ch0095s000019a0007"/>
        <anchor id="ch0095s000000a0085"/>
        <para id="ch0095s000000p0125">Resistance to the fluoroquinolones, which are agents commonly used for treating gastrointestinal infections caused by<emphasis>Campylobacter jejuni</emphasis> and <emphasis>Campylobacter coli</emphasis>, has been reported with increasing frequency in the United States among both human and animal isolates of these two species over the past 2 decades. The National Antimicrobial Resistance Monitoring System (NARMS) noted no ciprofloxacin resistance among <emphasis>C. jejuni</emphasis> human isolates in 1990 (<link linkend="ch0095s000000li0222">222</link>), 26% in 2007, 22.3% in 2013, and 29% resistance in 2018 (<link linkend="ch0095s000000li0223">223</link>). In 2013, NARMS documented that 34.5% of <emphasis>C. coli</emphasis> were ciprofloxacin resistant, and this increased to 40% in 2018 (<link linkend="ch0095s000000li0224">224</link>, <link linkend="ch0095s000000li0225">225</link>). Resistance among animal isolates, which may subsequently be transmitted to humans, has been associated with the addition of macrolides and fluoroquinolones to animal food as growth-promoting agents (<link linkend="ch0095s000000li0226">226</link>). In 2018, beef cattle cecal samples in the United States yielded the highest levels of ciprofloxacin resistance at 63% in <emphasis>C. coli</emphasis> (<link linkend="ch0095s000000li0225">225</link>). In the United States in 2004, the FDA reversed its approval for the therapeutic use of the veterinary fluoroquinolone enrofloxacin, because of concern for rising fluoroquinolone resistance in human isolates. Studies in other countries have demonstrated that fluoroquinolone-resistant <emphasis>Campylobacter</emphasis> persists in poultry populations after withdrawal of veterinary fluoroquinolones (<link linkend="ch0095s000000li0227">227</link>), suggesting little fitness cost to fluoroquinolone resistance in <emphasis>Campylobac</emphasis><emphasis>ter</emphasis> (<link linkend="ch0095s000000li0228">228</link>).</para>
        <anchor id="ch0095s000000a0086"/>
        <beginpage pagenum="1509"/>
        <para id="ch0095s000000p0126">Unlike<emphasis>Escherichia coli</emphasis> or <emphasis>Salmonella</emphasis>, which require multiple mutations to the QRDR of <emphasis>gyrA</emphasis> to achieve high-level quinolone resistance, a single mutation, T85I, in <emphasis>gyrA</emphasis> yields high-level resistance to both nalidixic acid and fluoroquinolones in <emphasis>Campylobacter</emphasis> (<link linkend="ch0095s000000li0229">229</link>). Despite reports of enhanced fitness associated with this mutation in <emphasis>Campylobacter</emphasis> in chicken models of infection (<link linkend="ch0095s000000li0228">228</link>), it is not thought that fluoroquinolone-resistant <emphasis>Campylobacter</emphasis> infections are more severe than infections caused by susceptible isolates (<link linkend="ch0095s000000li0230">230</link>). Macrolide resistance has been described in many countries, mainly due to 23S rRNA mutations and infrequently associated with <emphasis>ermB, rplD</emphasis>, and <emphasis>rplV</emphasis> mutations. The first case of <emphasis>ermB</emphasis>-positive <emphasis>C. jejuni</emphasis> in the United States was reported in 2018 (<link linkend="ch0095s000000li0231">231</link>). NARMS data documented only 2.0% of <emphasis>C. jejuni</emphasis> and 2.7% of <emphasis>C. coli</emphasis> as azithromycin or erythromycin resistant in 2013. Although the macrolide resistance rate remained &lt;3% for <emphasis>C. jejuni</emphasis> in 2018, the rate has increased to 13% among <emphasis>C. coli</emphasis> isolates (<link linkend="ch0095s000000li0232">232</link>). Investigation of a multistate outbreak of multidrug-resistant <emphasis>C. jejuni</emphasis> between 2016 and 2018 implicated puppies sold through pet stores as the source and highlighted the need to control antimicrobial use in the commercial dog industry (<link linkend="ch0095s000000li0233">233</link>).</para>
        <para id="ch0095s000000p0127">Because of the increasing incidence of resistance, testing of isolates from individual patients with severe illness or prolonged symptoms may be warranted, and isolates might also be tested for epidemiologic purposes. BMD susceptibility testing using CA-MHB-LHB and incubation in a microaerobic atmosphere (<link linkend="ch0095s000000a0033">Table 3</link>) is suggested by CLSI and EUCAST (<link linkend="ch0095s000000li0006">6</link>). For disk diffusion, CLSI recommends BMHA and EUCAST recommends MH-F agar. MIC and disk breakpoints for ciprofloxacin, erythromycin, and tetracycline are provided by CLSI and EUCAST. CLSI also provides MIC breakpoints for doxycycline, whereas EUCAST recommends using tetracycline to predict doxycycline susceptibility (<link linkend="ch0095s000000li0006">6</link>). The Etest correlated well with agar dilution in a study by Baker when ciprofloxacin, erythromycin, and tetracycline were tested (<link linkend="ch0095s000000li0234">234</link>).</para>
        <para id="ch0095s000000p0128">Currently, no testing methods have been validated, or interpretive criteria developed, for<emphasis>Campylobacter</emphasis> spp. other than <emphasis>C. jejuni</emphasis> or <emphasis>C. coli</emphasis>.</para>
      </sect2>
      <sect2 id="ch0095s0019s0007">
        <title>CORYNEBACTERIUM SPECIES AND CORYNEFORMS</title>
        <anchor id="ch0095s000019a0008"/>
        <anchor id="ch0095s000000a0087"/>
        <para id="ch0095s000000p0129"><emphasis>Corynebacterium</emphasis> spp. may exhibit a variety of susceptibility profiles, and many isolates are highly susceptible (<link linkend="ch0095s000000li0235">235</link>–<link linkend="ch0095s000000li0239">239</link>). However, most isolates of <emphasis>Corynebacterium amycolatum, Corynebacterium jeikeium, Corynebacterium resistens, Corynebacterium striatum</emphasis>, and <emphasis>Corynebacterium urealyticum</emphasis> are resistant to multiple antimicrobial agents often considered for therapy of Gram-positive infections, including penicillins, cephalosporins, macrolides, aminoglycosides, fluoroquinolones, tetracyclines, and clindamycin. Resistance to daptomycin was reported recently in a <emphasis>C. striatum</emphasis> isolate causing native valve endocarditis in a patient with 12 weeks of prior daptomycin therapy for the treatment of methicillin-resistant <emphasis>Staphylococcus aureus</emphasis> (MRSA) bacteremia and osteomyelitis (<link linkend="ch0095s000000li0240">240</link>). A recent study reported resistance to the majority of drugs tested on <emphasis>C. striatum</emphasis> isolates, including penicillins, cephalosporins, carbapenems, macrolides, and fluoroquinolones. Isolates were fully susceptible to vancomycin and linezolid. Initial susceptibility to daptomycin was 98%, but after 24 hours of incubation with daptomycin, 100% of isolates were nonsusceptible (<link linkend="ch0095s000000li0241">241</link>), indicating that resistance may develop during therapy. Most isolates of <emphasis>C. urealyticum</emphasis> are resistant to fluoroquinolones, which has important implications for empiric therapy for urinary tract infections due to this species (<link linkend="ch0095s000000li0237">237</link>, <link linkend="ch0095s000000li0242">242</link>). Macrolide resistance is frequently found in clinical isolates of <emphasis>Corynebacterium</emphasis> spp., mainly associated with the presence of an <emphasis>ermX</emphasis> methylase gene (<link linkend="ch0095s000000li0243">243</link>).</para>
        <para id="ch0095s000000p0130">Significant antimicrobial resistance is rare for<emphasis>C. diphtheriae</emphasis>, and very few reports of nonsusceptibility to antimicrobial agents exist (<link linkend="ch0095s000000li0244">244</link>–<link linkend="ch0095s000000li0246">246</link>). In a large study of 410 isolates from around the world, only 5 isolates showed reduced susceptibility to macrolides and ketolides (<link linkend="ch0095s000000li0244">244</link>). However, poor bactericidal activity of penicillins for <emphasis>C. diphtheriae</emphasis> has been reported. Investigators in Italy demonstrated penicillin tolerance among 17 of 24 nontoxigenic <emphasis>C. diphtheriae</emphasis> isolates from patients with pharyngitis or tonsillitis (<link linkend="ch0095s000000li0247">247</link>). A paradoxical effect (e.g., decreasing bactericidal activity with increasing antibiotic concentration) with amoxicillin has also been demonstrated with two strains of nontoxigenic <emphasis>C. diphtheriae</emphasis> isolated from patients with endocarditis (<link linkend="ch0095s000000li0248">248</link>). The investigators suggested that poor bactericidal activity of penicillins at high doses may contribute to poor outcomes when penicillins are included in the therapeutic regimen for <emphasis>C. diphtheriae</emphasis> endocarditis (<link linkend="ch0095s000000li0248">248</link>). Monoresistance to the folate pathway inhibitors trimethoprim, sulfamethoxazole, and cotrimoxazole has been reported, most recently in a <emphasis>C. diphtheriae</emphasis> biovar <emphasis>mitis</emphasis> strain isolated from a patient in Mayotte (<link linkend="ch0095s000000li0249">249</link>).</para>
        <para id="ch0095s000000p0131">Growth characteristics among the<emphasis>Corynebacterium</emphasis> spp. may vary, and previous studies have used a variety of methods, media, and incubation conditions for antimicrobial susceptibility testing. CLSI recommends BMD with CA-MHB-LHB and incubation in ambient air (<link linkend="ch0095s000000a0033">Table 3</link>). Some strains grow satisfactorily after 24 h of incubation, but others require 48 h of incubation for sufficient growth. The 48-h incubation is particularly important for detecting resistance to β-lactams, and it is recommended, if growth is not satisfactory or if an isolate appears susceptible to β-lactams at 24 h, that the test be reincubated and final results read after 48 h of incubation (<link linkend="ch0095s000000li0006">6</link>). Other antimicrobials can be reported after 24 h, provided sufficient growth is observed. Currently, disk diffusion testing of <emphasis>Corynebacterium</emphasis> spp. is not recommended by CLSI. EUCAST provides both MIC and zone diameter interpretative criteria for <emphasis>Corynebacterium</emphasis> spp. (<link linkend="ch0095s000000li0006">6</link>). For disk diffusion, MH-F agar is recommended, and plates can be read initially at 16 to 20 h or 40 to 44 h if growth is insufficient at the initial read. Several investigators have used Etest satisfactorily for testing <emphasis>Corynebacterium</emphasis> spp. (<link linkend="ch0095s000000li0235">235</link>, <link linkend="ch0095s000000li0245">245</link>, <link linkend="ch0095s000000li0250">250</link>). However, a recent study evaluating 421 human and veterinary isolates of <emphasis>C. diphtheriae</emphasis> and <emphasis>C. ulcerans</emphasis> found that Etest underestimated MICs of penicillin and overestimated MICs of clindamycin (<link linkend="ch0095s000000li0251">251</link>).</para>
        <anchor id="ch0095s000000a0088"/>
        <beginpage pagenum="1510"/>
        <para id="ch0095s000000p0132">Testing and reporting recommendations in CLSI M45-A3 are applicable to other coryneforms and include the genera<emphasis>Arcanobacterium, Arthrobacter, Brevibacterium, Cellulomonas, Cellulosimicrobium, Dermabacter, Leifsonia, Microbacterium, Oerskovia, Rothia</emphasis> (excluding <emphasis>Rothia mucilaginosa</emphasis>), <emphasis>Trueperella</emphasis>, and <emphasis>Turicella</emphasis> (<link linkend="ch0095s000000li0006">6</link>). Scarce data are available in the literature regarding antimicrobial susceptibility of these organisms, and methods used vary between studies. However, macrolide resistance has been noted for isolates of <emphasis>Brevibacterium, Dermabacter</emphasis>, and <emphasis>Turicella</emphasis> and fluoroquinolone resistance for <emphasis>Brevibacterium</emphasis> and <emphasis>Dermabacter</emphasis> (<link linkend="ch0095s000000li0237">237</link>). <emphasis>Arcanobacterium haemolyticum</emphasis> appears to be universally resistant to TMP-SMX (<link linkend="ch0095s000000li0252">252</link>), while some isolates may display tetracycline resistance (<link linkend="ch0095s000000li0253">253</link>). <emphasis>A. haemolyticum</emphasis> isolates are reportedly susceptible to other agents that might be considered for treatment, but clinical failure has been reported with penicillin (<link linkend="ch0095s000000li0252">252</link>). One study has reported <emphasis>A. haemolyticum</emphasis> and <emphasis>Oerskovia turbata</emphasis> harboring the <emphasis>vanA</emphasis> gene on a plasmid; both isolates were vancomycin resistant (<link linkend="ch0095s000000li0254">254</link>). A study of 50 clinical isolates of <emphasis>Microbacterium</emphasis> spp. demonstrated variable susceptibility profiles, but notably only 56% of isolates were susceptible to ciprofloxacin; one isolate, a <emphasis>Microbacterium resistens</emphasis>, was resistant to vancomycin, which is typical for this species (<link linkend="ch0095s000000li0255">255</link>). <emphasis>Turicella otitidis</emphasis> is susceptible to most β-lactams, ciprofloxacin, rifampin, tetracyclines, and gentamicin, but significant resistance to macrolides and lincosamides in association with 23S rRNA mutations has been reported (<link linkend="ch0095s000000li0256">256</link>, <link linkend="ch0095s000000li0257">257</link>). Susceptibility testing of <emphasis>Corynebacterium</emphasis> spp. and other coryneforms is warranted when the organisms are isolated from normally sterile sites.</para>
      </sect2>
      <sect2 id="ch0095s0019s0008">
        <title>ERYSIPELOTHRIX RHUSIOPATHIAE</title>
        <anchor id="ch0095s000019a0009"/>
        <anchor id="ch0095s000000a0089"/>
        <para id="ch0095s000000p0133"><emphasis>Erysipelothrix rhusiopathiae</emphasis> is intrinsically vancomycin resistant. Other agents that have little to no activity against isolates of this species are aminoglycosides and TMP-SMX. Antimicrobial susceptibility studies of isolates from a number of sources have shown all isolates of <emphasis>E. rhusiopathiae</emphasis> to be susceptible to penicillins, cephalosporins, carbapenems, and fluoroquinolones (<link linkend="ch0095s000000li0258">258</link>–<link linkend="ch0095s000000li0260">260</link>). Case reports document single cases of penicillin resistance (<link linkend="ch0095s000000li0261">261</link>, <link linkend="ch0095s000000li0262">262</link>). Resistance to clindamycin, erythromycin, and tetracycline does occur. The <emphasis>tet</emphasis>(M) gene found in tetracycline-resistant <emphasis>E. rhusiopathiae</emphasis> is 99% similar to that in <emphasis>Enterococcus faecalis.</emphasis> Resistance to macrolides is related to expression of the plasmid-borne <emphasis>erm</emphasis>(T) gene or an <emphasis>erm</emphasis>(A)-like gene (<link linkend="ch0095s000000li0263">263</link>, <link linkend="ch0095s000000li0264">264</link>). A recent study of <emphasis>E. rhusiopathiae</emphasis> isolated from cases of swine erysipelas is the most up-to-date survey of antimicrobial resistance in this organism by reference CLSI methods. This study demonstrated 51% resistance to tetracycline, 53% to erythromycin, 70% to clindamycin, 92% to ciprofloxacin, and 0% to meropenem and cefotaxime among 120 isolates (<link linkend="ch0095s000000li0264">264</link>).</para>
        <para id="ch0095s000000p0134">Isolates of<emphasis>E. rhusiopathiae</emphasis> are fastidious, so CA-MHB-LHB is recommended for BMD MIC testing (<link linkend="ch0095s000000li0006">6</link>). When the test organism is isolated from sterile sites, laboratories should primarily test ampicillin or penicillin (<link linkend="ch0095s000000li0006">6</link>).</para>
      </sect2>
      <sect2 id="ch0095s0019s0009">
        <title>GEMELLA</title>
        <anchor id="ch0095s000019a0010"/>
        <anchor id="ch0095s000000a0090"/>
        <para id="ch0095s000000p0135">Limited data in the literature demonstrate<emphasis>Gemella</emphasis> spp. to be susceptible to many antimicrobial agents, including penicillin. CLSI breakpoints for <emphasis>Gemella</emphasis> spp. are based on data from 45 isolates tested at three laboratories and demonstrated 95% susceptibility to penicillin and ceftriaxone, 98% to meropenem, and 96% to vancomycin. In contrast, only 56% of isolates were susceptible to erythromycin (<link linkend="ch0095s000000li0265">265</link>). Intrinsic resistance to TMP-SMX is reported (<link linkend="ch0095s000000li0266">266</link>). <emphasis>Gemella</emphasis> spp. demonstrate <emphasis>in vitro</emphasis> synergy between penicillin or vancomycin plus gentamicin or streptomycin (<link linkend="ch0095s000000li0266">266</link>).</para>
        <para id="ch0095s000000p0136">Isolates of<emphasis>Gemella</emphasis> are fastidious, and CA-MHB-LHB is recommended for BMD MIC testing (<link linkend="ch0095s000000li0006">6</link>). Isolates may require up to 48 h of incubation before sufficient growth is evident. <emphasis>Gemella morbillorum</emphasis> may display improved growth using CLSI anaerobic test conditions (i.e., agar dilution using brucella agar supplemented with 5% sheep blood, hemin, and vitamin K<subscript>1</subscript>, incubated anaerobically or in 5% CO<subscript>2</subscript>) (<link linkend="ch0095s000000li0267">267</link>, <link linkend="ch0095s000000li0268">268</link>). CLSI provides breakpoints for penicillin, cefotaxime, ceftriaxone, meropenem, vancomycin, erythromycin, levofloxacin, and clindamycin. When test organisms are isolated from sterile sites, laboratories should primarily test penicillin, cefotaxime or ceftriaxone, and vancomycin (<link linkend="ch0095s000000li0006">6</link>).</para>
      </sect2>
      <sect2 id="ch0095s0019s0010">
        <title>HACEK GROUP</title>
        <anchor id="ch0095s000019a0011"/>
        <anchor id="ch0095s000000a0091"/>
        <para id="ch0095s000000p0137">There are limited antimicrobial susceptibility test data on the HACEK organisms (i.e.,<emphasis>Aggregatibacter</emphasis> [formerly the <emphasis>aphrophilus</emphasis> group of <emphasis>Haemophilus</emphasis> and <emphasis>Actinobacillus</emphasis>], <emphasis>Cardiobacterium, Eikenella</emphasis>, and <emphasis>Kingella</emphasis> spp.) in part because these organisms are infrequently encountered and often difficult to grow.</para>
        <para id="ch0095s000000p0138">Members of HACEK are susceptible to extended-spectrum cephalosporins and fluoroquinolones and are often susceptible<emphasis>in vitro</emphasis> to ampicillin and penicillin (<link linkend="ch0095s000000li0057">57</link>, <link linkend="ch0095s000000li0269">269</link>, <link linkend="ch0095s000000li0270">270</link>), although isolates of <emphasis>Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens</emphasis>, and <emphasis>Kingella</emphasis> spp. can produce β-lactamase (<link linkend="ch0095s000000li0270">270</link>). Coburn and colleagues noted that 22.9% of 68 isolates belonging to the HACEK group were nonsusceptible to penicillin, but 95.8% of isolates remained susceptible to ampicillin, and all but two isolates were susceptible to amoxicillin-clavulanic acid. One <emphasis>E. corrodens</emphasis> isolate tested resistant to penicillin and ampicillin, but tested negative for the presence of β-lactamase by the Cefinase disk method (<link linkend="ch0095s000000li0270">270</link>). American Heart Association recommendations for treatment of patients with endocarditis caused by HACEK organisms suggest that HACEK organisms should be considered ampicillin resistant, unless sufficient growth is present to obtain susceptibility data (<link linkend="ch0095s000000li0178">178</link>).</para>
        <para id="ch0095s000000p0139">The<emphasis>Kingella kingae</emphasis> β-lactamase is encoded by the <emphasis>bla</emphasis><subscript>TEM-1</subscript> gene, which can be located on the chromosome or a plasmid (<link linkend="ch0095s000000li0271">271</link>), and is limited to distinct clones of <emphasis>K. kingae. bla</emphasis><subscript>TEM-1</subscript> was found in 20% of 15 United States isolates recovered from invasive infections, in 28.6% of 14 isolates recovered in Iceland, but in only 1.1% of 190 isolates recovered in Israel and 0% of isolates recovered in Canada (<emphasis>n</emphasis> = 24), France (<emphasis>n</emphasis> = 56), and Spain (<emphasis>n</emphasis> = 32) (<link linkend="ch0095s000000li0272">272</link>). Among a collection of 159 <emphasis>K. kingae</emphasis> evaluated by EUCAST when establishing clinical breakpoints for this species, β-lactamase was detected in 41 (26%) (<link linkend="ch0095s000000li0273">273</link>). Isolates with β-lactamase were also resistant to TMP-SMX in this study. <emphasis>K. kingae</emphasis> clindamycin MICs range from 0.5 to &gt;2 μg/ml, which led EUCAST to designate these isolates as intrinsically resistant to clindamycin (<link linkend="ch0095s000000li0273">273</link>), a challenge in regions where empiric regimens for pediatric skeletal infections include clindamycin. In the EUCAST study, 8% of isolates were resistant to tetracycline and, as is the case for other bacteria, tetracycline susceptibility could be used to predict doxycycline susceptibility.</para>
        <anchor id="ch0095s000000a0092"/>
        <beginpage pagenum="1511"/>
        <para id="ch0095s000000p0140">BMD with CA-MHB-LHB can be used for testing HACEK organisms. Some isolates may require 48 h of incubation to obtain adequate growth as evidenced by substantial turbidity in the positive growth control well. Coburn et al. demonstrated that 104 (59.8%) of 174 HACEK isolates failed to grow in CA-MHB-LHB. In particular, poor growth was noted for<emphasis>A. actinomycetemcomitans</emphasis> (83.3% of isolates), <emphasis>A. aphrophilus</emphasis> (60.7%), and <emphasis>C. hominis</emphasis> (60%) (<link linkend="ch0095s000000li0270">270</link>). This study led CLSI to evaluate alternative test media, including HTM or brucella broth with vitamin K, hemin, and 5% lysed horse blood. <emphasis>Aggregatibacter</emphasis> spp. appear to grow better in HTM broth and <emphasis>Eikenella</emphasis> spp. in brucella broth supplemented with vitamin K<subscript>1</subscript>, hemin, and 5% LHB (<link linkend="ch0095s000000li0006">6</link>). EUCAST disk and MIC breakpoints are available for <emphasis>K. kingae</emphasis> alone using MH-F test media (<link linkend="ch0095s000000li0002">2</link>). Susceptibility testing may be warranted for isolates from normally sterile sites, and β-lactamase testing should be performed on HACEK isolates (<link linkend="ch0095s000000li0006">6</link>), although laboratories should be aware that not all ampicillin-resistant isolates may be detected by this testing (<link linkend="ch0095s000000li0270">270</link>).</para>
      </sect2>
      <sect2 id="ch0095s0019s0011">
        <title>HELICOBACTER PYLORI</title>
        <anchor id="ch0095s000019a0012"/>
        <anchor id="ch0095s000000a0093"/>
      </sect2>
    </sect1>
    <sect1 id="ch0095s0020">
      <title>Incidence of Resistance</title>
      <anchor id="ch0095s000020a0001"/>
      <anchor id="ch0095s000000a0094"/>
      <para id="ch0095s000000p0141"><emphasis>H. pylori</emphasis> is intrinsically resistant to glycopeptides, polymyxins, nalidixic acid, trimethoprim, and sulfonamides. <emphasis>H. pylori</emphasis> is treated with triple therapy consisting of metronidazole, clarithromycin, and a fluoroquinolone. The rates of resistance for <emphasis>H. pylori</emphasis> vary considerably for these first-line agents. A summary of surveillance studies concluded that global clarithromycin resistance rates are &gt;15%, above the threshold where either alternative empiric regimens or routine clarithromycin susceptibility testing is recommended (<link linkend="ch0095s000000li0274">274</link>, <link linkend="ch0095s000000li0275">275</link>). Global levofloxacin resistance rates are 15 to 20%, and metronidazole resistance rates are 45 to 55%. The exception to this trend is <emphasis>H. pylori</emphasis> isolates recovered in studies conducted in China, where metronidazole resistance is &gt;75% (<link linkend="ch0095s000000li0276">276</link>, <link linkend="ch0095s000000li0277">277</link>). In 2017, the World Health Organization designated clarithromycin-resistant <emphasis>H. pylori</emphasis> a high priority for antibiotic research and development. Surveillance conducted in Europe in 2018 demonstrated that both clarithromycin and levofloxacin resistance rates were associated with community consumption rates of macrolides and fluoroquinolones, respectively (<link linkend="ch0095s000000li0276">276</link>, <link linkend="ch0095s000000li0278">278</link>). In contrast to first-line agents, resistance to amoxicillin or tetracycline is ≤10% globally, with the exception of the eastern Mediterranean region, where amoxicillin resistance is estimated at 14% (<link linkend="ch0095s000000li0277">277</link>). On a per-patient level, prior treatment with metronidazole and clarithromycin is associated with increased risk of resistance to these drugs (<link linkend="ch0095s000000li0277">277</link>, <link linkend="ch0095s000000li0279">279</link>).</para>
    </sect1>
    <sect1 id="ch0095s0021">
      <title>Reference Test Method</title>
      <anchor id="ch0095s000021a0001"/>
      <anchor id="ch0095s000000a0095"/>
      <para id="ch0095s000000p0142">CLSI describes an agar dilution MIC method for testing<emphasis>H. pylori.</emphasis> The test medium is MHA supplemented with 5% (vol/vol) aged (<emphasis role="underline">&gt;</emphasis>2-week-old) sheep blood. Aged sheep blood provides superior growth, and fresh sheep blood should not be used. The inoculum is prepared from 72-h-old growth on a blood agar plate to obtain a final concentration of bacteria approximating 10<superscript>5</superscript> CFU/spot. Incubation is for 3 days at 35°C in a microaerobic atmosphere produced by a gas-generating system typically used for <emphasis>Campylobacter. H. pylori</emphasis> ATCC 43504 has been designated as a QC strain, and currently there are only CLSI interpretive criteria for clarithromycin. Other antimicrobial agents that have been studied and for which there are CLSI QC ranges include amoxicillin, metronidazole, telithromycin, and tetracycline (<link linkend="ch0095s000000li0006">6</link>). EUCAST has defined MIC interpretive criteria, based on epidemiological cutoff values, for metronidazole, clarithromycin, amoxicillin, levofloxacin, tetracycline, and rifampin (<link linkend="ch0095s000000li0002">2</link>). Although there are currently no CLSI interpretive criteria for metronidazole, many investigators use the EUCAST cutoff of &gt;8 mg/liter for resistance. CLSI cautions, in the M45-A3, that testing of metronidazole under the CLSI reference MIC method for <emphasis>H. pylori</emphasis> does not reliably predict treatment outcome, and that testing of metronidazole is not recommended (<link linkend="ch0095s000000li0006">6</link>). The European <emphasis>Helicobacter pylori</emphasis> Study Group has published an agar dilution method that is similar to the CLSI method; however, they recommend horse blood-supplemented MHA and a higher inoculum (<link linkend="ch0095s000000li0280">280</link>). Although there is no standard method for disk diffusion testing, Grignon et al. have demonstrated that this method is reliable for testing clarithromycin (<link linkend="ch0095s000000li0281">281</link>), the drug that is usually of greatest interest.</para>
    </sect1>
    <sect1 id="ch0095s0022">
      <title>Commercial Test Methods</title>
      <anchor id="ch0095s000022a0001"/>
      <anchor id="ch0095s000000a0096"/>
      <para id="ch0095s000000p0143">No commercial methods are FDA cleared for antimicrobial susceptibility testing of<emphasis>H. pylori</emphasis>, but several investigators have examined the performance of Etest. Drawing a conclusion for the performance of Etest across studies is complicated by the fact that significant differences in methods, including media types, inoculum concentration, and incubation conditions, exist (<link linkend="ch0095s000000li0280">280</link>, <link linkend="ch0095s000000li0282">282</link>, <link linkend="ch0095s000000li0283">283</link>). The Etest manufacturer recommends alternative incubation conditions for <emphasis>H. pylori</emphasis> when testing metronidazole, for example, incubation in an anaerobic environment for 24 h, followed by 48 h of incubation in a microaerophilic environment (Etest Package Insert 2012, bioMérieux). Preincubation in an anaerobic environment was shown to significantly improve Etest agreement with agar dilution (<link linkend="ch0095s000000li0284">284</link>), although MHA supplemented with 5% horse blood, as opposed to aged sheep blood, was used for agar dilution in this study. A recent multicenter study using standardized test methodology demonstrated that Etest performed well for evaluation of clarithromycin, ciprofloxacin, and clindamycin (<link linkend="ch0095s000000li0285">285</link>).</para>
    </sect1>
    <sect1 id="ch0095s0023">
      <title>Molecular Approaches to Susceptibility Testing of H. pylori</title>
      <anchor id="ch0095s000023a0001"/>
      <anchor id="ch0095s000000a0097"/>
      <para id="ch0095s000000p0144"><emphasis>H. pylori</emphasis> resistance mechanisms for clarithromycin and fluoroquinolones are relatively well known. For the former, resistance is mainly associated with point mutations to domain V of the 23S rRNA gene, namely at positions A2146 and A2147. Fluoroquinolone resistance is associated with mutation to the QRDR of <emphasis>gyrA</emphasis> at codons 87 and 91, either alone or in combination with mutation to <emphasis>gyrB</emphasis> (<link linkend="ch0095s000000li0286">286</link>). With this knowledge, genotypic methods are increasingly used as a surrogate for phenotypic susceptibility testing, particularly for clarithromycin (<link linkend="ch0095s000000li0287">287</link>, <link linkend="ch0095s000000li0288">288</link>). A recent study conducted in Rhode Island evaluated <emphasis>H. pylori</emphasis> resistance determinants using a whole-genome sequencing approach. The investigators found that patients with predicted clarithromycin-resistant <emphasis>H. pylori</emphasis> had a significantly higher rate of eradication failure (56%) compared to eradication success (14%) when a clarithromycin-containing regimen was prescribed. Similarly, Kim et al. conducted a retrospective study of 464 patients with <emphasis>H. pylori</emphasis> infection and found that bismuth-quadruple therapy was superior to standard triple therapy for patients with PCR-predicted clarithromycin resistance (i.e., A2143 or A2142 mutations) (<link linkend="ch0095s000000li0288">288</link>). In contrast, metronidazole resistance was not different between patients with eradication failures and successes (<link linkend="ch0095s000000li0289">289</link>). This factor may be due to the relatively more complex array of resistance pathways associated with metronidazole resistance in <emphasis>H. pylori</emphasis> (<link linkend="ch0095s000000li0286">286</link>). At present, no commercial tests are available for molecular detection of <emphasis>H. pylori</emphasis> resistance, but such testing is available at some reference laboratories.</para>
      <anchor id="ch0095s000000a0098"/>
      <beginpage pagenum="1512"/>
    </sect1>
    <sect1 id="ch0095s0024">
      <title>Strategies for Testing and Reporting of Results</title>
      <anchor id="ch0095s000024a0001"/>
      <anchor id="ch0095s000000a0099"/>
      <para id="ch0095s000000p0145">Growth requirements and complex antimicrobial susceptibility testing recommendations for only a limited number of drugs make testing of<emphasis>H. pylori</emphasis> impractical for the routine clinical laboratory. However, because of the significant resistance noted for metronidazole and clarithromycin, testing is recommended for patients with ≥2 treatment failures, in which case a reliable reference laboratory should be used. Resistant isolates may not be evenly distributed throughout the stomach, and susceptibility results for isolates from a single biopsy may not be representative of the entire population (<link linkend="ch0095s000000li0290">290</link>, <link linkend="ch0095s000000li0291">291</link>). A recent United States consensus document recommended routine evaluation of amoxicillin, clarithromycin, levofloxacin, metronidazole, and tetracycline when susceptibility testing is performed (<link linkend="ch0095s000000li0292">292</link>).</para>
      <sect2 id="ch0095s0024s0001">
        <title>LACTOBACILLUS, PEDIOCOCCUS, AND LEUCONOSTOC SPECIES</title>
        <anchor id="ch0095s000024a0002"/>
        <anchor id="ch0095s000000a0100"/>
        <para id="ch0095s000000p0146"><emphasis>Pediococcus</emphasis> spp., <emphasis>Leuconostoc</emphasis> spp., and most <emphasis>Lactobacillus</emphasis> spp. are intrinsically vancomycin resistant. <emphasis>Lactobacillus gasseri, Lactobacillus delbrueckii</emphasis>, and <emphasis>Lactobacillus acidophilus</emphasis> may be vancomycin susceptible (<link linkend="ch0095s000000li0293">293</link>–<link linkend="ch0095s000000li0296">296</link>).</para>
        <para id="ch0095s000000p0147"><emphasis>Lactobacillus</emphasis> spp. are generally resistant to metronidazole, aminoglycosides, and ciprofloxacin (<link linkend="ch0095s000000li0297">297</link>), but their MICs for penicillin and cephalosporins can vary (<link linkend="ch0095s000000li0293">293</link>–<link linkend="ch0095s000000li0296">296</link>, <link linkend="ch0095s000000li0298">298</link>). In a study of 85 blood isolates, MICs ranged from 0.06 μg/ml to 4 μg/ml for penicillin and from 0.25 to ≥256 μg/ml for ceftriaxone, with <emphasis>Lactobacillus casei</emphasis> and <emphasis>Lactobacillus rhamnosus</emphasis> being among the species with the least susceptibility to these agents (<link linkend="ch0095s000000li0296">296</link>). <emphasis>L. acidophilus</emphasis> is susceptible to penicillin and vancomycin, whereas <emphasis>L. rhamnosus</emphasis> and <emphasis>L. casei</emphasis> are resistant (<link linkend="ch0095s000000li0297">297</link>). Fluoroquinolones have poor activity against most <emphasis>Lactobacillus</emphasis> spp. (<link linkend="ch0095s000000li0293">293</link>, <link linkend="ch0095s000000li0294">294</link>, <link linkend="ch0095s000000li0296">296</link>, <link linkend="ch0095s000000li0298">298</link>).</para>
        <para id="ch0095s000000p0148"><emphasis>Leuconostoc</emphasis> spp. are usually susceptible to clindamycin and erythromycin, and penicillin MICs are generally less than 0.5 μg/ml (<link linkend="ch0095s000000li0298">298</link>–<link linkend="ch0095s000000li0300">300</link>). Ceftriaxone MICs have been shown to vary from 1 to &gt;128 μg/ml, and elevated imipenem MICs (&gt;0.5 μg/ml) and meropenem MICs (&gt;8 μg/ml) have been described (<link linkend="ch0095s000000li0298">298</link>–<link linkend="ch0095s000000li0300">300</link>). <emphasis>Leuconostoc</emphasis> spp. daptomycin MICs are low (&lt;0.5 μg/ml), and linezolid MICs range from 2 to 8.0 μg/ml (<link linkend="ch0095s000000li0301">301</link>).</para>
        <para id="ch0095s000000p0149"><emphasis>Pediococcus</emphasis> spp. are generally susceptible to clindamycin and erythromycin (<link linkend="ch0095s000000li0295">295</link>, <link linkend="ch0095s000000li0298">298</link>, <link linkend="ch0095s000000li0299">299</link>, <link linkend="ch0095s000000li0302">302</link>), but resistant strains have been reported (<link linkend="ch0095s000000li0299">299</link>). A penicillin MIC<subscript>90</subscript> of 0.5 μg/ml was reported for 49 isolates (<link linkend="ch0095s000000li0295">295</link>), but penicillin MICs as high as 2 μg/ml have been noted (<link linkend="ch0095s000000li0299">299</link>). MICs for ceftriaxone are generally ≥16 μg/ml; however, most isolates are very susceptible to imipenem (MICs of &lt;0.25 μg/ml) (<link linkend="ch0095s000000li0298">298</link>, <link linkend="ch0095s000000li0299">299</link>). <emphasis>Pediococcus</emphasis> spp. are resistant to ciprofloxacin (<link linkend="ch0095s000000li0298">298</link>, <link linkend="ch0095s000000li0299">299</link>, <link linkend="ch0095s000000li0302">302</link>). Gentamicin, which would only be used in combination therapy, has variable activity against isolates of all three genera (<link linkend="ch0095s000000li0295">295</link>, <link linkend="ch0095s000000li0298">298</link>, <link linkend="ch0095s000000li0299">299</link>, <link linkend="ch0095s000000li0302">302</link>).</para>
        <para id="ch0095s000000p0150">The medium recommended by CLSI for BMD testing of<emphasis>Lactobacillus</emphasis> spp., <emphasis>Pediococcus</emphasis> spp., and <emphasis>Leuconostoc</emphasis> spp. is CA-MHB-LHB (<link linkend="ch0095s000000a0033">Table 3</link>) (<link linkend="ch0095s000000li0006">6</link>). EUCAST provides MIC interpretative criteria for only <emphasis>Lactobacillus</emphasis> spp. as part of the Gram-positive anaerobes. Some have performed susceptibility testing by agar dilution using either unsupplemented MHA or BMHA (<link linkend="ch0095s000000li0298">298</link>). If testing by agar dilution, incubation in 5% CO<subscript>2</subscript> may be necessary to achieve sufficient growth.</para>
      </sect2>
      <sect2 id="ch0095s0024s0002">
        <title>LISTERIA MONOCYTOGENES</title>
        <anchor id="ch0095s000024a0003"/>
        <anchor id="ch0095s000000a0101"/>
        <para id="ch0095s000000p0151">Clinical isolates of<emphasis>L. monocytogenes</emphasis> remain susceptible to the drugs of choice, including ampicillin (or penicillin) and TMP-SMX. With the exception of occasional resistance to tetracyclines, expressed by a <emphasis>tetM</emphasis> or <emphasis>tetS</emphasis> gene, and ciprofloxacin, mediated by active efflux (<link linkend="ch0095s000000li0303">303</link>), <emphasis>L. monocytogenes</emphasis> is typically susceptible <emphasis>in vitro</emphasis> to other agents active against Gram-positive bacteria, including vancomycin and macrolides (<link linkend="ch0095s000000li0303">303</link>, <link linkend="ch0095s000000li0304">304</link>). Daptomycin MICs are elevated (MIC<subscript>90</subscript>, 4 μg/ml) and linezolid MICs range from 1 to 2 μg/ml (<link linkend="ch0095s000000li0304">304</link>). Although <emphasis>L. monocytogenes</emphasis> may appear susceptible to cephalosporins <emphasis>in vitro</emphasis>, these agents are not effective clinically.</para>
        <para id="ch0095s000000p0152">Antimicrobial susceptibilities of 2,862<emphasis>L. monocytogenes</emphasis> from national food surveillance conducted in China between 2012 and 2015 confirmed universal susceptibility to ampicillin, although 28 isolates were resitant to TMP-SMX (1%) (<link linkend="ch0095s000000li0305">305</link>). All isolates were susceptible to ciprofloxacin, gentamicin, meropenem, and vancomycin. Sporadic isolates were resistant to tetracycline (8.7%), erythromycin (2.2%), and chloramphenicol (0.8%). Whole-genome sequencing confirmed that TMP-SMX resistance was associated with the presence of a dihydrofolate reductase <emphasis>drfG</emphasis> gene. It is suggested that this resistance mechanism was acquired via mobile genetic elements from <emphasis>S. pyogenes</emphasis> (<link linkend="ch0095s000000li0305">305</link>). Other studies have recently reported resistance to one or more clinically relevant antibiotics in <emphasis>L. monocytogenes</emphasis> isolated from food and food processing environments (<link linkend="ch0095s000000li0306">306</link>). Overexpression of efflux systems has been shown to be selected for by the disinfectant benzalkonium chloride, used in commercial food production facilities (<link linkend="ch0095s000000li0307">307</link>). A recent study documented an increasing rate of unfavorable outcomes among adults with listerial meningitis in the Netherlands. These cases were associated with the emergence of the ST6 strain of <emphasis>L. monocytogenes</emphasis>, which displays reduced susceptibility to these disinfectants. ST6 strains harbor the multidrug efflux protein Emr, which is associated with quaternary ammonia tolerance, and also elevated MICs for gentamicin (0.125 mg/liter) and amoxicillin (0.25 mg/liter) as compared to wild-type strains (<link linkend="ch0095s000000li0308">308</link>).</para>
        <para id="ch0095s000000p0153"><emphasis>Listeria</emphasis> infections are generally treated empirically, and antimicrobial susceptibility testing is usually not necessary. Susceptibility-only breakpoints (<emphasis role="underline">&lt;</emphasis>2 μg/ml) are listed for ampicillin and penicillin in CLSI guidelines (<link linkend="ch0095s000000li0006">6</link>). EUCAST breakpoints differ slightly, with an MIC of <emphasis role="underline">&lt;</emphasis>1 mg/liter defining susceptibility for ampicillin and penicillin and &gt;1 mg/liter defining resistance (<link linkend="ch0095s000000li0002">2</link>). In addition, the CLSI TMP-SMX breakpoint for susceptibility is ≤0.25 μg/ml, whereas EUCAST defines a much lower cutoff of ≤0.06 μg/ml. CLSI recommends using CA-MHB-LHB for MIC testing, and EUCAST recommends MH-F. In addition to MIC breakpoints, EUCAST publishes disk diffusion interpretations for penicillin, ampicillin, meropenem, erythromycin, and TMP-SMX (<link linkend="ch0095s000000li0002">2</link>). It is important to remember that cephalosporins should not be tested or reported for <emphasis>L. monocytogenes</emphasis> because some isolates may, for example, have ceftriaxone MICs as low as 8 μg/ml, which could suggest false susceptibility (<link linkend="ch0095s000000li0309">309</link>). Because cephalosporins are frequently used empirically for the treatment of meningitis, the laboratory should quickly communicate smear or culture findings suspicious for <emphasis>Listeria</emphasis> whenever they occur.</para>
        <anchor id="ch0095s000000a0102"/>
        <beginpage pagenum="1513"/>
      </sect2>
      <sect2 id="ch0095s0024s0003">
        <title>MICROCOCCUS</title>
        <anchor id="ch0095s000024a0004"/>
        <anchor id="ch0095s000000a0103"/>
        <para id="ch0095s000000p0154">Limited data in the literature demonstrate<emphasis>Micrococcus</emphasis> spp. to be susceptible to many antimicrobial agents, although resistance to β-lactams and erythromycin has been reported (<link linkend="ch0095s000000li0310">310</link>, <link linkend="ch0095s000000li0311">311</link>). CLSI recently developed breakpoints for <emphasis>Micrococcus</emphasis> spp., which can be applied to <emphasis>Kocuria, Nesterenkonia, Dermacoccus</emphasis>, and <emphasis>Kytococcus</emphasis> spp.</para>
        <para id="ch0095s000000p0155">Isolates of<emphasis>Micrococcus</emphasis> can be tested in routine CA-MHB in ambient air (<link linkend="ch0095s000000li0006">6</link>). CLSI provides breakpoints for penicillin, vancomycin, erythromycin, and clindamycin. When test strains are isolated from sterile sites, laboratories should primarily test penicillin and vancomycin (<link linkend="ch0095s000000li0006">6</link>).</para>
      </sect2>
      <sect2 id="ch0095s0024s0004">
        <title>MORAXELLA CATARRHALIS</title>
        <anchor id="ch0095s000024a0005"/>
        <anchor id="ch0095s000000a0104"/>
        <para id="ch0095s000000p0156"><emphasis>M. catarrhalis</emphasis> has maintained a high degree of susceptibility to all antimicrobial agents that might be used to treat associated infections, with the exception of penicillinase-susceptible penicillins. More than 90% of <emphasis>M. catarrhalis</emphasis> isolates produce β-lactamase and are resistant to amoxicillin, ampicillin, and penicillin (<link linkend="ch0095s000000li0019">19</link>, <link linkend="ch0095s000000li0081">81</link>, <link linkend="ch0095s000000li0082">82</link>, <link linkend="ch0095s000000li0086">86</link>, <link linkend="ch0095s000000li0312">312</link>). These isolates remain susceptible to amoxicillin-clavulanic acid, which is often prescribed for <emphasis>M. catarrhalis</emphasis> infections.</para>
        <para id="ch0095s000000p0157">Most clinical isolates produce one of two types of β-lactamase: BRO-1 or BRO-2 (<link linkend="ch0095s000000li0312">312</link>, <link linkend="ch0095s000000li0313">313</link>). Both enzymes are encoded by chromosomal genes and are phenotypically identical and membrane associated. BRO-1-producing strains are more prevalent than BRO-2-producing strains, and ampicillin and penicillin MICs for BRO-1 are often higher (e.g., ≥4 μg/ml) than those for BRO-2 strains (e.g., <emphasis role="underline">&lt;</emphasis>0.5 μg/ml) (<link linkend="ch0095s000000li0312">312</link>–<link linkend="ch0095s000000li0314">314</link>). The clinical significance in response to β-lactamase-labile penicillins of BRO-2 strains is questionable. Resistance rates for TMP-SMX are less than 5% in most studies (<link linkend="ch0095s000000li0081">81</link>, <link linkend="ch0095s000000li0082">82</link>, <link linkend="ch0095s000000li0312">312</link>, <link linkend="ch0095s000000li0313">313</link>), although investigators reported that 18.5% of 314 isolates from 11 hospitals in Taiwan (<link linkend="ch0095s000000li0312">312</link>) and 11.4% of 140 isolates from 19 hospitals in China were resistant to TMP-SMX (<link linkend="ch0095s000000li0072">72</link>). A recent study from two county hospitals in China reported a resistance rate of 19.1% using EUCAST clinical breakpoints, and 10.1% using CLSI clinical breakpoints (<link linkend="ch0095s000000li0315">315</link>). Resistance to macrolides and tetracyclines is generally low (&lt;1% from isolates in the Western Hemisphere in 2009–2011) (<link linkend="ch0095s000000li0075">75</link>, <link linkend="ch0095s000000li0083">83</link>, <link linkend="ch0095s000000li0086">86</link>, <link linkend="ch0095s000000li0312">312</link>). In the Asia-Pacific region, clarithromycin and tetracycline resistances were 7.6% and 3.2%, respectively, and the majority of nonsusceptible isolates were from China (<link linkend="ch0095s000000li0316">316</link>). A recent study from China reported tetracycline resistance at 16.4% (<link linkend="ch0095s000000li0072">72</link>).</para>
        <para id="ch0095s000000p0158">Only the chromogenic cephalosporin method has reliably detected the β-lactamases produced by<emphasis>M. catarrhalis</emphasis> (<link linkend="ch0095s000000li0317">317</link>). Routine β-lactamase testing may not be necessary because of the high incidence of β-lactamase-positive strains. Nevertheless, some advocate reporting of β-lactamase results to highlight the fact that this pathogen is generally unresponsive to some agents commonly prescribed for the treatment of respiratory tract infections (e.g., amoxicillin). MIC testing in the absence of β-lactamase testing can be problematic, as there is some overlap in ampicillin and amoxicillin MICs in β-lactamase-positive and -negative strains. Since <emphasis>M. catarrhalis</emphasis> typically responds to the drugs of choice, testing beyond the β-lactamase test is rarely indicated. CLSI document M45-A3 addresses MIC testing of <emphasis>M. catarrhalis</emphasis> (<link linkend="ch0095s000000li0006">6</link>). Recommendations for disk diffusion testing of amoxicillin-clavulanic acid, azithromycin, clarithromycin, erythromycin, tetracycline, and TMP-SMX using MHA and incubation in 5% CO<subscript>2</subscript> are included in CLSI M45-A3 (<link linkend="ch0095s000000a0033">Table 3</link>). EUCAST offers MIC and zone diameter breakpoints for <emphasis>M. catarrhalis.</emphasis> In contrast to CLSI guidelines, MIC breakpoints (≤1 μg/ml) are provided by EUCAST. In addition, the nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance, and isolates that are susceptible to nalidixic acid can be considered susceptible to ciprofloxacin, levofloxacin, moxifloxacin, and ofloxacin (<link linkend="ch0095s000000li0006">6</link>).</para>
      </sect2>
      <sect2 id="ch0095s0024s0005">
        <title>PASTEURELLA SPECIES</title>
        <anchor id="ch0095s000024a0006"/>
        <anchor id="ch0095s000000a0105"/>
        <para id="ch0095s000000p0159">Human isolates of<emphasis>Pasteurella</emphasis> spp. are generally susceptible to penicillin, with MICs of ≤0.5 μg/ml (<link linkend="ch0095s000000li0318">318</link>, <link linkend="ch0095s000000li0319">319</link>). Sporadic reports of human infections with β-lactamase-producing isolates demonstrated positive reactions with a nitrocefin-impregnated disk test, amoxicillin MICs of 8 to 64 μg/ml, and amoxicillin-clavulanic acid MICs of 0.25 to 1 μg/ml (<link linkend="ch0095s000000li0320">320</link>). <emphasis>Pasteurella</emphasis> spp. are generally very susceptible to antimicrobial agents commonly used for the treatment of acute bacterial skin and skin structure infections: a recent study documented very low MICs to cefazolin, ceftriaxone, ampicillin-sulbactam, ertapenem, azithromycin, doxycycline, and TMP-SMX among 156 <emphasis>Pasteurella</emphasis> spp. isolated from patients with animal bite wounds (<link linkend="ch0095s000000li0321">321</link>). No studies have documented resistance among clinical isolates for parenteral cephalosporins, fluoroquinolones, tetracyclines, chloramphenicol, or TMP-SMX (<link linkend="ch0095s000000li0318">318</link>, <link linkend="ch0095s000000li0319">319</link>). Resistance to erythromycin is fairly widespread, with reported MICs of 0.5 to 4 μg/ml (<link linkend="ch0095s000000li0318">318</link>), and there is at least one report of erythromycin failure with subsequent meningitis in a cat bite victim (<link linkend="ch0095s000000li0322">322</link>).</para>
        <para id="ch0095s000000p0160">BMD and disk diffusion methods are described by CLSI for testing<emphasis>Pasteurella</emphasis> spp. (<link linkend="ch0095s000000a0033">Table 3</link>). Similarly, EUCAST also provides guidance for MIC and disk diffusion testing. Due to the absence of nonsusceptible strains, CLSI only provides susceptible interpretive criteria for agents that might be tested, with the exception of erythromycin. In contrast, EUCAST provides resistant interpretative criteria for <emphasis>Pasteurella</emphasis> spp. and infers ampicillin and amoxicillin susceptibility based on the penicillin result. In addition, the nalidixic acid disk diffusion test can also be set up to screen for fluoroquinolone susceptibility, as described for <emphasis>M. catarrhalis</emphasis> (<link linkend="ch0095s000000li0322">322</link>).</para>
        <para id="ch0095s000000p0161">Susceptibility testing may be warranted for isolates from normally sterile sites, and β-lactamase testing should be performed on these isolates as well as those from respiratory sources (<link linkend="ch0095s000000li0006">6</link>). Testing of isolates recovered from bite wounds is not necessary, as they are generally treated empirically with agents that would cover a variety of organisms likely to be implicated in the infection (e.g., amoxicillin-clavulanic acid).</para>
      </sect2>
      <sect2 id="ch0095s0024s0006">
        <title>ROTHIA MUCILAGINOSA</title>
        <anchor id="ch0095s000024a0007"/>
        <anchor id="ch0095s000000a0106"/>
        <para id="ch0095s000000p0162">Limited data exist in the literature regarding susceptibility of<emphasis>R. mucilaginosa.</emphasis> Resistance to β-lactams, clindamycin, erythromycin, and fluoroquinolones has been reported (<link linkend="ch0095s000000li0310">310</link>). A recent report from the Mayo Clinic documented difficulty in testing <emphasis>R. mucilaginosa</emphasis> on MHA-LHB by agar dilution, with only a quarter of isolates demonstrating sufficient growth. Of those tested, all were susceptible to penicillin (9/9) and vancomycin (13/13) (<link linkend="ch0095s000000li0323">323</link>).</para>
        <anchor id="ch0095s000000a0107"/>
        <beginpage pagenum="1514"/>
        <para id="ch0095s000000p0163">Isolates of<emphasis>R. mucilaginosa</emphasis> are generally fastidious, and testing must be performed on blood-supplemented media to obtain adequate growth. CLSI recommends CA-MHB-LHB (<link linkend="ch0095s000000li0006">6</link>). CLSI provides breakpoints for penicillin, vancomycin, erythromycin, clindamycin, levofloxacin, and TMP-SMX. When test organisms are isolated from sterile sites, laboratories should primarily test penicillin and vancomycin (<link linkend="ch0095s000000li0006">6</link>).</para>
      </sect2>
      <sect2 id="ch0095s0024s0007">
        <title>VIBRIO SPECIES</title>
        <anchor id="ch0095s000024a0008"/>
        <anchor id="ch0095s000000a0108"/>
        <para id="ch0095s000000p0164">Both<emphasis>Vibrio cholerae</emphasis> and the non-cholera <emphasis>Vibrio</emphasis> spp. are often susceptible to most antimicrobial agents, including newer cephalosporins, aminoglycosides, fluoroquinolones, and tetracyclines; however, resistance to one or more of these can occur (<link linkend="ch0095s000000li0324">324</link>).</para>
        <para id="ch0095s000000p0165">Historically, resistance in<emphasis>V. cholerae</emphasis> emerged via spontaneous mutation to the targets of individual antimicrobial agents. However, more recently, antimicrobial resistance has been facilitated by horizontal gene transfer (<link linkend="ch0095s000000li0325">325</link>). Multidrug-resistant <emphasis>V. cholerae</emphasis> has been attributed to the presence of genetic elements harbored on a R plasmid (<link linkend="ch0095s000000li0326">326</link>), whereas the integrating conjugative resistance element SXT, which encodes resistance to trimethoprim, sulfamethoxazole, and streptomycin, has been observed among <emphasis>V. cholerae</emphasis> strains from multiple cholera outbreaks (<link linkend="ch0095s000000li0324">324</link>, <link linkend="ch0095s000000li0327">327</link>). Antimicrobial susceptibility testing of 550 <emphasis>V. cholerae</emphasis> El Tor biotype O1 organisms isolated in China between 1961 and 2010 documented significant increases in resistance to TMP-SMX (from 0 to 38.5%), tetracycline (from 0 to 89%), and nalidixic acid (0 to 45.9%) (<link linkend="ch0095s000000li0328">328</link>). In contrast, a study of 340 <emphasis>V. cholerae</emphasis> O139 isolates in China between 1993 and 2009 displayed high rates of resistance to nalidixic acid (83.1%), tetracycline (83.4%), azithromycin (50.3%), and TMP-SMX (90.7%) (<link linkend="ch0095s000000li0329">329</link>). A <emphasis>V. cholerae</emphasis> El Tor Ogawa strain was isolated from a child in India that harbored both the <emphasis>bla</emphasis><subscript><emphasis>DHA</emphasis></subscript> and <emphasis>bla</emphasis><subscript><emphasis>NDM-1</emphasis></subscript> genes, with resistance to third-generation cephalosporins detected by Etest and agar dilution (<link linkend="ch0095s000000li0330">330</link>).</para>
        <para id="ch0095s000000p0166">When a double-blind randomized study was conducted to compare the equivalence of azithromycin and ciprofloxacin, 78% of 97 patients had a bacteriologic cure with azithromycin, compared with only 10% of 98 patients who received ciprofloxacin. The 168 isolates from these patients were susceptible to both azithromycin and ciprofloxacin when tested by disk diffusion and Etest, but the median ciprofloxacin MIC for 91<emphasis>V. cholerae</emphasis> serogroup O1 isolates was 0.25 μg/ml, which is significantly above the wild-type MIC (<link linkend="ch0095s000000li0331">331</link>). The elevated MICs and poor outcomes suggest the possibility of a resistance mechanism not detectable when the CLSI breakpoint of ≤1 μg/ml is used to define ciprofloxacin susceptibility. Isolates from the 2010 Haitian <emphasis>V. cholerae</emphasis> O1 outbreak were found to have reduced susceptibility to ciprofloxacin (0.25 to 1.0 μg/ml), which was associated with mutation to the QRDR region of <emphasis>gyrA</emphasis> and <emphasis>parC</emphasis> (<link linkend="ch0095s000000li0332">332</link>). Recently published EUCAST breakpoints for <emphasis>Vibrio</emphasis> indicate ≤0.25 mg/liter as the cutoff for susceptibility to ciprofloxacin and levofloxacin.</para>
        <para id="ch0095s000000p0167">Since 2009, the CDC has been annually tracking antimicrobial resistance in<emphasis>Vibrio</emphasis> spp. other than <emphasis>V. cholerae.</emphasis> In each year studied, <emphasis>Vibrio parahaemolyticus</emphasis> represented the largest number of isolates submitted to the CDC for testing, followed by <emphasis>Vibrio alginolyticus</emphasis> and <emphasis>Vibrio vulnificus.</emphasis> Fewer than 50 isolates of other species were submitted for testing. In 2019, 96% of <emphasis>V. alginolyticus</emphasis> were resistant to ampicillin, in contrast to 49% of <emphasis>V. parahaemolyticus</emphasis> and 4% of <emphasis>V. vulnificus.</emphasis> No isolates of <emphasis>Vibrio</emphasis> spp. tested were resistant to ceftazidime or quinolones, and 0.3% of isolates were resistant to TMP-SMX and tetracycline (<link linkend="ch0095s000000li0223">223</link>).</para>
        <para id="ch0095s000000p0168">Antibiotics (primarily azithromycin or ciprofloxacin) are given to patients with cholera after fluid restoration and vomiting has ceased. These have been shown to reduce the total volume of stool passed and to shorten the duration of fecal excretion of<emphasis>V. cholerae.</emphasis> Although the non-cholera <emphasis>Vibrio</emphasis> spp. cause diarrheal disease, otherwise healthy individuals with diarrhea due to these bacteria usually recover spontaneously without treatment. When <emphasis>Vibrio</emphasis> spp. are isolated from sources associated with serious infections, antimicrobial susceptibility testing is warranted. Both CLSI and EUCAST suggest BMD or disk diffusion using methodologies similar to those for testing <emphasis>Enterobacterales.</emphasis> For testing of the halophilic <emphasis>Vibrio</emphasis> spp., some have suggested use of MHA containing 1% NaCl. However, CLSI recommends preparation of the inoculum suspension in 0.85% NaCl solution for both disk diffusion and BMD MIC testing with MHA or CA-MHB (both without NaCl supplementation), respectively (<link linkend="ch0095s000000li0006">6</link>).</para>
      </sect2>
      <sect2 id="ch0095s0024s0008">
        <title>CONCLUSION</title>
        <anchor id="ch0095s000024a0009"/>
        <anchor id="ch0095s000000a0109"/>
        <para id="ch0095s000000p0169">With the exception of serious streptococcal infections, extraintestinal<emphasis>Aeromonas</emphasis> or <emphasis>Vibrio</emphasis> infections, and device-associated coryneform infections, infections caused by many of the fastidious bacteria discussed in this chapter are treated empirically, as these bacteria are often susceptible to the drugs of choice. Consequently, susceptibility testing is infrequently needed for many of these organisms. In certain circumstances, testing may be warranted, such as when there appears to be clinical failure, patient intolerance to the drug(s) of choice, or serious infections for which there are limited appropriate drugs that might be prescribed. Additionally, susceptibility testing may aid in species identification (e.g., differentiating <emphasis>C. jeikeium</emphasis> from other <emphasis>Corynebacterium</emphasis> spp.). If a caregiver seems unsure about requesting antimicrobial susceptibility testing on a fastidious organism, he/she should be encouraged to seek assistance from an infectious diseases clinician or pharmacist.</para>
        <para id="ch0095s000000p0170">Requests for susceptibility testing of fastidious bacteria are often for isolates associated with serious infections, and MIC results are likely to be more useful than qualitative results. The disk diffusion test should be used only for bacteria for which there are CLSI or EUCAST interpretive criteria. It is important for laboratory workers to maintain an awareness of the methods available for testing fastidious bacteria and their strengths and limitations. If testing must be performed, it should be done by a laboratory that has validated the susceptibility methods used for the organism to be tested.</para>
      </sect2>
      <sect2 id="ch0095s0024s0009">
        <title>REFERENCES</title>
        <anchor id="ch0095s000024a0010"/>
        <anchor id="ch0095s000000a0110"/>
        <anchor id="ch0095s000000a0111"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0095s000000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 11th ed. Approved standard M07-A11. CLSI, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0095s000000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">EUCAST.</emphasis> 2022. European Commitee on Antimicrobial Susceptibility Testing breakpoint tables for interpretation of MICs and zone diameters, version 12.0. <ulink url="https://www.eucast.org/clinical_breakpoints">https://www.eucast.org/clinical_breakpoints</ulink>. Accessed March 9 2023.</para>
          </listitem>
          <listitem id="ch0095s000000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">ISO.</emphasis> 2019. <citetitle><emphasis>ISO 20776-1: Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility devices.</emphasis></citetitle> International Organization for Standardization, Geneva, Switzerland.</para>
          </listitem>
          <listitem id="ch0095s000000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2018. Performance standards for antimicrobial disk susceptibility tests. 13th ed. Approved standard M02-A13. CLSI, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0095s000000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2022. <citetitle><emphasis>Performance standards for antimicrobial susceptibility testing. 27th Informational Supplement, M100S.</emphasis></citetitle> 32nd ed. CLSI, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0095s000000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2016. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. 3rd ed. Approved guideline M45-A3. CLSI, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0095s000000li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">EUCAST.</emphasis> 2021. Antimicrobial susceptibility tests on groups of organisms or agents for which there are no EUCAST breakpoints. <ulink url="https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/When_there_are_no_breakpoints_Guidance_1_Dec_2021.pdf">https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/When_there_are_no_breakpoints_Guidance_1_Dec_2021.pdf</ulink>. Accessed 19 June 2022.</para>
          </listitem>
          <listitem id="ch0095s000000li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Hakenbeck R, Brückner R, Denapaite D, Maurer P.</emphasis> 2012. Molecular mechanisms of β-lactam resistance in <citetitle><emphasis>Streptococcus pneumoniae. Future Microbiol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>395–410.</para>
          </listitem>
          <listitem id="ch0095s000000li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Kim L, McGee L, Tomczyk S, Beall B.</emphasis> 2016. Biological and epidemiological features of antibiotic-resistant <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle> in pre- and post-conjugate vaccine eras: a United States perspective. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">29:</emphasis>525–552.</para>
          </listitem>
          <listitem id="ch0095s000000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Link-Gelles R, Thomas A, Lynfield R, Petit S, Schaffner W, Harrison L, Farley MM, Aragon D, Nicols M, Kirley PD, Zansky S, Jorgensen J, Juni BA, Jackson D, Moore MR, Lipsitch M.</emphasis> 2013. Geographic and temporal trends in antimicrobial nonsusceptibility in <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle> in the post-vaccine era in the United States. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">208:</emphasis>1266–1273.</para>
          </listitem>
          <listitem id="ch0095s000000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Wroe PC, Lee GM, Finkelstein JA, Pelton SI, Hanage WP, Lipsitch M, Stevenson AE, Rifas-Shiman SL, Kleinman K, Dutta-Linn MM, Hinrichsen VL, Lakoma M, Huang SS.</emphasis> 2012. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">31:</emphasis>249–254.</para>
          </listitem>
          <listitem id="ch0095s000000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Lo SW, Gladstone RA, van Tonder AJ, Lees JA, du Plessis M, Benisty R, Givon-Lavi N, Hawkins PA, Cornick JE, Kwambana-Adams B, Law PY, Ho PL, Antonio M, Everett DB, Dagan R, von Gottberg A, Klugman KP, McGee L, Breiman RF, Bentley SD, Global Pneumococcal Sequencing Consortium.</emphasis> 2019. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">19:</emphasis>759–769.</para>
          </listitem>
          <listitem id="ch0095s000000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Weinstein MP, Klugman KP, Jones RN.</emphasis> 2009. Rationale for revised penicillin susceptibility breakpoints versus <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle>: coping with antimicrobial susceptibility in an era of resistance. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1596–1600.</para>
          </listitem>
          <listitem id="ch0095s000000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">CDC.</emphasis> 2019. Active bacterial core surveillance report, Emerging Infections Program Network, <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle>, 2019. Centers for Disease Control, Atlanta, GA.</para>
          </listitem>
          <listitem id="ch0095s000000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Sader HS, Mendes RE, Le J, Denys G, Flamm RK, Jones RN.</emphasis> 2019. Antimicrobial susceptibility of <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle> from North America, Europe, Latin America, and the Asia-Pacific Region: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). <citetitle><emphasis>Open Forum Infect Dis</emphasis></citetitle> <emphasis role="strong">6</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S14–S23.</para>
          </listitem>
          <listitem id="ch0095s000000li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Nagai K, Davies TA, Jacobs MR, Appelbaum PC.</emphasis> 2002. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1273–1280.</para>
          </listitem>
          <listitem id="ch0095s000000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Pfaller MA, Mendes RE, Flamm RK, Jones RN, Sader HS.</emphasis> 2017. Ceftaroline activity against multidrug-resistant Streptococcus pneumoniae from U.S. medical centers (2014) and molecular characterization of a single ceftaroline nonsusceptible isolate. <citetitle><emphasis>Microb Drug Resist</emphasis></citetitle> <emphasis role="strong">23:</emphasis>571–579.</para>
          </listitem>
          <listitem id="ch0095s000000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG, Active Bacterial Core Surveillance of the Emerging Infections Program Network.</emphasis> 2006. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant <citetitle><emphasis>Streptococcus pneumoniae. N Engl J Med</emphasis></citetitle> <emphasis role="strong">354:</emphasis>1455–1463.</para>
          </listitem>
          <listitem id="ch0095s000000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Hu F, Zhu D, Wang F, Morrissey I, Wang J, Torumkuney D.</emphasis> 2016. Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 and 2013-14 in China. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">71</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>i33–i43.</para>
          </listitem>
          <listitem id="ch0095s000000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Peyrani P, Mandell L, Torres A, Tillotson GS.</emphasis> 2019. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. <citetitle><emphasis>Expert Rev Respir Med</emphasis></citetitle> <emphasis role="strong">13:</emphasis>139–152.</para>
          </listitem>
          <listitem id="ch0095s000000li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echagüen A, Gareen IF, Reiss PT, Medeiros AA.</emphasis> 2002. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant <citetitle><emphasis>Streptococcus pneumoniae. Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">35:</emphasis>556–564.</para>
          </listitem>
          <listitem id="ch0095s000000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Jorgensen JH, McElmeel ML, Fulcher LC, McGee L, Glennen A.</emphasis> 2011. Evaluation of disk approximation and single-well broth tests for detection of inducible clindamycin resistance in <citetitle><emphasis>Streptococcus pneumoniae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>3332–3333.</para>
          </listitem>
          <listitem id="ch0095s000000li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Patel SN, McGeer A, Melano R, Tyrrell GJ, Green K, Pillai DR, Low DE, Canadian Bacterial Surveillance Network.</emphasis> 2011. Susceptibility of <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle> to fluoroquinolones in Canada. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>3703–3708.</para>
          </listitem>
          <listitem id="ch0095s000000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Adam HJ, Baxter MR, Davidson RJ, Rubinstein E, Fanella S, Karlowsky JA, Lagacé-Wiens PR, Hoban DJ, Zhanel GG, Zhanel GG, Hoban DJ, Adam HJ, Karlowsky JA, Baxter MR, Nichol KA, Lagace-Wiens PRS, Walkty A, Canadian Antimicrobial Resistance Alliance (CARA).</emphasis> 2013. Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">68</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>i31–i37.</para>
          </listitem>
          <listitem id="ch0095s000000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Cools F, Delputte P, Cos P.</emphasis> 2021. The search for novel treatment strategies for <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle> infections. <citetitle><emphasis>FEMS Microbiol Rev</emphasis></citetitle> <emphasis role="strong">45:</emphasis>fuaa072.</para>
          </listitem>
          <listitem id="ch0095s000000li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S, Sader HS.</emphasis> 2016. In vitro activity of lefamulin tested against <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle> with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>4407–4411.</para>
          </listitem>
          <listitem id="ch0095s000000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Humphries R, Bobenchik AM, Hindler JA, Schuetz AN.</emphasis> 2021. Overview of changes to the Clinical and Laboratory Standards Institute Performance Standards for antimicrobial susceptibility testing, M100, 31st edition. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59</emphasis><emphasis role="strong">:</emphasis>e0021321.</para>
          </listitem>
          <listitem id="ch0095s000000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Jorgensen JH, Ferraro MJ, McElmeel ML, Spargo J, Swenson JM, Tenover FC.</emphasis> 1994. Detection of penicillin and extended-spectrum cephalosporin resistance among <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle> clinical isolates by use of the E test. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">32:</emphasis>159–163.</para>
          </listitem>
          <listitem id="ch0095s000000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Mittman SA, Huard RC, Della-Latta P, Whittier S.</emphasis> 2009. Comparison of BD Phoenix to VITEK 2, Microscan MICroSTREP, and Etest for antimicrobial susceptibility testing of <citetitle><emphasis>Streptococcus pneumoniae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3557–3561.</para>
          </listitem>
          <listitem id="ch0095s000000li0030" role="bibliographyEntry">
            <anchor id="ch0095s000000a0112"/>
            <para>30.<emphasis role="strong">Jorgensen JH, Barry AL, Traczewski MM, Sahm DF, McElmeel ML, Crawford SA.</emphasis> 2000. Rapid automated antimicrobial susceptibility testing of <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle> by use of the bioMérieux VITEK 2. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>2814–2818.</para>
          </listitem>
          <listitem id="ch0095s000000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Richter SS, Howard WJ, Weinstein MP, Bruckner DA, Hindler JF, Saubolle M, Doern GV.</emphasis> 2007. Multicenter evaluation of the BD Phoenix Automated Microbiology System for antimicrobial susceptibility testing of <citetitle><emphasis>Streptococcus</emphasis></citetitle> species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2863–2871.</para>
          </listitem>
          <listitem id="ch0095s000000li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Dahesh S, Hensler ME, Van Sorge NM, Gertz RE Jr, Schrag S, Nizet V, Beall BW.</emphasis> 2008. Point mutation in the group B streptococcal <citetitle><emphasis>pbp2x</emphasis></citetitle> gene conferring decreased susceptibility to beta-lactam antibiotics. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">52:</emphasis>2915–2918.</para>
          </listitem>
          <listitem id="ch0095s000000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Fuursted K, Stegger M, Hoffmann S, Lambertsen L, Andersen PS, Deleuran M, Thomsen MK.</emphasis> 2016. Description and characterization of a penicillin-resistant <citetitle><emphasis>Streptococcus dysgalactiae</emphasis></citetitle> subsp. <citetitle><emphasis>equisimilis</emphasis></citetitle> clone isolated from blood in three epidemiologically linked patients. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">71:</emphasis>3376–3380.</para>
          </listitem>
          <listitem id="ch0095s000000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Metcalf BJ, Chochua S, Gertz RE, Jr, Hawkins PA, Ricaldi J, Li Z, Walker H, Tran T, Rivers J, Mathis S, Jackson D, Glennen A, Lynfield R, McGee L, Beall B, Active Bacterial Core Surveillance Team.</emphasis> 2017. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive <citetitle><emphasis>Streptococcus agalactiae</emphasis></citetitle> recovered in the USA. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">23:</emphasis>574.e7–574.e14.</para>
          </listitem>
          <listitem id="ch0095s000000li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Vannice KS, Ricaldi J, Nanduri S, Fang FC, Lynch JB, Bryson-Cahn C, Wright T, Duchin J, Kay M, Chochua S, Van Beneden CA, Beall B.</emphasis> 2020. Streptococcus pyogenes pbp2x mutation confers reduced susceptibility to β-lactam antibiotics. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">71:</emphasis>201–204.</para>
          </listitem>
          <listitem id="ch0095s000000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N, Nagano N, Kato H, Shibayama K, Arakawa Y.</emphasis> 2008. First molecular characterization of group B streptococci with reduced penicillin susceptibility. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">52:</emphasis>2890–2897.</para>
          </listitem>
          <listitem id="ch0095s000000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Kimura K, Nagano N, Nagano Y, Suzuki S, Wachino J, Shibayama K, Arakawa Y.</emphasis> 2013. High frequency of fluoroquinolone- and macrolide-resistant streptococci among clinically isolated group B streptococci with reduced penicillin susceptibility. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">68:</emphasis>539–542.</para>
          </listitem>
          <listitem id="ch0095s000000li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Hays C, Louis M, Plainvert C, Dmytruk N, Touak G, Trieu-Cuot P, Poyart C, Tazi A.</emphasis> 2016. Changing epidemiology of group B streptococcus susceptibility to fluoroquinolones and aminoglycosides in France. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>7424–7430.</para>
          </listitem>
          <listitem id="ch0095s000000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Flamm RK, Mendes RE, Hogan PA, Streit JM, Ross JE, Jones RN.</emphasis> 2016. Linezolid surveillance results for the United States (LEADER Surveillance Program 2014). <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>2273–2280.</para>
          </listitem>
          <listitem id="ch0095s000000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Nanduri SA, Petit S, Smelser C, Apostol M, Alden NB, Harrison LH, Lynfield R, Vagnone PS, Burzlaff K, Spina NL, Dufort EM, Schaffner W, Thomas AR, Farley MM, Jain JH, Pondo T, McGee L, Beall BW, Schrag SJ.</emphasis> 2019. Epidemiology of invasive early-onset and late-onset group B streptococcal disease in the United States, 2006 to 2015: multistate laboratory and population-based surveillance. <citetitle><emphasis>JAMA Pediatr</emphasis></citetitle> <emphasis role="strong">173:</emphasis>224–233.</para>
          </listitem>
          <listitem id="ch0095s000000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Fay K, Onukwube J, Chochua S, Schaffner W, Cieslak P, Lynfield R, Muse A, Smelser C, Harrison LH, Farley M, Petit S, Alden N, Apostal M, Snippes Vagnone P, Nanduri S, Beall B, Van Beneden CA.</emphasis> 2021. Patterns of antibiotic nonsusceptibility among invasive group A Streptococcus infections—United States, 2006-2017. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>1957–1964.</para>
          </listitem>
          <listitem id="ch0095s000000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Ma A, Thompson LA, Corsiatto T, Hurteau D, Tyrrell GJ.</emphasis> 2021. Epidemiological characterization of group B streptococcus infections in Alberta, Canada: an update from 2014 to 2020. <citetitle><emphasis>Microbiol Spectr</emphasis></citetitle> <emphasis role="strong">9</emphasis><emphasis role="strong">:</emphasis>e0128321.</para>
          </listitem>
          <listitem id="ch0095s000000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Vuillemin X, Hays C, Plainvert C, Dmytruk N, Louis M, Touak G, Saint-Pierre B, Adoux L, Letourneur F, Frigo A, Poyart C, Tazi A.</emphasis> 2021. Invasive group B Streptococcus infections in non-pregnant adults: a retrospective study, France, 2007-2019. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">27:</emphasis>129.e1–129.e4.</para>
          </listitem>
          <listitem id="ch0095s000000li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Park C, Nichols M, Schrag SJ.</emphasis> 2014. Two cases of invasive vancomycin-resistant group B streptococcus infection. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">370:</emphasis>885–886.</para>
          </listitem>
          <listitem id="ch0095s000000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Sader HS, Flamm RK, Jones RN.</emphasis> 2013. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">75:</emphasis>417–422.</para>
          </listitem>
          <listitem id="ch0095s000000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagacé-Wiens PR, Walkty A, Karlowsky JA, Schweizer F, Hoban DJ, Zhanel GG, Hoban DJ, Adam HJ, Karlowsky JA, Baxter MR, Nichol KA, Lagace-Wiens PRS, Walkty A, Canadian Antimicrobial Resistance Alliance.</emphasis> 2013. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">68</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>i7–i22.</para>
          </listitem>
          <listitem id="ch0095s000000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Moet GJ, Dowzicky MJ, Jones RN.</emphasis> 2007. Tigecycline (GAR-936) activity against <citetitle><emphasis>Streptococcus gallolyticus (bovis)</emphasis></citetitle> and viridans group streptococci. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">57:</emphasis>333–336.</para>
          </listitem>
          <listitem id="ch0095s000000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Jones RN, Ross JE, Castanheira M, Mendes RE.</emphasis> 2008. United States resistance surveillance results for linezolid (LEADER Program for 2007). <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">62:</emphasis>416–426.</para>
          </listitem>
          <listitem id="ch0095s000000li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Poyart C, Pierre C, Quesne G, Pron B, Berche P, Trieu-Cuot P.</emphasis> 1997. Emergence of vancomycin resistance in the genus <citetitle><emphasis>Streptococcus</emphasis></citetitle>: characterization of a <citetitle><emphasis>vanB</emphasis></citetitle> transferable determinant in <citetitle><emphasis>Streptococcus bovis. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">41:</emphasis>24–29.</para>
          </listitem>
          <listitem id="ch0095s000000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Krcmery V Jr, Spanik S, Trupl J.</emphasis> 1996. First report of vancomycin-resistant <citetitle><emphasis>Streptococcus mitis</emphasis></citetitle> bacteremia in a leukemic patient after prophylaxis with quinolones and during treatment with vancomycin. <citetitle><emphasis>J Chemother</emphasis></citetitle> <emphasis role="strong">8:</emphasis>325–326.</para>
          </listitem>
          <listitem id="ch0095s000000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Srinivasan V, Metcalf BJ, Knipe KM, Ouattara M, McGee L, Shewmaker PL, Glennen A, Nichols M, Harris C, Brimmage M, Ostrowsky B, Park CJ, Schrag SJ, Frace MA, Sammons SA, Beall B.</emphasis> 2014. <citetitle><emphasis>vanG</emphasis></citetitle> element insertions within a conserved chromosomal site conferring vancomycin resistance to <citetitle><emphasis>Streptococcus agalactiae</emphasis></citetitle> and <citetitle><emphasis>Streptococcus anginosus. MBio</emphasis></citetitle> <emphasis role="strong">5:</emphasis>e01386–e14.</para>
          </listitem>
          <listitem id="ch0095s000000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Du F, Lv X, Duan D, Wang L, Huang J.</emphasis> 2019. Characterization of a linezolid- and vancomycin-resistant <citetitle><emphasis>Streptococcus suis</emphasis></citetitle> isolate that harbors <citetitle><emphasis>optrA</emphasis></citetitle> and <citetitle><emphasis>vanG</emphasis></citetitle> operons. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">10:</emphasis>2026.</para>
          </listitem>
          <listitem id="ch0095s000000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Jones RN, Stilwell MG, Hogan PA, Sheehan DJ.</emphasis> 2007. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1491–1493.</para>
          </listitem>
          <listitem id="ch0095s000000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Sader HS, Streit JM, Fritsche TR, Jones RN.</emphasis> 2006. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">12:</emphasis>844–852.</para>
          </listitem>
          <listitem id="ch0095s000000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Streit JM, Steenbergen JN, Thorne GM, Alder J, Jones RN.</emphasis> 2005. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>574–578.</para>
          </listitem>
          <listitem id="ch0095s000000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Palacio F, Lewis JS II, Sadkowski L, Echevarria K, Jorgensen JH.</emphasis> 2011. Breakthrough bacteremia and septic shock due to <citetitle><emphasis>Streptococcus anginosus</emphasis></citetitle> resistant to daptomycin in a patient receiving daptomycin therapy. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>3639–3640.</para>
          </listitem>
          <listitem id="ch0095s000000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association, Infectious Diseases Society of America.</emphasis> 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. <citetitle><emphasis>Circulation</emphasis></citetitle> <emphasis role="strong">111:</emphasis>e394–e434.</para>
          </listitem>
          <listitem id="ch0095s000000li0058" role="bibliographyEntry">
            <anchor id="ch0095s000000a0113"/>
            <para>58.<emphasis role="strong">Galimand M, Lambert T, Gerbaud G, Courvalin P.</emphasis> 1999. High-level aminoglycoside resistance in the beta-hemolytic group G <citetitle><emphasis>Streptococcus</emphasis></citetitle> isolate BM2721. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">43:</emphasis>3008–3010.</para>
          </listitem>
          <listitem id="ch0095s000000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Brigante GR, Luzzaro FA, Pini B, Lombardi G, Sokeng G, Toniolo AQ.</emphasis> 2007. Drug susceptibility testing of clinical isolates of streptococci and enterococci by the Phoenix automated microbiology system. <citetitle><emphasis>BMC Microbiol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>46.</para>
          </listitem>
          <listitem id="ch0095s000000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Kim SJ, Uh Y, Jang IH, Lee KS, Park SD, Yoon KJ.</emphasis> 2011. Evaluation of the MicroScan MICroSTREP plus antimicrobial panel for testing β-hemolytic streptococci and viridans group streptococci. <citetitle><emphasis>Korean J Lab Med</emphasis></citetitle> <emphasis role="strong">31:</emphasis>185–190.</para>
          </listitem>
          <listitem id="ch0095s000000li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Kimura K, Nagano N, Nagano Y, Wachino J, Shibayama K, Arakawa Y.</emphasis> 2013. Ability of the VITEK(R) 2 system to detect group B streptococci with reduced penicillin susceptibility (PRGBS). <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">68:</emphasis>1442–1444.</para>
          </listitem>
          <listitem id="ch0095s000000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Ligozzi M, Bernini C, Bonora MG, De Fatima M, Zuliani J, Fontana R.</emphasis> 2002. Evaluation of the VITEK 2 system for identification and antimicrobial susceptibility testing of medically relevant gram-positive cocci. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1681–1686.</para>
          </listitem>
          <listitem id="ch0095s000000li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Jones RN, Johnson DM, Erwin ME, Beach ML, Biedenbach DJ, Pfaller MA, Quality Control Study Group.</emphasis> 1999. Comparative antimicrobial activity of gatifloxacin tested against <citetitle><emphasis>Streptococcus</emphasis></citetitle> spp. including quality control guidelines and etest method validation. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">34:</emphasis>91–98.</para>
          </listitem>
          <listitem id="ch0095s000000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Rosser SJ, Alfa MJ, Hoban S, Kennedy J, Harding GK.</emphasis> 1999. E test versus agar dilution for antimicrobial susceptibility testing of viridans group streptococci. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>26–30.</para>
          </listitem>
          <listitem id="ch0095s000000li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Chun S, Huh HJ, Lee NY.</emphasis> 2015. Species-specific difference in antimicrobial susceptibility among viridans group streptococci. <citetitle><emphasis>Ann Lab Med</emphasis></citetitle> <emphasis role="strong">35:</emphasis>205–211.</para>
          </listitem>
          <listitem id="ch0095s000000li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Farrell DJ, Morrissey I, Bakker S, Buckridge S, Felmingham D.</emphasis> 2005. Global distribution of TEM-1 and ROB-1 beta-lactamases in <citetitle><emphasis>Haemophilus influenzae. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>773–776.</para>
          </listitem>
          <listitem id="ch0095s000000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Trepod CM, Mott JE.</emphasis> 2005. Elucidation of essential and nonessential genes in the <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> Rd cell wall biosynthetic pathway by targeted gene disruption. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">49:</emphasis>824–826.</para>
          </listitem>
          <listitem id="ch0095s000000li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Barbosa AR, Giufrè M, Cerquetti M, Bajanca-Lavado MP.</emphasis> 2011. Polymorphism in ftsI gene and beta-lactam susceptibility in Portuguese <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> strains: clonal dissemination of beta-lactamase-positive isolates with decreased susceptibility to amoxicillin/clavulanic acid. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">66:</emphasis>788–796.</para>
          </listitem>
          <listitem id="ch0095s000000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Witherden EA, Montgomery J, Henderson B, Tristram SG.</emphasis> 2011. Prevalence and genotypic characteristics of beta-lactamase-negative ampicillin-resistant <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in Australia. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">66:</emphasis>1013–1015.</para>
          </listitem>
          <listitem id="ch0095s000000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Dabernat H, Delmas C.</emphasis> 2012. Epidemiology and evolution of antibiotic resistance of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in children 5 years of age or less in France, 2001-2008: a retrospective database analysis. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">31:</emphasis>2745–2753.</para>
          </listitem>
          <listitem id="ch0095s000000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Soyletir G, Altinkanat G, Gur D, Altun B, Tunger A, Aydemir S, Kayacan C, Aktas Z, Gunaydin M, Karadag A, Gorur H, Morrissey I, Torumkuney D.</emphasis> 2016. Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Turkey. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">71</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>i71–i83.</para>
          </listitem>
          <listitem id="ch0095s000000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Zhang Y, Zhang F, Wang H, Zhao C, Wang Z, Cao B, Du Y, Feng X, Hu Y, Hu B, Ji P, Liu Z, Liu Y, Liao W, Lu J, Sun H, Wang Z, Xu X, Xu X, Yang Q, Yu Y, Zhang R, Zhuo C.</emphasis> 2016. Antimicrobial susceptibility of <citetitle><emphasis>Streptococcus pneumoniae</emphasis></citetitle>, <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> and <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> isolated from community-acquired respiratory tract infections in China: results from the CARTIPS Antimicrobial Surveillance Program. <citetitle><emphasis>J Glob Antimicrob Resist</emphasis></citetitle> <emphasis role="strong">5:</emphasis>36–41.</para>
          </listitem>
          <listitem id="ch0095s000000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Potts CC, Rodriguez-Rivera LD, Retchless AC, Buono SA, Chen AT, Marjuki H, Blain AE, Wang X.</emphasis> 2022. Antimicrobial susceptibility survey of invasive <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in the United States in 2016. <citetitle><emphasis>Microbiol Spectr</emphasis></citetitle> <emphasis role="strong">10</emphasis><emphasis role="strong">:</emphasis>e0257921.</para>
          </listitem>
          <listitem id="ch0095s000000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Sader HS, Carvalhaes CG, Duncan LR, Shortridge D.</emphasis> 2020. Antimicrobial activity of ceftolozane-tazobactam and comparators against clinical isolates of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> from the United States and Europe. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">64:</emphasis>e00211–20.</para>
          </listitem>
          <listitem id="ch0095s000000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Paukner S, Sader HS, Ivezic-Schoenfeld Z, Jones RN.</emphasis> 2013. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>4489–4495.</para>
          </listitem>
          <listitem id="ch0095s000000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Pfaller MA, Huband MD, Rhomberg PR, Flamm RK.</emphasis> 2017. Surveillance of omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e00018–17.</para>
          </listitem>
          <listitem id="ch0095s000000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Resman F, Ristovski M, Forsgren A, Kaijser B, Kronvall G, Medstrand P, Melander E, Odenholt I, Riesbeck K.</emphasis> 2012. Increase of β-lactam-resistant invasive <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in Sweden, 1997 to 2010. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>4408–4415.</para>
          </listitem>
          <listitem id="ch0095s000000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Shiro H, Sato Y, Toyonaga Y, Hanaki H, Sunakawa K.</emphasis> 2015. Nationwide survey of the development of drug resistance in the pediatric field in 2000-2001, 2004, 2007, 2010, and 2012: evaluation of the changes in drug sensitivity of <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> and patients’ background factors. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">21:</emphasis>247–256.</para>
          </listitem>
          <listitem id="ch0095s000000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Kiedrowska M, Foryś WJ, Gołębiewska A, Waśko I, Ronkiewicz P, Kuch A, Wróbel-Pawelczyk I, Wroczyński M, Hryniewicz W, Skoczyńska A.</emphasis> 2022. Antimicrobial resistance among Haemophilus influenzae isolates responsible for lower respiratory tract infections in Poland, 2005-2019. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">41:</emphasis>961–969.</para>
          </listitem>
          <listitem id="ch0095s000000li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Lâm TT, Nürnberg S, Claus H, Vogel U.</emphasis> 2020. Molecular epidemiology of imipenem resistance in invasive <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> infections in Germany in 2016. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">75:</emphasis>2076–2086.</para>
          </listitem>
          <listitem id="ch0095s000000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Farrell DJ, Flamm RK, Jones RN, Sader HS.</emphasis> 2013. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">75:</emphasis>86–88.</para>
          </listitem>
          <listitem id="ch0095s000000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Pfaller MA, Farrell DJ, Sader HS, Jones RN.</emphasis> 2012. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>, and <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> in the United States. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">55</emphasis>(Suppl 3)<emphasis role="strong">:</emphasis>S187–S193.</para>
          </listitem>
          <listitem id="ch0095s000000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Sader HS, Flamm RK, Jones RN.</emphasis> 2013. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">76:</emphasis>61–68.</para>
          </listitem>
          <listitem id="ch0095s000000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Pfaller MA, Mendes RE, Castanheira M, Flamm RK, Jones RN, Sader HS.</emphasis> 2017. Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012-2014. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">36:</emphasis>486–491.</para>
          </listitem>
          <listitem id="ch0095s000000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Tsang RSW, Shuel M, Whyte K, Hoang L, Tyrrell G, Horsman G, Wylie J, Jamieson F, Lefebvre B, Haldane D, Gad RR, German GJ, Needle R.</emphasis> 2017. Antibiotic susceptibility and molecular analysis of invasive <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> in Canada, 2007 to 2014. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">72:</emphasis>1314–1319.</para>
          </listitem>
          <listitem id="ch0095s000000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Wang H, Chen M, Xu Y, Sun H, Yang Q, Hu Y, Cao B, Chu Y, Liu Y, Zhang R, Yu Y, Sun Z, Zhuo C, Ni Y, Hu B, Tan TY, Hsueh PR, Wang JH, Ko WC, Chen YH, Wahjono H.</emphasis> 2011. Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009-2010. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">38:</emphasis>376–383.</para>
          </listitem>
          <listitem id="ch0095s000000li0087" role="bibliographyEntry">
            <anchor id="ch0095s000000a0114"/>
            <para>87.<emphasis role="strong">Kuo SC, Chen PC, Shiau YR, Wang HY, Lai JF, Huang W, Lauderdale TL.</emphasis> 2014. Levofloxacin-resistant <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>, Taiwan, 2004-2010. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>1386–1390.</para>
          </listitem>
          <listitem id="ch0095s000000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">García-Cobos S, Arroyo M, Pérez-Vázquez M, Aracil B, Oteo J, Campos J.</emphasis> 2013. Evaluation of the EUCAST disc diffusion susceptibility testing method for <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> based on the resistance mechanism to β-lactam antibiotics. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">68:</emphasis>159–163.</para>
          </listitem>
          <listitem id="ch0095s000000li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Billal DS, Hotomi M, Yamanaka N.</emphasis> 2007. Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle>? <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>3463–3464.</para>
          </listitem>
          <listitem id="ch0095s000000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Rennie RP, Turnbull L, Brosnikoff C, Cloke J.</emphasis> 2012. First comprehensive evaluation of the M.I.C. evaluator device compared to Etest and CLSI reference dilution methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1153–1157.</para>
          </listitem>
          <listitem id="ch0095s000000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Skaare D, Lia A, Hannisdal A, Tveten Y, Matuschek E, Kahlmeter G, Kristiansen BE.</emphasis> 2015. <citetitle><emphasis>Haemophilus influenzae</emphasis></citetitle> with non-beta-lactamase-mediated beta-lactam resistance: easy to find but hard to categorize. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>3589–3595.</para>
          </listitem>
          <listitem id="ch0095s000000li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Barbee LA, St Cyr SB.</emphasis> 2022. Management of Neisseria gonorrhoeae in the United States: summary of evidence from the development of the 2020 Gonorrhea Treatment Recommendations and the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Treatment Guidelines. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">74</emphasis>(Suppl_2)<emphasis role="strong">:</emphasis>S95–S111.</para>
          </listitem>
          <listitem id="ch0095s000000li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS.</emphasis> 2020. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. <citetitle><emphasis>Int J STD AIDS</emphasis></citetitle> 2020. doi:10.1177/0956462420949126.</para>
          </listitem>
          <listitem id="ch0095s000000li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Romanowski B, Robinson J, Wong T.</emphasis> 2013. Gonococcal infections. <citetitle><emphasis>In Canadian guidelines on sexually transmitted infections.</emphasis></citetitle> Public Health Agency of Canada, Ottawa, ON. <ulink url="https://www.eucast.org/clinical_breakpoints">https://www.eucast.org/clinical_breakpoints</ulink>. Accessed March 9 2023.</para>
          </listitem>
          <listitem id="ch0095s000000li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM).</emphasis> 2021. Gonorrhoea. Australian STI Management Guidelines for Use in Primary Care. <ulink url="https://sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea/">https://sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea/</ulink>. Accessed March 9 2023.</para>
          </listitem>
          <listitem id="ch0095s000000li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">WHO.</emphasis> 2016. <citetitle><emphasis>WHO guidelines for the treatment of Neisseria gonorrhoeae.</emphasis></citetitle> WHO Press, Geneva, Switzerland.</para>
          </listitem>
          <listitem id="ch0095s000000li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Sathia L, Ellis B, Phillip S, Winston A, Smith A.</emphasis> 2007. Pharyngeal gonorrhoea—is dual therapy the way forward? <citetitle><emphasis>Int J STD AIDS</emphasis></citetitle> <emphasis role="strong">18:</emphasis>647–648.</para>
          </listitem>
          <listitem id="ch0095s000000li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Furuya R, Nakayama H, Kanayama A, Saika T, Iyoda T, Tatewaki M, Matsuzaki K, Kobayashi I, Tanaka M.</emphasis> 2006. In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of <citetitle><emphasis>Neisseria gonorrhoeae. J Infect Chemother</emphasis></citetitle> <emphasis role="strong">12:</emphasis>172–176.</para>
          </listitem>
          <listitem id="ch0095s000000li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, Unemo M.</emphasis> 2016. Failure of dual antimicrobial therapy in treatment of gonorrhea. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">374:</emphasis>2504–2506.</para>
          </listitem>
          <listitem id="ch0095s000000li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Ohnishi M, Ono E, Shimuta K, Watanabe H, Okamura N.</emphasis> 2010. Identification of TEM-135 beta-lactamase in penicillinase-producing <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> strains in Japan. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>3021–3023.</para>
          </listitem>
          <listitem id="ch0095s000000li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Osaka K, Takakura T, Narukawa K, Takahata M, Endo K, Kiyota H, Onodera S.</emphasis> 2008. Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> with reduced susceptibility to cefixime and ceftriaxone. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">14:</emphasis>195–203.</para>
          </listitem>
          <listitem id="ch0095s000000li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Ison CA, Town K, Obi C, Chisholm S, Hughes G, Livermore DM, Lowndes CM, GRASP Collaborative Group.</emphasis> 2013. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">13:</emphasis>762–768.</para>
          </listitem>
          <listitem id="ch0095s000000li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE.</emphasis> 2013. <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> treatment failure and susceptibility to cefixime in Toronto, Canada. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">309:</emphasis>163–170.</para>
          </listitem>
          <listitem id="ch0095s000000li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Pandori M, Barry PM, Wu A, Ren A, Whittington WL, Liska S, Klausner JD.</emphasis> 2009. Mosaic penicillin-binding protein 2 in <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> isolates collected in 2008 in San Francisco, California. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">53:</emphasis>4032–4034.</para>
          </listitem>
          <listitem id="ch0095s000000li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Lindberg R, Fredlund H, Nicholas R, Unemo M.</emphasis> 2007. <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in <citetitle><emphasis>penA</emphasis></citetitle>, <citetitle><emphasis>mtrR</emphasis></citetitle>, <citetitle><emphasis>porB1b</emphasis></citetitle>, and <citetitle><emphasis>ponA. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>2117–2122.</para>
          </listitem>
          <listitem id="ch0095s000000li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H.</emphasis> 2010. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">15:</emphasis>19721.</para>
          </listitem>
          <listitem id="ch0095s000000li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Day MJ, Jacobsson S, Spiteri G, Kulishev C, Sajedi N, Woodford N, Blumel B, van der Werf MJ, Amato-Gauci AJ, Unemo M, Cole MJ, Euro G,</emphasis> Euro-GASP network. 2022. Significant increase in azithromycin “resistance” and susceptibility to ceftriaxone and cefixime in <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> isolates in 26 European countries, 2019. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">22:</emphasis>524.</para>
          </listitem>
          <listitem id="ch0095s000000li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Yan J, Xue J, Chen Y, Chen S, Wang Q, Zhang C, Wu S, Lv H, Yu Y, van der Veen S.</emphasis> 2019. Increasing prevalence of <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> with decreased susceptibility to ceftriaxone and resistance to azithromycin in Hangzhou, China (2015-17). <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">74:</emphasis>29–37.</para>
          </listitem>
          <listitem id="ch0095s000000li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M.</emphasis> 2011. Is <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>3538–3545.</para>
          </listitem>
          <listitem id="ch0095s000000li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P.</emphasis> 2012. High-level cefixime- and ceftriaxone-resistant <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> in France: novel <citetitle><emphasis>penA</emphasis></citetitle> mosaic allele in a successful international clone causes treatment failure. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>1273–1280.</para>
          </listitem>
          <listitem id="ch0095s000000li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Unemo M, Golparian D, Limnios A, Whiley D, Ohnishi M, Lahra MM, Tapsall JW.</emphasis> 2012. In vitro activity of ertapenem versus ceftriaxone against <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>3603–3609.</para>
          </listitem>
          <listitem id="ch0095s000000li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">CDC.</emphasis> 2021. <citetitle><emphasis>Sexually Transmitted Disease Surveillance 2019: Gonococcal Isolate Surveillance Project (GISP) Supplement and Profiles.</emphasis></citetitle> U.S. Department of Health and Human Services, Atlanta, GA.</para>
          </listitem>
          <listitem id="ch0095s000000li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, Eremin SR, Bolan G, Unemo M.</emphasis> 2017. Antimicrobial resistance in <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle>: global surveillance and a call for international collaborative action. <citetitle><emphasis>PLoS Med</emphasis></citetitle> <emphasis role="strong">14</emphasis><emphasis role="strong">:</emphasis>e1002344.</para>
          </listitem>
          <listitem id="ch0095s000000li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Chisholm SA, Dave J, Ison CA.</emphasis> 2010. High-level azithromycin resistance occurs in <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> as a result of a single point mutation in the 23S rRNA genes. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>3812–3816.</para>
          </listitem>
          <listitem id="ch0095s000000li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Golparian D, Shafer WM, Ohnishi M, Unemo M.</emphasis> 2014. Importance of multidrug efflux pumps in the antimicrobial resistance property of clinical multidrug-resistant isolates of <citetitle><emphasis>Neisseria gonorrhoeae. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">58:</emphasis>3556–3559.</para>
          </listitem>
          <listitem id="ch0095s000000li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Tanaka M, Furuya R, Irie S, Kanayama A, Kobayashi I.</emphasis> 2015. High prevalence of azithromycin-resistant <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> isolates with a multidrug resistance phenotype in Fukuoka, Japan. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">42:</emphasis>337–341.</para>
          </listitem>
          <listitem id="ch0095s000000li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA, Van de Laar MJ.</emphasis> 2013. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. <citetitle><emphasis>Euro Surveill</emphasis></citetitle> <emphasis role="strong">18:</emphasis>20358.</para>
          </listitem>
          <listitem id="ch0095s000000li0118" role="bibliographyEntry">
            <anchor id="ch0095s000000a0115"/>
            <para>118.<emphasis role="strong">Liu H, Taylor TH Jr, Pettus K, Trees D.</emphasis> 2014. Assessment of Etest as an alternative to agar dilution for antimicrobial susceptibility testing of <citetitle><emphasis>Neisseria gonorrhoeae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>1435–1440.</para>
          </listitem>
          <listitem id="ch0095s000000li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Papp JR, Rowlinson MC, O’Connor NP, Wholehan J, Razeq JH, Glennen A, Ware D, Iwen PC, Lee LV, Hagan C.</emphasis> 2018. Accuracy and reproducibility of the Etest to detect drug-resistant <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> to contemporary treatment. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">67:</emphasis>68–73.</para>
          </listitem>
          <listitem id="ch0095s000000li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Raphael BH, Pham CD, Sharpe S, Mauk K, Harvey A, Khubbar M, Triplett L, Soge OO, Denny M, Palavecino EL, Finney R, Olsen A, Carlson J, St Cyr SB, Schlanger K, Kersh EN, Strengthening the US Response to Resistant Gonorrhea Working Group.</emphasis> 2021. Implementation and evaluation of gradient strip antimicrobial susceptibility testing in US public health laboratories to respond to resistant gonorrhea. <citetitle><emphasis>Sex Transm Dis</emphasis></citetitle> <emphasis role="strong">48</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>S157–S160.</para>
          </listitem>
          <listitem id="ch0095s000000li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Goire N, Ohnishi M, Limnios AE, Lahra MM, Lambert SB, Nimmo GR, Nissen MD, Sloots TP, Whiley DM.</emphasis> 2012. Enhanced gonococcal antimicrobial surveillance in the era of ceftriaxone resistance: a real-time PCR assay for direct detection of the <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> H041 strain. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">67:</emphasis>902–905.</para>
          </listitem>
          <listitem id="ch0095s000000li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Balashov S, Mordechai E, Adelson ME, Gygax SE.</emphasis> 2013. Multiplex bead suspension array for screening Neisseria gonorrhoeae antibiotic resistance genetic determinants in noncultured clinical samples. <citetitle><emphasis>J Mol Diagn</emphasis></citetitle> <emphasis role="strong">15:</emphasis>116–129.</para>
          </listitem>
          <listitem id="ch0095s000000li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Allan-Blitz LT, Humphries RM, Hemarajata P, Bhatti A, Pandori MW, Siedner MJ, Klausner JD.</emphasis> 2017. Implementation of a rapid genotypic assay to promote targeted ciprofloxacin therapy of <citetitle><emphasis>Neisseria gonorrhoeae</emphasis></citetitle> in a large health system. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">64:</emphasis>1268–1270.</para>
          </listitem>
          <listitem id="ch0095s000000li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">du Plessis M, Moodley C, Mothibeli KM, Fali A, Klugman KP, von Gottberg A, Group for Enteric, Respiratory and Meningeal Disease Surveillance–South Africa.</emphasis> 2012. Population snapshot of invasive serogroup B meningococci in South Africa from 2005 to 2008. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>2577–2584.</para>
          </listitem>
          <listitem id="ch0095s000000li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Harcourt BH, Anderson RD, Wu HM, Cohn AC, MacNeil JR, Taylor TH, Wang X, Clark TA, Messonnier NE, Mayer LW.</emphasis> 2015. Population-based surveillance of <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> antimicrobial resistance in the United States. <citetitle><emphasis>Open Forum Infect Dis</emphasis></citetitle> <emphasis role="strong">2:</emphasis>ofv117.</para>
          </listitem>
          <listitem id="ch0095s000000li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Ibarz-Pavón AB, Lemos AP, Gorla MC, Regueira M, Gabastou JM, SIREVA Working Group II.</emphasis> 2012. Laboratory-based surveillance of <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e44102.</para>
          </listitem>
          <listitem id="ch0095s000000li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Jorgensen JH, Crawford SA, Fiebelkorn KR.</emphasis> 2005. Susceptibility of <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>3162–3171.</para>
          </listitem>
          <listitem id="ch0095s000000li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Richter SS, Gordon KA, Rhomberg PR, Pfaller MA, Jones RN.</emphasis> 2001. <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-99. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">41:</emphasis>83–88.</para>
          </listitem>
          <listitem id="ch0095s000000li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Potts CC, Rodriguez-Rivera LD, Retchless AC, Hu F, Marjuki H, Blain AE, McNamara LA, Wang X.</emphasis> 2022. Antimicrobial susceptibility survey of invasive <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle>, United States 2012-2016. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">225:</emphasis>1871–1875.</para>
          </listitem>
          <listitem id="ch0095s000000li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Willerton L, Lucidarme J, Walker A, Lekshmi A, Clark SA, Walsh L, Bai X, Lee-Jones L, Borrow R.</emphasis> 2021. Antibiotic resistance among invasive <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> isolates in England, Wales and Northern Ireland (2010/11 to 2018/19). <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">16</emphasis><emphasis role="strong">:</emphasis>e0260677.</para>
          </listitem>
          <listitem id="ch0095s000000li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Vacca P, Fazio C, Neri A, Ambrosio L, Palmieri A, Stefanelli P.</emphasis> 2018. <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> antimicrobial resistance in Italy, 2006 to 2016. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">62:</emphasis>e00207–18.</para>
          </listitem>
          <listitem id="ch0095s000000li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Vázquez JA, Enriquez R, Abad R, Alcalá B, Salcedo C, Arreaza L.</emphasis> 2007. Antibiotic resistant meningococci in Europe: any need to act? <citetitle><emphasis>FEMS Microbiol Rev</emphasis></citetitle> <emphasis role="strong">31:</emphasis>64–70.</para>
          </listitem>
          <listitem id="ch0095s000000li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Brown EM, Fisman DN, Drews SJ, Dolman S, Rawte P, Brown S, Jamieson F.</emphasis> 2010. Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1016–1021.</para>
          </listitem>
          <listitem id="ch0095s000000li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Trotter CL, Fox AJ, Ramsay ME, Sadler F, Gray SJ, Mallard R, Kaczmarski EB.</emphasis> 2002. Fatal outcome from meningococcal disease—an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>855–860.</para>
          </listitem>
          <listitem id="ch0095s000000li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Manchanda V, Bhalla P.</emphasis> 2006. Emergence of non-ceftriaxone-susceptible <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> in India. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>4290–4291.</para>
          </listitem>
          <listitem id="ch0095s000000li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Deghmane AE, Hong E, Taha MK.</emphasis> 2017. Emergence of meningococci with reduced susceptibility to third-generation cephalosporins. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">72:</emphasis>95–98.</para>
          </listitem>
          <listitem id="ch0095s000000li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Taha MK, Hedberg ST, Szatanik M, Hong E, Ruckly C, Abad R, Bertrand S, Carion F, Claus H, Corso A, Enríquez R, Heuberger S, Hryniewicz W, Jolley KA, Kriz P, Mollerach M, Musilek M, Neri A, Olcén P, Pana M, Skoczynska A, Sorhouet Pereira C, Stefanelli P, Tzanakaki G, Unemo M, Vázquez JA, Vogel U, Wasko I.</emphasis> 2010. Multicenter study for defining the breakpoint for rifampin resistance in <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> by <citetitle><emphasis>rpoB</emphasis></citetitle> sequencing. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>3651–3658.</para>
          </listitem>
          <listitem id="ch0095s000000li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Skoczyńska A, Waśko I, Kuch A, Kadłubowski M, Gołębiewska A, Fory</emphasis>ś <emphasis role="strong">M, Markowska M, Ronkiewicz P, Wasiak K, Kozińska A, Matynia B, Hryniewicz W, participants of a laboratory-based surveillance of community acquired invasive bacterial infections (BINet).</emphasis> 2013. A decade of invasive meningococcal disease surveillance in Poland. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e71943.</para>
          </listitem>
          <listitem id="ch0095s000000li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">du Plessis M, de Gouveia L, Skosana H, Thomas J, Blumberg L, Klugman KP, von Gottberg A, GERMS-SA.</emphasis> 2010. Invasive <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> with decreased susceptibility to fluoroquinolones in South Africa, 2009. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">65:</emphasis>2258–2260.</para>
          </listitem>
          <listitem id="ch0095s000000li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Rodriguez CN, Rodriguez-Morales AJ, Garcia A, Pastran B, Rios A, Calvo A, Jimenez I, Meijomil P.</emphasis> 2005. Quinolone and azithromycin-resistant <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> serogroup C causing urethritis in a heterosexual man. <citetitle><emphasis>Int J STD AIDS</emphasis></citetitle> <emphasis role="strong">16:</emphasis>649–650.</para>
          </listitem>
          <listitem id="ch0095s000000li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Enríquez R, Abad R, Salcedo C, Pérez S, Vázquez JA.</emphasis> 2008. Fluoroquinolone resistance in <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> in Spain. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>286–290.</para>
          </listitem>
          <listitem id="ch0095s000000li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">McNamara LA, Potts C, Blain AE, Retchless AC, Reese N, Swint S, Lonsway D, Karlsson M, Lunquest K, Sweitzer JJ, Wang X, Hariri S, Fox LM, Dhungana N, Gabrio-Brannon R, Kyle J, Martin B, Barnes M, Moore A, Hannagan S, Keating P, Li S, Albertson J, Fleming W, Lurie P, Russell C, Reid K, Sanders K, DeBolt C, Graff N, Lam E, Hanisch B, Taormina G, Antimicrobial-Resistant Neisseria meningitidis Team.</emphasis> 2020. Detection of ciprofloxacin-resistant, β-lactamase-producing <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> serogroup Y isolates—United States, 2019-2020. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">69:</emphasis>735–739.</para>
          </listitem>
          <listitem id="ch0095s000000li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 10th ed. Approved standard M07-A10. CLSI, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0095s000000li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Pérez-Trallero E, Gomez N, García-Arenzana JM.</emphasis> 1994. E test as susceptibility test for evaluation of <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">32:</emphasis>2341–2342.</para>
          </listitem>
          <listitem id="ch0095s000000li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Vázquez JA, Arreaza L, Block C, Ehrhard I, Gray SJ, Heuberger S, Hoffmann S, Kriz P, Nicolas P, Olcen P, Skoczynska A, Spanjaard L, Stefanelli P, Taha M-K, Tzanakaki G.</emphasis> 2003. Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of <citetitle><emphasis>Neisseria meningitidis</emphasis></citetitle> infections. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3430–3434.</para>
          </listitem>
          <listitem id="ch0095s000000li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Ross CL, Thomason KS, Koehler TM.</emphasis> 2009. An extracytoplasmic function sigma factor controls beta-lactamase gene expression in <citetitle><emphasis>Bacillus anthracis</emphasis></citetitle> and other <citetitle><emphasis>Bacillus cereus</emphasis></citetitle> group species. <citetitle><emphasis>J Bacteriol</emphasis></citetitle> <emphasis role="strong">191:</emphasis>6683–6693.</para>
          </listitem>
          <listitem id="ch0095s000000li0147" role="bibliographyEntry">
            <anchor id="ch0095s000000a0116"/>
            <para>147.<emphasis role="strong">Stern EJUK, Shadomy SV, Messonnier N.</emphasis> 2008. Conference report on public health and clinical guidelines for anthrax. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">14:</emphasis>e1.</para>
          </listitem>
          <listitem id="ch0095s000000li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Choe CH, Bouhaouala SS, Brook I, Elliot TB, Knudson GB.</emphasis> 2000. In vitro development of resistance to ofloxacin and doxycycline in <citetitle><emphasis>Bacillus anthracis</emphasis></citetitle> Sterne. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1766.</para>
          </listitem>
          <listitem id="ch0095s000000li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Price LB, Vogler A, Pearson T, Busch JD, Schupp JM, Keim P.</emphasis> 2003. In vitro selection and characterization of <citetitle><emphasis>Bacillus anthracis</emphasis></citetitle> mutants with high-level resistance to ciprofloxacin. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">47:</emphasis>2362–2365.</para>
          </listitem>
          <listitem id="ch0095s000000li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Galimand M, Guiyoule A, Gerbaud G, Rasoamanana B, Chanteau S, Carniel E, Courvalin P.</emphasis> 1997. Multidrug resistance in <citetitle><emphasis>Yersinia pestis</emphasis></citetitle> mediated by a transferable plasmid. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">337:</emphasis>677–680.</para>
          </listitem>
          <listitem id="ch0095s000000li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Guiyoule A, Gerbaud G, Buchrieser C, Galimand M, Rahalison L, Chanteau S, Courvalin P, Carniel E.</emphasis> 2001. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of <citetitle><emphasis>Yersinia pestis. Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">7:</emphasis>43–48.</para>
          </listitem>
          <listitem id="ch0095s000000li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Urich SK, Chalcraft L, Schriefer ME, Yockey BM, Petersen JM.</emphasis> 2012. Lack of antimicrobial resistance in <citetitle><emphasis>Yersinia pestis</emphasis></citetitle> isolates from 17 countries in the Americas, Africa, and Asia. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>555–558.</para>
          </listitem>
          <listitem id="ch0095s000000li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Wagner DM, Runberg J, Vogler AJ, Lee J, Driebe E, Price LB, Engelthaler DM, Fricke WF, Ravel J, Keim P.</emphasis> 2010. No resistance plasmid in <citetitle><emphasis>Yersinia pestis</emphasis></citetitle>, North America. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">16:</emphasis>885–887.</para>
          </listitem>
          <listitem id="ch0095s000000li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Sarovich DS, Price EP, Von Schulze AT, Cook JM, Mayo M, Watson LM, Richardson L, Seymour ML, Tuanyok A, Engelthaler DM, Pearson T, Peacock SJ, Currie BJ, Keim P, Wagner DM.</emphasis> 2012. Characterization of ceftazidime resistance mechanisms in clinical isolates of <citetitle><emphasis>Burkholderia pseudomallei</emphasis></citetitle> from Australia. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e30789.</para>
          </listitem>
          <listitem id="ch0095s000000li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Sam IC, See KH, Puthucheary SD.</emphasis> 2010. Susceptibility of <citetitle><emphasis>Burkholderia pseudomallei</emphasis></citetitle> to tigecycline and other antimicrobials. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">67:</emphasis>308–309.</para>
          </listitem>
          <listitem id="ch0095s000000li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Schweizer HP.</emphasis> 2012. Mechanisms of antibiotic resistance in <citetitle><emphasis>Burkholderia pseudomallei</emphasis></citetitle>: implications for treatment of melioidosis. <citetitle><emphasis>Future Microbiol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>1389–1399.</para>
          </listitem>
          <listitem id="ch0095s000000li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo J-D.</emphasis> 2004. Antibiotic susceptibility of 65 isolates of <citetitle><emphasis>Burkholderia pseudomallei</emphasis></citetitle> and <citetitle><emphasis>Burkholderia mallei</emphasis></citetitle> to 35 antimicrobial agents. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1134–1138.</para>
          </listitem>
          <listitem id="ch0095s000000li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Sam IC, See KH, Puthucheary SD.</emphasis> 2009. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of <citetitle><emphasis>Burkholderia pseudomallei. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1556–1558.</para>
          </listitem>
          <listitem id="ch0095s000000li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Saiprom N, Amornchai P, Wuthiekanun V, Day NP, Limmathurotsakul D, Peacock SJ, Chantratita N.</emphasis> 2015. Trimethoprim/sulfamethoxazole resistance in clinical isolates of <citetitle><emphasis>Burkholderia pseudomallei</emphasis></citetitle> from Thailand. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">45:</emphasis>557–559.</para>
          </listitem>
          <listitem id="ch0095s000000li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Baykam N, Esener H, Ergönül O, Eren S, Celikbas AK, Dokuzoguz B.</emphasis> 2004. In vitro antimicrobial susceptibility of <citetitle><emphasis>Brucella</emphasis></citetitle> species. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">23:</emphasis>405–407.</para>
          </listitem>
          <listitem id="ch0095s000000li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Kinsara A, Al-Mowallad A, Osoba AO.</emphasis> 1999. Increasing resistance of <citetitle><emphasis>Brucellae</emphasis></citetitle> to co-trimoxazole. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">43:</emphasis>1531.</para>
          </listitem>
          <listitem id="ch0095s000000li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Memish Z, Mah MW, Al Mahmoud S, Al Shaalan M, Khan MY.</emphasis> 2000. <citetitle><emphasis>Brucella</emphasis></citetitle> bacteraemia: clinical and laboratory observations in 160 patients. <citetitle><emphasis>J Infect</emphasis></citetitle> <emphasis role="strong">40:</emphasis>59–63.</para>
          </listitem>
          <listitem id="ch0095s000000li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Sayan M, Kılıc S, Uyanık MH.</emphasis> 2012. Epidemiological survey of rifampicin resistance in clinic isolates of <citetitle><emphasis>Brucella melitensis</emphasis></citetitle> obtained from all regions of Turkey. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">18:</emphasis>41–46.</para>
          </listitem>
          <listitem id="ch0095s000000li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Torkaman Asadi F, Hashemi SH, Alikhani MY, Moghimbeigi A, Naseri Z.</emphasis> 2017. Clinical and diagnostic aspects of brucellosis and antimicrobial susceptibility of <citetitle><emphasis>Brucella</emphasis></citetitle> isolates in Hamedan, <citetitle><emphasis>Iran. Jpn J Infect Dis</emphasis></citetitle> <emphasis role="strong">70:</emphasis>235–238.</para>
          </listitem>
          <listitem id="ch0095s000000li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Marianelli C, Ciuchini F, Tarantino M, Pasquali P, Adone R.</emphasis> 2004. Genetic bases of the rifampin resistance phenotype in <citetitle><emphasis>Brucella</emphasis></citetitle> spp. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>5439–5443.</para>
          </listitem>
          <listitem id="ch0095s000000li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Valdezate S, Navarro A, Medina-Pascual MJ, Carrasco G, Saéz-Nieto JA.</emphasis> 2010. Molecular screening for rifampicin and fluoroquinolone resistance in a clinical population of <citetitle><emphasis>Brucella melitensis. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">65:</emphasis>51–53.</para>
          </listitem>
          <listitem id="ch0095s000000li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Antunes NT, Frase H, Toth M, Vakulenko SB.</emphasis> 2012. The class A β-lactamase FTU-1 is native to <citetitle><emphasis>Francisella tularensis. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>666–671.</para>
          </listitem>
          <listitem id="ch0095s000000li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Baker CN, Hollis DG, Thornsberry C.</emphasis> 1985. Antimicrobial susceptibility testing of <citetitle><emphasis>Francisella tularensis</emphasis></citetitle> with a modified Mueller-Hinton broth. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">22:</emphasis>212–215.</para>
          </listitem>
          <listitem id="ch0095s000000li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Ikäheimo I, Syrjälä H, Karhukorpi J, Schildt R, Koskela M.</emphasis> 2000. In vitro antibiotic susceptibility of <citetitle><emphasis>Francisella tularensis</emphasis></citetitle> isolated from humans and animals. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">46:</emphasis>287–290.</para>
          </listitem>
          <listitem id="ch0095s000000li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Yesilyurt M, Kiliç S, Celebi B, Celik M, Gül S, Erdogan F, Ozel G.</emphasis> 2011. Antimicrobial susceptibilities of <citetitle><emphasis>Francisella tularensis</emphasis></citetitle> subsp. <citetitle><emphasis>holarctica</emphasis></citetitle> strains isolated from humans in the Central Anatolia region of Turkey. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">66:</emphasis>2588–2592.</para>
          </listitem>
          <listitem id="ch0095s000000li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Lonsway DR, Jevitt LA, Uhl JR, Cockerill FR III, Anderson ME, Sullivan MM, De BK, Edwards JR, Patel JB.</emphasis> 2010. Effect of carbon dioxide on broth microdilution susceptibility testing of <citetitle><emphasis>Brucella</emphasis></citetitle> spp. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>952–956.</para>
          </listitem>
          <listitem id="ch0095s000000li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Mohammed MJ, Marston CK, Popovic T, Weyant RS, Tenover FC.</emphasis> 2002. Antimicrobial susceptibility testing of <citetitle><emphasis>Bacillus anthracis</emphasis></citetitle>: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1902–1907.</para>
          </listitem>
          <listitem id="ch0095s000000li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Turnbull PCB, Sirianni NM, LeBron CI, Samaan MN, Sutton FN, Reyes AE, Peruski LF Jr.</emphasis> 2004. MICs of selected antibiotics for <citetitle><emphasis>Bacillus anthracis</emphasis></citetitle>, <citetitle><emphasis>Bacillus cereus</emphasis></citetitle>, <citetitle><emphasis>Bacillus thuringiensis</emphasis></citetitle>, and <citetitle><emphasis>Bacillus mycoides</emphasis></citetitle> from a range of clinical and environmental sources as determined by the Etest. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>3626–3634.</para>
          </listitem>
          <listitem id="ch0095s000000li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Lonsway DR, Urich SK, Heine HS, McAllister SK, Banerjee SN, Schriefer ME, Patel JB.</emphasis> 2011. Comparison of Etest method with reference broth microdilution method for antimicrobial susceptibility testing of <citetitle><emphasis>Yersinia pestis. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>1956–1960.</para>
          </listitem>
          <listitem id="ch0095s000000li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Lonsway DR, Elrod MG, Kendrick N, Tiller R, Sullivan MM, Edwards JR, Blaney DD, Karlsson M.</emphasis> 2020. Correlation between Etest and reference broth microdilution for antimicrobial susceptibility testing of <citetitle><emphasis>Burkholderia pseudomallei. Microb Drug Resist</emphasis></citetitle> <emphasis role="strong">26:</emphasis>311–318.</para>
          </listitem>
          <listitem id="ch0095s000000li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Dance DAB, Wuthiekanun V, Baird RW, Norton R, Limmathurotsakul D, Currie BJ.</emphasis> 2021. Interpreting <citetitle><emphasis>Burkholderia pseudomallei</emphasis></citetitle> disc diffusion susceptibility test results by the EUCAST method. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">27:</emphasis>827–829.</para>
          </listitem>
          <listitem id="ch0095s000000li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Wilson DE, Chosewood LC (ed).</emphasis> 2020. <citetitle><emphasis>Biosafety in Microbiological and Biomedical Laboratories.</emphasis></citetitle> U.S. Government Printing Office, Washington, DC.</para>
          </listitem>
          <listitem id="ch0095s000000li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O’Gara P, Taubert KA, American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council.</emphasis> 2015. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <citetitle><emphasis>Circulation</emphasis></citetitle> <emphasis role="strong">132:</emphasis>1435–1486.</para>
          </listitem>
          <listitem id="ch0095s000000li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL, ESC Scientific Document Group.</emphasis> 2015. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). <citetitle><emphasis>Eur Heart J</emphasis></citetitle> <emphasis role="strong">36:</emphasis>3075–3128.</para>
          </listitem>
          <listitem id="ch0095s000000li0180" role="bibliographyEntry">
            <anchor id="ch0095s000000a0117"/>
            <para>180.<emphasis role="strong">Alberti MO, Hindler JA, Humphries RM.</emphasis> 2015. Antimicrobial susceptibilities of <citetitle><emphasis>Abiotrophia defectiva</emphasis></citetitle>, <citetitle><emphasis>Granulicatella adiacens</emphasis></citetitle>, and <citetitle><emphasis>Granulicatella elegans. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>1411–1420.</para>
          </listitem>
          <listitem id="ch0095s000000li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Mushtaq A, Greenwood-Quaintance KE, Cole NC, Kohner PC, Ihde SM, Strand GJ, Harper LW, Virk A, Patel R.</emphasis> 2016. Differential antimicrobial susceptibilities of <citetitle><emphasis>Granulicatella adiacens</emphasis></citetitle> and <citetitle><emphasis>Abiotrophia defectiva. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>5036–5039.</para>
          </listitem>
          <listitem id="ch0095s000000li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Prasidthrathsint K, Fisher MA.</emphasis> 2017. Antimicrobial susceptibility patterns among a large, nationwide cohort of <citetitle><emphasis>Abiotrophia</emphasis></citetitle> and <citetitle><emphasis>Granulicatella</emphasis></citetitle> clinical isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>1025–1031.</para>
          </listitem>
          <listitem id="ch0095s000000li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Namdari H, Kintner K, Jackson BA, Namdari S, Hughes JL, Peairs RR, Savage DJ.</emphasis> 1999. <citetitle><emphasis>Abiotrophia</emphasis></citetitle> species as a cause of endophthalmitis following cataract extraction. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>1564–1566.</para>
          </listitem>
          <listitem id="ch0095s000000li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Alberti MO, Hindler JA, Humphries RM.</emphasis> 2016. Performance of Etest for antimicrobial susceptibility testing of <citetitle><emphasis>Abiotrophia defectiva</emphasis></citetitle> and <citetitle><emphasis>Granulicatella</emphasis></citetitle> species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2194–2196.</para>
          </listitem>
          <listitem id="ch0095s000000li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Carkaci D, Nielsen XC, Fuursted K, Skov R, Skovgaard O, Trallero EP, Lienhard R, Åhman J, Matuschek E, Kahlmeter G, Christensen JJ.</emphasis> 2017. <citetitle><emphasis>Aerococcus urinae</emphasis></citetitle> and <citetitle><emphasis>Aerococcus sanguinicola</emphasis></citetitle>: susceptibility testing of 120 isolates to six antimicrobial agents using disk diffusion (EUCAST), Etest, and broth microdilution techniques. <citetitle><emphasis>Open Microbiol J</emphasis></citetitle> <emphasis role="strong">11:</emphasis>160–166.</para>
          </listitem>
          <listitem id="ch0095s000000li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Roy FE, Berteau T, Bestman-Smith J, Grandjean Lapierre S, Dufresne SF, Domingo MC, Leduc JM.</emphasis> 2021. Validation of a gradient diffusion method (Etest) for testing of antimicrobial susceptibility of <citetitle><emphasis>Aerococcus urinae</emphasis></citetitle> to fluoroquinolones. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59</emphasis><emphasis role="strong">:</emphasis>e0025921.</para>
          </listitem>
          <listitem id="ch0095s000000li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">Senneby E, Petersson AC, Rasmussen M.</emphasis> 2012. Clinical and microbiological features of bacteraemia with <citetitle><emphasis>Aerococcus urinae. Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">18:</emphasis>546–550.</para>
          </listitem>
          <listitem id="ch0095s000000li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">Humphries RM, Hindler JA.</emphasis> 2014. In vitro antimicrobial susceptibility of <citetitle><emphasis>Aerococcus urinae. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>2177–2180.</para>
          </listitem>
          <listitem id="ch0095s000000li0189" role="bibliographyEntry">
            <para>189.<emphasis role="strong">Scholtz SL, Faron ML, Buchan BW, Ledeboer NA.</emphasis> 2022. Comparison of methods for determining the antibiotic susceptibility of <citetitle><emphasis>Aerococcus</emphasis></citetitle> species in a clinical setting. <citetitle><emphasis>Am J Clin Pathol</emphasis></citetitle> <emphasis role="strong">157:</emphasis>781–788.</para>
          </listitem>
          <listitem id="ch0095s000000li0190" role="bibliographyEntry">
            <para>190.<emphasis role="strong">Humphries RM.</emphasis> 2014. <citetitle><emphasis>Clinical and Laboratory Standards Institute, January 2014 Antimicrobial Susceptibility Testing Subcommittee Agenda Book.</emphasis></citetitle> Clinical and Laborary Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0095s000000li0191" role="bibliographyEntry">
            <para>191.<emphasis role="strong">Shelton-Dodge K, Vetter EA, Kohner PC, Nyre LM, Patel R.</emphasis> 2011. Clinical significance and antimicrobial susceptibilities of <citetitle><emphasis>Aerococcus sanguinicola</emphasis></citetitle> and <citetitle><emphasis>Aerococcus urinae. Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">70:</emphasis>448–451.</para>
          </listitem>
          <listitem id="ch0095s000000li0192" role="bibliographyEntry">
            <para>192.<emphasis role="strong">Hirzel C, Guilarte YN, Hirzberger L, Furrer H, Marschall J, Endimiani A.</emphasis> 2015. In vitro susceptibility of <citetitle><emphasis>Aerococcus urinae</emphasis></citetitle> isolates to antibiotics used for uncomplicated urinary tract infection. <citetitle><emphasis>J Infect</emphasis></citetitle> <emphasis role="strong">71:</emphasis>395–397.</para>
          </listitem>
          <listitem id="ch0095s000000li0193" role="bibliographyEntry">
            <para>193.<emphasis role="strong">Skov R, Christensen JJ, Korner B, Frimodt-Møller N, Espersen F.</emphasis> 2001. In vitro antimicrobial susceptibility of <citetitle><emphasis>Aerococcus urinae</emphasis></citetitle> to 14 antibiotics, and time-kill curves for penicillin, gentamicin and vancomycin. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">48:</emphasis>653–658.</para>
          </listitem>
          <listitem id="ch0095s000000li0194" role="bibliographyEntry">
            <para>194.<emphasis role="strong">Hirzel C, Hirzberger L, Furrer H, Endimiani A.</emphasis> 2016. Bactericidal activity of penicillin, ceftriaxone, gentamicin and daptomycin alone and in combination against <citetitle><emphasis>Aerococcus urinae. Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">48:</emphasis>271–276.</para>
          </listitem>
          <listitem id="ch0095s000000li0195" role="bibliographyEntry">
            <para>195.<emphasis role="strong">Sunnerhagen T, Nilson B, Olaison L, Rasmussen M.</emphasis> 2016. Clinical and microbiological features of infective endocarditis caused by aerococci. <citetitle><emphasis>Infection</emphasis></citetitle> <emphasis role="strong">44:</emphasis>167–173.</para>
          </listitem>
          <listitem id="ch0095s000000li0196" role="bibliographyEntry">
            <para>196.<emphasis role="strong">Cattoir V, Kobal A, Legrand P.</emphasis> 2011. First molecular characterization of fluoroquinolone resistance in <citetitle><emphasis>Aerococcus</emphasis></citetitle> spp. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>451–452.</para>
          </listitem>
          <listitem id="ch0095s000000li0197" role="bibliographyEntry">
            <para>197.<emphasis role="strong">Humphries RM, Lee C, Hindler JA.</emphasis> 2011. <citetitle><emphasis>Aerococcus urinae</emphasis></citetitle> and trimethoprim-sulfamethoxazole. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>3934–3935.</para>
          </listitem>
          <listitem id="ch0095s000000li0198" role="bibliographyEntry">
            <para>198.<emphasis role="strong">Ahn K, Hwang GY, Uh Y, Yoon KJ, Hyun S.</emphasis> 2017. Vancomycin resistance due to vanA gene expression in an <citetitle><emphasis>Aerococcus viridans</emphasis></citetitle> isolate: first case in Korea. <citetitle><emphasis>Ann Lab Med</emphasis></citetitle> <emphasis role="strong">37:</emphasis>288–289.</para>
          </listitem>
          <listitem id="ch0095s000000li0199" role="bibliographyEntry">
            <para>199.<emphasis role="strong">Zhou WQ, Niu DM, Zhang ZZ, Ning MZ, Shen H, Zhang K.</emphasis> 2014. Vancomycin resistance due to VanA in an <citetitle><emphasis>Aerococcus viridans</emphasis></citetitle> isolate. <citetitle><emphasis>Indian J Med Microbiol</emphasis></citetitle> <emphasis role="strong">32:</emphasis>462–465.</para>
          </listitem>
          <listitem id="ch0095s000000li0200" role="bibliographyEntry">
            <para>200.<emphasis role="strong">Lamy B, Kodjo A, colBVH Study Group, Laurent</emphasis> F<emphasis role="strong">.</emphasis> 2009. Prospective nationwide study of <citetitle><emphasis>Aeromonas</emphasis></citetitle> infections in France. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>1234–1237.</para>
          </listitem>
          <listitem id="ch0095s000000li0201" role="bibliographyEntry">
            <para>201.<emphasis role="strong">Ko WC, Yu KW, Liu CY, Huang CT, Leu HS, Chuang YC.</emphasis> 1996. Increasing antibiotic resistance in clinical isolates of <citetitle><emphasis>Aeromonas</emphasis></citetitle> strains in Taiwan. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1260–1262.</para>
          </listitem>
          <listitem id="ch0095s000000li0202" role="bibliographyEntry">
            <para>202.<emphasis role="strong">Vila J, Marco F, Soler L, Chacon M, Figueras MJ.</emphasis> 2002. In vitro antimicrobial susceptibility of clinical isolates of <citetitle><emphasis>Aeromonas caviae</emphasis></citetitle>, <citetitle><emphasis>Aeromonas hydrophila</emphasis></citetitle> and <citetitle><emphasis>Aeromonas veronii</emphasis></citetitle> biotype <citetitle><emphasis>sobria. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">49:</emphasis>701–702.</para>
          </listitem>
          <listitem id="ch0095s000000li0203" role="bibliographyEntry">
            <para>203.<emphasis role="strong">Janda JM, Abbott SL.</emphasis> 2010. The genus <citetitle><emphasis>Aeromonas</emphasis></citetitle>: taxonomy, pathogenicity, and infection. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">23:</emphasis>35–73.</para>
          </listitem>
          <listitem id="ch0095s000000li0204" role="bibliographyEntry">
            <para>204.<emphasis role="strong">Ko W-C, Wu H-M, Chang T-C, Yan J-J, Wu J-J.</emphasis> 1998. Inducible beta-lactam resistance in <citetitle><emphasis>Aeromonas hydrophila</emphasis></citetitle>: therapeutic challenge for antimicrobial therapy. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>3188–3192.</para>
          </listitem>
          <listitem id="ch0095s000000li0205" role="bibliographyEntry">
            <para>205.<emphasis role="strong">Libisch B, Giske CG, Kovács B, Tóth TG, Füzi M.</emphasis> 2008. Identification of the first VIM metallo-beta-lactamase-producing multiresistant <citetitle><emphasis>Aeromonas hydrophila</emphasis></citetitle> strain. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1878–1880.</para>
          </listitem>
          <listitem id="ch0095s000000li0206" role="bibliographyEntry">
            <para>206.<emphasis role="strong">Neuwirth C, Siebor E, Robin F, Bonnet R.</emphasis> 2007. First occurrence of an IMP metallo-beta-lactamase in <citetitle><emphasis>Aeromonas caviae</emphasis></citetitle>: IMP-19 in an isolate from France. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>4486–4488.</para>
          </listitem>
          <listitem id="ch0095s000000li0207" role="bibliographyEntry">
            <para>207.<emphasis role="strong">Xu S, Tu J, Zhang L, Chen Y, Dong X, Chi X, Xu H.</emphasis> 2022. Detection of NDM-1-positive <citetitle><emphasis>Aeromonas caviae</emphasis></citetitle> from bacteremia by using whole-genome sequencing. <citetitle><emphasis>Infect Drug Resist</emphasis></citetitle> <emphasis role="strong">15:</emphasis>2835–2841.</para>
          </listitem>
          <listitem id="ch0095s000000li0208" role="bibliographyEntry">
            <para>208.<emphasis role="strong">Sinclair HA, Heney C, Sidjabat HE, George NM, Bergh H, Anuj SN, Nimmo GR, Paterson DL.</emphasis> 2016. Genotypic and phenotypic identification of Aeromonas species and CphA-mediated carbapenem resistance in Queensland, Australia. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">85:</emphasis>98–101.</para>
          </listitem>
          <listitem id="ch0095s000000li0209" role="bibliographyEntry">
            <para>209.<emphasis role="strong">Rossolini GM, Zanchi A, Chiesurin A, Amicosante G, Satta G, Guglielmetti P.</emphasis> 1995. Distribution of <citetitle><emphasis>cphA</emphasis></citetitle> or related carbapenemase-encoding genes and production of carbapenemase activity in members of the genus <citetitle><emphasis>Aeromonas. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">39:</emphasis>346–349.</para>
          </listitem>
          <listitem id="ch0095s000000li0210" role="bibliographyEntry">
            <para>210.<emphasis role="strong">Yang S, He T, Sun J, Sun S.</emphasis> 2019. Distinct antimicrobial resistance profiling of clinically important <citetitle><emphasis>Aeromonas</emphasis></citetitle> spp. in Southwest China: a seven-year surveillance study. <citetitle><emphasis>Infect Drug Resist</emphasis></citetitle> <emphasis role="strong">12:</emphasis>2971–2978.</para>
          </listitem>
          <listitem id="ch0095s000000li0211" role="bibliographyEntry">
            <para>211.<emphasis role="strong">Liu YM, Chen YS, Toh HS, Huang CC, Lee YL, Ho CM, Lu PL, Ko WC, Chen YH, Wang JH, Tang HJ, Yu KW, Liu YC, Chuang YC, Xu Y, Ni Y, Liu CE, Hsueh PR.</emphasis> 2012. In vitro susceptibilities of non-<citetitle><emphasis>Enterobacteriaceae</emphasis></citetitle> isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">40</emphasis>(Suppl)<emphasis role="strong">:</emphasis>S11–S17.</para>
          </listitem>
          <listitem id="ch0095s000000li0212" role="bibliographyEntry">
            <para>212.<emphasis role="strong">Arias A, Seral C, Gude MJ, Castillo FJ.</emphasis> 2010. Molecular mechanisms of quinolone resistance in clinical isolates of <citetitle><emphasis>Aeromonas caviae</emphasis></citetitle> and <citetitle><emphasis>Aeromonas veronii</emphasis></citetitle> bv. sobria. <citetitle><emphasis>Int Microbiol</emphasis></citetitle> <emphasis role="strong">13:</emphasis>135–141.</para>
          </listitem>
          <listitem id="ch0095s000000li0213" role="bibliographyEntry">
            <para>213.<emphasis role="strong">Sinha S, Chattopadhyay S, Bhattacharya SK, Nair GB, Ramamurthy T.</emphasis> 2004. An unusually high level of quinolone resistance associated with type II topoisomerase mutations in quinolone resistance-determining regions of <citetitle><emphasis>Aeromonas caviae</emphasis></citetitle> isolated from diarrhoeal patients. <citetitle><emphasis>Res Microbiol</emphasis></citetitle> <emphasis role="strong">155:</emphasis>827–829.</para>
          </listitem>
          <listitem id="ch0095s000000li0214" role="bibliographyEntry">
            <para>214.<emphasis role="strong">Giltner CL, Bobenchik AM, Uslan DZ, Deville JG, Humphries RM.</emphasis> 2013. Ciprofloxacin-resistant <citetitle><emphasis>Aeromonas hydrophila</emphasis></citetitle> cellulitis following leech therapy. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1324–1326.</para>
          </listitem>
          <listitem id="ch0095s000000li0215" role="bibliographyEntry">
            <para>215.<emphasis role="strong">Patel KM, Svestka M, Sinkin J, Ruff P IV.</emphasis> 2013. Ciprofloxacin-resistant <citetitle><emphasis>Aeromonas hydrophila</emphasis></citetitle> infection following leech therapy: a case report and review of the literature. <citetitle><emphasis>J Plast Reconstr Aesthet Surg</emphasis></citetitle> <emphasis role="strong">66:</emphasis>e20–e22.</para>
          </listitem>
          <listitem id="ch0095s000000li0216" role="bibliographyEntry">
            <anchor id="ch0095s000000a0118"/>
            <para>216.<emphasis role="strong">González-Rey C, Svenson SB, Bravo L, Siitonen A, Pasquale V, Dumontet S, Ciznar I, Krovacek K.</emphasis> 2004. Serotypes and anti-microbial susceptibility of <citetitle><emphasis>Plesiomonas shigelloides</emphasis></citetitle> isolates from humans, animals and aquatic environments in different countries. <citetitle><emphasis>Comp Immunol Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">27:</emphasis>129–139.</para>
          </listitem>
          <listitem id="ch0095s000000li0217" role="bibliographyEntry">
            <para>217.<emphasis role="strong">Citron DM, Appleman MD.</emphasis> 2006. In vitro activities of daptomycin, ciprofloxacin, and other antimicrobial agents against the cells and spores of clinical isolates of <citetitle><emphasis>Bacillus</emphasis></citetitle> species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>3814–3818.</para>
          </listitem>
          <listitem id="ch0095s000000li0218" role="bibliographyEntry">
            <para>218.<emphasis role="strong">Luna VA, King DS, Gulledge J, Cannons AC, Amuso PT, Cattani J.</emphasis> 2007. Susceptibility of <citetitle><emphasis>Bacillus anthracis</emphasis></citetitle>, <citetitle><emphasis>Bacillus cereus</emphasis></citetitle>, <citetitle><emphasis>Bacillus mycoides</emphasis></citetitle>, <citetitle><emphasis>Bacillus pseudomycoides</emphasis></citetitle> and <citetitle><emphasis>Bacillus thuringiensis</emphasis></citetitle> to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">60:</emphasis>555–567.</para>
          </listitem>
          <listitem id="ch0095s000000li0219" role="bibliographyEntry">
            <para>219.<emphasis role="strong">Ikeda M, Yagihara Y, Tatsuno K, Okazaki M, Okugawa S, Moriya K.</emphasis> 2015. Clinical characteristics and antimicrobial susceptibility of <citetitle><emphasis>Bacillus cereus</emphasis></citetitle> blood stream infections. <citetitle><emphasis>Ann Clin Microbiol Antimicrob</emphasis></citetitle> <emphasis role="strong">14:</emphasis>43.</para>
          </listitem>
          <listitem id="ch0095s000000li0220" role="bibliographyEntry">
            <para>220.<emphasis role="strong">Kiyomizu K, Yagi T, Yoshida H, Minami R, Tanimura A, Karasuno T, Hiraoka A.</emphasis> 2008. Fulminant septicemia of <citetitle><emphasis>Bacillus cereus</emphasis></citetitle> resistant to carbapenem in a patient with biphenotypic acute leukemia. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">14:</emphasis>361–367.</para>
          </listitem>
          <listitem id="ch0095s000000li0221" role="bibliographyEntry">
            <para>221.<emphasis role="strong">Katsuya H, Takata T, Ishikawa T, Sasaki H, Ishitsuka K, Takamatsu Y, Tamura K.</emphasis> 2009. A patient with acute myeloid leukemia who developed fatal pneumonia caused by carbapenem-resistant <citetitle><emphasis>Bacillus cereus. J Infect Chemother</emphasis></citetitle> <emphasis role="strong">15:</emphasis>39–41.</para>
          </listitem>
          <listitem id="ch0095s000000li0222" role="bibliographyEntry">
            <para>222.<emphasis role="strong">Gupta A, Nelson JM, Barrett TJ, Tauxe RV, Rossiter SP, Friedman CR, Joyce KW, Smith KE, Jones TF, Hawkins MA, Shiferaw B, Beebe JL, Vugia DJ, Rabatsky-Ehr T, Benson JA, Root TP, Angulo FJ, Group NW, NARMS Working Group.</emphasis> 2004. Antimicrobial resistance among <citetitle><emphasis>Campylobacter</emphasis></citetitle> strains, United States, 1997-2001. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">10:</emphasis>1102–1109.</para>
          </listitem>
          <listitem id="ch0095s000000li0223" role="bibliographyEntry">
            <para>223.<emphasis role="strong">CDC.</emphasis> 2022. National Antimicrobial Resistance Monitoring System (NARMS) Now: Human Data. <ulink url="https://wwwn.cdc.gov/narmsnow/">https://wwwn.cdc.gov/narmsnow/</ulink>. Accessed 19 June 2022.</para>
          </listitem>
          <listitem id="ch0095s000000li0224" role="bibliographyEntry">
            <para>224.<emphasis role="strong">CDC.</emphasis> 2013. <citetitle><emphasis>National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2011.</emphasis></citetitle> U.S. Department of Health and Human Services, CDC, Atlanta, GA.</para>
          </listitem>
          <listitem id="ch0095s000000li0225" role="bibliographyEntry">
            <para>225.<emphasis role="strong">CDC.</emphasis> 2020. <citetitle><emphasis>National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS): Human Isolates Final Report, 2018.</emphasis></citetitle> U.S. Department of Health and Human Services, CDC, Atlanta, GA.</para>
          </listitem>
          <listitem id="ch0095s000000li0226" role="bibliographyEntry">
            <para>226.<emphasis role="strong">Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I.</emphasis> 2001. Quinolone and macrolide resistance in <citetitle><emphasis>Campylobacter jejuni</emphasis></citetitle> and <citetitle><emphasis>C. coli</emphasis></citetitle>: resistance mechanisms and trends in human isolates. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">7:</emphasis>24–34.</para>
          </listitem>
          <listitem id="ch0095s000000li0227" role="bibliographyEntry">
            <para>227.<emphasis role="strong">Griggs DJ, Johnson MM, Frost JA, Humphrey T, Jørgensen F, Piddock LJ.</emphasis> 2005. Incidence and mechanism of ciprofloxacin resistance in <citetitle><emphasis>Campylobacter</emphasis></citetitle> spp. isolated from commercial poultry flocks in the United Kingdom before, during, and after fluoroquinolone treatment. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">49:</emphasis>699–707.</para>
          </listitem>
          <listitem id="ch0095s000000li0228" role="bibliographyEntry">
            <para>228.<emphasis role="strong">Luo N, Pereira S, Sahin O, Lin J, Huang S, Michel L, Zhang Q.</emphasis> 2005. Enhanced in vivo fitness of fluoroquinolone-resistant <citetitle><emphasis>Campylobacter jejuni</emphasis></citetitle> in the absence of antibiotic selection pressure. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">102:</emphasis>541–546.</para>
          </listitem>
          <listitem id="ch0095s000000li0229" role="bibliographyEntry">
            <para>229.<emphasis role="strong">Bakeli G, Sato K, Kumita W, Saito R, Ono E, Chida T, Okamura N, Saito R, Ono E.</emphasis> 2008. Antimicrobial susceptibility and mechanism of quinolone resistance in <citetitle><emphasis>Campylobacter jejuni</emphasis></citetitle> strains isolated from diarrheal patients in a hospital in Tokyo. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">14:</emphasis>342–348.</para>
          </listitem>
          <listitem id="ch0095s000000li0230" role="bibliographyEntry">
            <para>230.<emphasis role="strong">Wassenaar TM, Kist M, de Jong A.</emphasis> 2007. Re-analysis of the risks attributed to ciprofloxacin-resistant <citetitle><emphasis>Campylobacter jejuni</emphasis></citetitle> infections. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">30:</emphasis>195–201.</para>
          </listitem>
          <listitem id="ch0095s000000li0231" role="bibliographyEntry">
            <para>231.<emphasis role="strong">Chen JC, Tagg KA, Joung YJ, Bennett C, Francois Watkins L, Eikmeier D, Folster JP.</emphasis> 2018. Report of <citetitle><emphasis>erm</emphasis></citetitle>(B)<superscript>+</superscript> <citetitle><emphasis>Campylobacter jejuni</emphasis></citetitle> in the United States. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">62:</emphasis>e02615–17.</para>
          </listitem>
          <listitem id="ch0095s000000li0232" role="bibliographyEntry">
            <para>232.<emphasis role="strong">CDC.</emphasis> 2019. <citetitle><emphasis>Antibiotic resistance threats in the United States, 2019.</emphasis></citetitle> U.S. Department of Health and Human Services, CDC, Atlanta, GA.</para>
          </listitem>
          <listitem id="ch0095s000000li0233" role="bibliographyEntry">
            <para>233.<emphasis role="strong">Montgomery MP, Robertson S, Koski L, Salehi E, Stevenson LM, Silver R, Sundararaman P, Singh A, Joseph LA, Weisner MB, Brandt E, Prarat M, Bokanyi R, Chen JC, Folster JP, Bennett CT, Watkins LKF, Aubert RD, Chu A, Jackson J, Blanton J, Ginn A, Ramadugu K, Stanek D, DeMent J, Cui J, Zhang Y, Basler C, Friedman CR, Geissler AL, Crowe SJ, Dowell N, Dixon S, Whitlock L, Williams I, Jhung MA, Nichols MC, de Fijter S, Laughlin ME.</emphasis> 2018. Multidrug-resistant <citetitle><emphasis>Campylobacter jejuni</emphasis></citetitle> outbreak linked to puppy exposure—United States, 2016–2018. <citetitle><emphasis>MMWR Morb Mortal Wkly Rep</emphasis></citetitle> <emphasis role="strong">67:</emphasis>1032–1035.</para>
          </listitem>
          <listitem id="ch0095s000000li0234" role="bibliographyEntry">
            <para>234.<emphasis role="strong">Baker CN.</emphasis> 1992. The E-Test and <citetitle><emphasis>Campylobacter jejuni. Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">15:</emphasis>469–472.</para>
          </listitem>
          <listitem id="ch0095s000000li0235" role="bibliographyEntry">
            <para>235.<emphasis role="strong">Fernandez-Roblas R, Adames H, Martín-de-Hijas NZ, Almeida DG, Gadea I, Esteban J.</emphasis> 2009. In vitro activity of tigecycline and 10 other antimicrobials against clinical isolates of the genus <citetitle><emphasis>Corynebacterium. Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">33:</emphasis>453–455.</para>
          </listitem>
          <listitem id="ch0095s000000li0236" role="bibliographyEntry">
            <para>236.<emphasis role="strong">Funke G, Pünter V, von Graevenitz A.</emphasis> 1996. Antimicrobial susceptibility patterns of some recently established coryneform bacteria. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2874–2878.</para>
          </listitem>
          <listitem id="ch0095s000000li0237" role="bibliographyEntry">
            <para>237.<emphasis role="strong">Gómez-Garcés JL, Alos JI, Tamayo J.</emphasis> 2007. In vitro activity of linezolid and 12 other antimicrobials against coryneform bacteria. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">29:</emphasis>688–692.</para>
          </listitem>
          <listitem id="ch0095s000000li0238" role="bibliographyEntry">
            <para>238.<emphasis role="strong">Weiss K, Laverdière M, Rivest R.</emphasis> 1996. Comparison of antimicrobial susceptibilities of <citetitle><emphasis>Corynebacterium</emphasis></citetitle> species by broth microdilution and disk diffusion methods. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">40:</emphasis>930–933.</para>
          </listitem>
          <listitem id="ch0095s000000li0239" role="bibliographyEntry">
            <para>239.<emphasis role="strong">Bernard K.</emphasis> 2012. The genus <citetitle><emphasis>Corynebacterium</emphasis></citetitle> and other medically relevant coryneform-like bacteria. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>3152–3158.</para>
          </listitem>
          <listitem id="ch0095s000000li0240" role="bibliographyEntry">
            <anchor id="ch0095s000000a0119"/>
            <para>240.<emphasis role="strong">Tran TT, Jaijakul S, Lewis CT, Diaz L, Panesso D, Kaplan HB, Murray BE, Wanger A, Arias CA.</emphasis> 2012. Native valve endocarditis caused by <citetitle><emphasis>Corynebacterium striatum</emphasis></citetitle> with heterogeneous high-level daptomycin resistance: collateral damage from daptomycin therapy? <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>3461–3464.</para>
          </listitem>
          <listitem id="ch0095s000000li0241" role="bibliographyEntry">
            <para>241.<emphasis role="strong">McMullen AR, Anderson N, Wallace MA, Shupe A, Burnham CA.</emphasis> 2017. When good bugs go bad: epidemiology and antimicrobial resistance profiles of <citetitle><emphasis>Corynebacterium striatum</emphasis></citetitle>, an emerging multidrug-resistant, opportunistic pathogen. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e01111–17.</para>
          </listitem>
          <listitem id="ch0095s000000li0242" role="bibliographyEntry">
            <para>242.<emphasis role="strong">Soriano F, Tauch A.</emphasis> 2008. Microbiological and clinical features of <citetitle><emphasis>Corynebacterium urealyticum</emphasis></citetitle>: urinary tract stones and genomics as the Rosetta Stone. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">14:</emphasis>632–643.</para>
          </listitem>
          <listitem id="ch0095s000000li0243" role="bibliographyEntry">
            <para>243.<emphasis role="strong">Ortiz-Pérez A, Martín-de-Hijas NZ, Esteban J, Fernández-Natal MI, García-Cía JI, Fernández-Roblas R.</emphasis> 2010. High frequency of macrolide resistance mechanisms in clinical isolates of <citetitle><emphasis>Corynebacterium</emphasis></citetitle> species. <citetitle><emphasis>Microb Drug Resist</emphasis></citetitle> <emphasis role="strong">16:</emphasis>273–277.</para>
          </listitem>
          <listitem id="ch0095s000000li0244" role="bibliographyEntry">
            <para>244.<emphasis role="strong">Engler KH, Warner M, George RC.</emphasis> 2001. In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against <citetitle><emphasis>Corynebacterium diphtheriae. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">47:</emphasis>27–31.</para>
          </listitem>
          <listitem id="ch0095s000000li0245" role="bibliographyEntry">
            <para>245.<emphasis role="strong">Pereira GA, Pimenta FP, Santos FR, Damasco PV, Hirata Júnior R, Mattos-Guaraldi AL.</emphasis> 2008. Antimicrobial resistance among Brazilian <citetitle><emphasis>Corynebacterium diphtheriae</emphasis></citetitle> strains. <citetitle><emphasis>Mem Inst Oswaldo Cruz</emphasis></citetitle> <emphasis role="strong">103:</emphasis>507–510.</para>
          </listitem>
          <listitem id="ch0095s000000li0246" role="bibliographyEntry">
            <para>246.<emphasis role="strong">Mina NV, Burdz T, Wiebe D, Rai JS, Rahim T, Shing F, Hoang L, Bernard K.</emphasis> 2011. Canada’s first case of a multidrug-resistant <citetitle><emphasis>Corynebacterium diphtheriae</emphasis></citetitle> strain, isolated from a skin abscess. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>4003–4005.</para>
          </listitem>
          <listitem id="ch0095s000000li0247" role="bibliographyEntry">
            <para>247.<emphasis role="strong">von Hunolstein C, Scopetti F, Efstratiou A, Engler K.</emphasis> 2002. Penicillin tolerance amongst non-toxigenic <citetitle><emphasis>Corynebacterium diphtheriae</emphasis></citetitle> isolated from cases of pharyngitis. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">50:</emphasis>125–128.</para>
          </listitem>
          <listitem id="ch0095s000000li0248" role="bibliographyEntry">
            <para>248.<emphasis role="strong">Grandière-Pérez L, Jacqueline C, Lemabecque V, Patey O, Potel G, Caillon J.</emphasis> 2005. Eagle effect in <citetitle><emphasis>Corynebacterium diphtheriae. J Infect Dis</emphasis></citetitle> <emphasis role="strong">191:</emphasis>2118–2120.</para>
          </listitem>
          <listitem id="ch0095s000000li0249" role="bibliographyEntry">
            <para>249.<emphasis role="strong">Barraud O, Badell E, Denis F, Guiso N, Ploy MC.</emphasis> 2011. Antimicrobial drug resistance in <citetitle><emphasis>Corynebacterium diphtheriae mitis. Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>2078–2080.</para>
          </listitem>
          <listitem id="ch0095s000000li0250" role="bibliographyEntry">
            <para>250.<emphasis role="strong">Benamrouche N, Hasnaoui S, Badell E, Guettou B, Lazri M, Guiso N, Rahal K.</emphasis> 2016. Microbiological and molecular characterization of <citetitle><emphasis>Corynebacterium diphtheriae</emphasis></citetitle> isolated in Algeria between 1992 and 2015. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">22:</emphasis>1005.e1–1005.e7.</para>
          </listitem>
          <listitem id="ch0095s000000li0251" role="bibliographyEntry">
            <para>251.<emphasis role="strong">Marosevic DV, Berger A, Kahlmeter G, Payer SK, Hörmansdorfer S, Sing A.</emphasis> 2020. Antimicrobial susceptibility of <citetitle><emphasis>Corynebacterium diphtheriae</emphasis></citetitle> and <citetitle><emphasis>Corynebacterium ulcerans</emphasis></citetitle> in Germany 2011-17. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">75:</emphasis>2885–2893.</para>
          </listitem>
          <listitem id="ch0095s000000li0252" role="bibliographyEntry">
            <para>252.<emphasis role="strong">Carlson P, Kontiainen S, Renkonen OV.</emphasis> 1994. Antimicrobial susceptibility of <citetitle><emphasis>Arcanobacterium haemolyticum. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">38:</emphasis>142–143.</para>
          </listitem>
          <listitem id="ch0095s000000li0253" role="bibliographyEntry">
            <para>253.<emphasis role="strong">García-de-la-Fuente C, Ruiz De Alegría C, Cano ME, Campo AB, Unda F, Agüero J, Martínez-Martínez L.</emphasis> 2012. Phenotypic and molecular characterization of <citetitle><emphasis>Arcanobacterium haemolyticum</emphasis></citetitle> isolated from clinical samples. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">72:</emphasis>1–7.</para>
          </listitem>
          <listitem id="ch0095s000000li0254" role="bibliographyEntry">
            <para>254.<emphasis role="strong">Power EG, Abdulla YH, Talsania HG, Spice W, Aathithan S, French GL.</emphasis> 1995. vanA genes in vancomycin-resistant clinical isolates of <citetitle><emphasis>Oerskovia turbata</emphasis></citetitle> and <citetitle><emphasis>Arcanobacterium (Corynebacterium) haemolyticum. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">36:</emphasis>595–606.</para>
          </listitem>
          <listitem id="ch0095s000000li0255" role="bibliographyEntry">
            <para>255.<emphasis role="strong">Funke G, Lawson PA, Nolte FS, Weiss N, Collins MD.</emphasis> 1998. Aureobacterium resistens sp. nov., exhibiting vancomycin resistance and teicoplanin susceptibility. <citetitle><emphasis>FEMS Microbiol Lett</emphasis></citetitle> <emphasis role="strong">158:</emphasis>89–93.</para>
          </listitem>
          <listitem id="ch0095s000000li0256" role="bibliographyEntry">
            <para>256.<emphasis role="strong">Boumghar-Bourtchai L, Chardon H, Malbruny B, Mezghani S, Leclercq R, Dhalluin A.</emphasis> 2009. Resistance to macrolides by ribosomal mutation in clinical isolates of <citetitle><emphasis>Turicella otitidis. Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">34:</emphasis>274–277.</para>
          </listitem>
          <listitem id="ch0095s000000li0257" role="bibliographyEntry">
            <para>257.<emphasis role="strong">Gomez-Garces JL, Alhambra A, Alos JI, Barrera B, García G.</emphasis> 2004. Acute and chronic otitis media and <citetitle><emphasis>Turicella otitidis</emphasis></citetitle>: a controversial association. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">10:</emphasis>854–857.</para>
          </listitem>
          <listitem id="ch0095s000000li0258" role="bibliographyEntry">
            <para>258.<emphasis role="strong">Fidalgo SG, Longbottom CJ, Rjley TV.</emphasis> 2002. Susceptibility of <citetitle><emphasis>Erysipelothrix rhusiopathiae</emphasis></citetitle> to antimicrobial agents and home disinfectants. <citetitle><emphasis>Pathology</emphasis></citetitle> <emphasis role="strong">34:</emphasis>462–465.</para>
          </listitem>
          <listitem id="ch0095s000000li0259" role="bibliographyEntry">
            <para>259.<emphasis role="strong">Ozawa M, Yamamoto K, Kojima A, Takagi M, Takahashi T.</emphasis> 2009. Etiological and biological characteristics of <citetitle><emphasis>Erysipelothrix rhusiopathiae</emphasis></citetitle> isolated between 1994 and 2001 from pigs with swine erysipelas in Japan. <citetitle><emphasis>J Vet Med Sci</emphasis></citetitle> <emphasis role="strong">71:</emphasis>697–702.</para>
          </listitem>
          <listitem id="ch0095s000000li0260" role="bibliographyEntry">
            <para>260.<emphasis role="strong">Yamamoto K, Kijima M, Yoshimura H, Takahashi T.</emphasis> 2001. Antimicrobial susceptibilities of <citetitle><emphasis>Erysipelothrix rhusiopathiae</emphasis></citetitle> isolated from pigs with swine erysipelas in Japan, 1988-1998. <citetitle><emphasis>J Vet Med B Infect Dis Vet Public Health</emphasis></citetitle> <emphasis role="strong">48:</emphasis>115–126.</para>
          </listitem>
          <listitem id="ch0095s000000li0261" role="bibliographyEntry">
            <para>261.<emphasis role="strong">Rihana N, Hemminger A, Green S.</emphasis> 2018. Novel case of penicillin resistant <citetitle><emphasis>E. rhusiopathiae</emphasis></citetitle> septicemia: case report with review of the literature. <citetitle><emphasis>IDCases</emphasis></citetitle> <emphasis role="strong">11:</emphasis>67–69.</para>
          </listitem>
          <listitem id="ch0095s000000li0262" role="bibliographyEntry">
            <para>262.<emphasis role="strong">Liu Z, Zhao M.</emphasis> 2017. Shock caused by multidrug-resistant <citetitle><emphasis>Erysipelothrix rhusiopathiae</emphasis></citetitle> bacteremia: a rare case report and literature review. <citetitle><emphasis>J Infect Dev Ctries</emphasis></citetitle> <emphasis role="strong">11:</emphasis>508–512.</para>
          </listitem>
          <listitem id="ch0095s000000li0263" role="bibliographyEntry">
            <para>263.<emphasis role="strong">Xu CW, Zhang AY, Yang CM, Pan Y, Guan ZB, Lei CW, Peng LY, Li QZ, Wang HN.</emphasis> 2015. First report of macrolide resistance gene <citetitle><emphasis>erm</emphasis></citetitle>(T) harbored by a novel small plasmid from <citetitle><emphasis>Erysipelothrix rhusiopathiae. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>2462–2465.</para>
          </listitem>
          <listitem id="ch0095s000000li0264" role="bibliographyEntry">
            <para>264.<emphasis role="strong">Wu C, Lv C, Zhao Y, Zhu W, Liu L, Wang T, Kang C, Yang Y, Sun X, Zhang Q, Jin M.</emphasis> 2021. Characterization of <citetitle><emphasis>Erysipelothrix rhusiopathiae</emphasis></citetitle> isolates from diseased pigs in 15 Chinese provinces from 2012 to 2018. <citetitle><emphasis>Microorganisms</emphasis></citetitle> <emphasis role="strong">9:</emphasis>2615.</para>
          </listitem>
          <listitem id="ch0095s000000li0265" role="bibliographyEntry">
            <para>265.<emphasis role="strong">Richter SS.</emphasis> 2014. <citetitle><emphasis>Clinical and Laboratory Standards Institute, January 2014 Antimicrobial Susceptibility Testing Subcommittee Agenda Book.</emphasis></citetitle> <ulink url="https://clsi.org/meetings/ast-file-resources/">https://clsi.org/meetings/ast-file-resources/</ulink>. Accessed March 9 2023.</para>
          </listitem>
          <listitem id="ch0095s000000li0266" role="bibliographyEntry">
            <para>266.<emphasis role="strong">Buu-Hoï A, Sapoetra A, Branger C, Acar JF.</emphasis> 1982. Antimicrobial susceptibility of <citetitle><emphasis>Gemella haemolysans</emphasis></citetitle> isolated from patients with subacute endocarditis. <citetitle><emphasis>Eur J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">1:</emphasis>102–106.</para>
          </listitem>
          <listitem id="ch0095s000000li0267" role="bibliographyEntry">
            <para>267.<emphasis role="strong">Goldstein EJ, Merriam CV, Claros MC, Citron DM.</emphasis> 2022. Comparative susceptibility of <citetitle><emphasis>Gemella morbillorum</emphasis></citetitle> to 13 antimicrobial agents. <citetitle><emphasis>Anaerobe</emphasis></citetitle> <emphasis role="strong">75:</emphasis>102573.</para>
          </listitem>
          <listitem id="ch0095s000000li0268" role="bibliographyEntry">
            <para>268.<emphasis role="strong">Tanveer F, Pawlak J, Youssef D, Saravolatz LD.</emphasis> 2021. A case of <citetitle><emphasis>Gemella morbillorum</emphasis></citetitle> native valve endocarditis and results of <citetitle><emphasis>in vitro</emphasis></citetitle> susceptibility testing. <citetitle><emphasis>IDCases</emphasis></citetitle> <emphasis role="strong">23:</emphasis>e01045.</para>
          </listitem>
          <listitem id="ch0095s000000li0269" role="bibliographyEntry">
            <para>269.<emphasis role="strong">Kugler KC, Biedenbach DJ, Jones RN.</emphasis> 1999. Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">34:</emphasis>73–76.</para>
          </listitem>
          <listitem id="ch0095s000000li0270" role="bibliographyEntry">
            <para>270.<emphasis role="strong">Coburn B, Toye B, Rawte P, Jamieson FB, Farrell DJ, Patel SN.</emphasis> 2013. Antimicrobial susceptibilities of clinical isolates of HACEK organisms. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>1989–1991.</para>
          </listitem>
          <listitem id="ch0095s000000li0271" role="bibliographyEntry">
            <para>271.<emphasis role="strong">Basmaci R, Bidet P, Jost C, Yagupsky P, Bonacorsi S.</emphasis> 2015. Penicillinase-encoding gene <citetitle><emphasis>bla</emphasis></citetitle><subscript>TEM-1</subscript> may be plasmid borne or chromosomally located in <citetitle><emphasis>Kingella kingae</emphasis></citetitle> species. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>1377–1378.</para>
          </listitem>
          <listitem id="ch0095s000000li0272" role="bibliographyEntry">
            <para>272.<emphasis role="strong">Basmaci R, Bonacorsi S, Bidet P, Balashova NV, Lau J, Muñoz-Almagro C, Gene A, Yagupsky P.</emphasis> 2014. Genotyping, local prevalence and international dissemination of β-lactamase-producing <citetitle><emphasis>Kingella kingae</emphasis></citetitle> strains. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">20:</emphasis>O811–O817.</para>
          </listitem>
          <listitem id="ch0095s000000li0273" role="bibliographyEntry">
            <para>273.<emphasis role="strong">Matuschek E, Ahman J, Kahlmeter G, Yagupsky P.</emphasis> 2018. Antimicrobial susceptibility testing of <citetitle><emphasis>Kingella kingae</emphasis></citetitle> with broth microdilution and disk diffusion using EUCAST recommended media. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> 24<emphasis role="strong">:</emphasis>396–401.</para>
          </listitem>
          <listitem id="ch0095s000000li0274" role="bibliographyEntry">
            <para>274.<emphasis role="strong">Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK.</emphasis> 2016. The Toronto consensus for the treatment of <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> infection in adults. <citetitle><emphasis>Gastroenterology</emphasis></citetitle> <emphasis role="strong">151:</emphasis>51–69.e14.</para>
          </listitem>
          <listitem id="ch0095s000000li0275" role="bibliographyEntry">
            <para>275.<emphasis role="strong">Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM, European Helicobacter and Microbiota Study Group and Consensus panel.</emphasis> 2017. Management of <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> infection—the Maastricht V/Florence Consensus Report. <citetitle><emphasis>Gu</emphasis></citetitle><citetitle><emphasis>t</emphasis></citetitle> <emphasis role="strong">66:</emphasis>6–30.</para>
          </listitem>
          <listitem id="ch0095s000000li0276" role="bibliographyEntry">
            <para>276.<emphasis role="strong">Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, Bénéjat L, Lehours P, Goossens H, Glupczynski Y, European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group.</emphasis> 2021. <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. <citetitle><emphasis>Gut</emphasis></citetitle> <emphasis role="strong">70:</emphasis>1815–1822.</para>
          </listitem>
          <listitem id="ch0095s000000li0277" role="bibliographyEntry">
            <para>277.<emphasis role="strong">Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E.</emphasis> 2018. Prevalence of antibiotic resistance in <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle>: a systematic review and meta-analysis in World Health Organization regions. <citetitle><emphasis>Gastroenterology</emphasis></citetitle> <emphasis role="strong">155:</emphasis>1372–1382.e17.</para>
          </listitem>
          <listitem id="ch0095s000000li0278" role="bibliographyEntry">
            <para>278.<emphasis role="strong">Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y, Study Group Participants.</emphasis> 2013. <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> resistance to antibiotics in Europe and its relationship to antibiotic consumption. <citetitle><emphasis>Gut</emphasis></citetitle> <emphasis role="strong">62:</emphasis>34–42.</para>
          </listitem>
          <listitem id="ch0095s000000li0279" role="bibliographyEntry">
            <para>279.<emphasis role="strong">McNulty CA, Lasseter G, Shaw I, Nichols T, D’Arcy S, Lawson AJ, Glocker E.</emphasis> 2012. Is <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> antibiotic resistance surveillance needed and how can it be delivered? <citetitle><emphasis>Aliment Pharmacol Ther</emphasis></citetitle> <emphasis role="strong">35:</emphasis>1221–1230.</para>
          </listitem>
          <listitem id="ch0095s000000li0280" role="bibliographyEntry">
            <para>280.<emphasis role="strong">Glupczynski Y, Broutet N, Cantagrel A, Andersen LP, Alarcon T, López-Brea M, Mégraud F.</emphasis> 2002. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of <citetitle><emphasis>Helicobacter pylor</emphasis></citetitle>i. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>549–552.</para>
          </listitem>
          <listitem id="ch0095s000000li0281" role="bibliographyEntry">
            <para>281.<emphasis role="strong">Grignon B, Tankovic J, Mégraud F, Glupczynski Y, Husson MO, Conroy MC, Emond JP, Loulergue J, Raymond J, Fauchère JL.</emphasis> 2002. Validation of diffusion methods for macrolide susceptibility testing of <citetitle><emphasis>Helicobacter pylori. Microb Drug Resis</emphasis></citetitle><citetitle><emphasis>t</emphasis></citetitle> <emphasis role="strong">8:</emphasis>61–66.</para>
          </listitem>
          <listitem id="ch0095s000000li0282" role="bibliographyEntry">
            <para>282.<emphasis role="strong">Piccolomini R, Di Bonaventura G, Catamo G, Carbone F, Neri M.</emphasis> 1997. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> strains to 20 antimicrobial agents. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>1842–1846.</para>
          </listitem>
          <listitem id="ch0095s000000li0283" role="bibliographyEntry">
            <para>283.<emphasis role="strong">Best LM, Haldane DJ, Keelan M, Taylor DE, Thomson AB, Loo V, Fallone CA, Lyn P, Smaill FM, Hunt R, Gaudreau C, Kennedy J, Alfa M, Pelletier R, Veldhuyzen Van Zanten SJ.</emphasis> 2003. Multilaboratory comparison of proficiencies in susceptibility testing of <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> and correlation between agar dilution and E test methods. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3138–3144.</para>
          </listitem>
          <listitem id="ch0095s000000li0284" role="bibliographyEntry">
            <anchor id="ch0095s000000a0120"/>
            <para>284.<emphasis role="strong">Chida-Sakata N, Baba M, Inagawa H, Wada A, Tanaka T, Hoshihara Y, Takemoto T.</emphasis> 1999. Significance of anaerobic preincubation of <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> for measuring metronidazole susceptibility by the Etest. <citetitle><emphasis>Microbiol Immunol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>397–401.</para>
          </listitem>
          <listitem id="ch0095s000000li0285" role="bibliographyEntry">
            <para>285.<emphasis role="strong">Shakir SM, Otiso J, Keller G, Heule HV, Osborn LJ, Cole N, Schuetz AN, Richter SS, Couturier MR.</emphasis> 2022. Multicenter evaluation of a gradient diffusion method for antimicrobial susceptibility testing of <citetitle><emphasis>Helicobacter pylori. Microbiol Spectr</emphasis></citetitle> <emphasis role="strong">10</emphasis><emphasis role="strong">:</emphasis>e0211121.</para>
          </listitem>
          <listitem id="ch0095s000000li0286" role="bibliographyEntry">
            <para>286.<emphasis role="strong">Lauener FN, Imkamp F, Lehours P, Buissonnière A, Benejat L, Zbinden R, Keller PM, Wagner K.</emphasis> 2019. Genetic determinants and prediction of antibiotic resistance phenotypes in <citetitle><emphasis>Helicobacter pylori. J Clin Med</emphasis></citetitle> <emphasis role="strong">8:</emphasis>53.</para>
          </listitem>
          <listitem id="ch0095s000000li0287" role="bibliographyEntry">
            <para>287.<emphasis role="strong">Owen RJ.</emphasis> 2002. Molecular testing for antibiotic resistance in <citetitle><emphasis>Helicobacter pylor</emphasis></citetitle>i. <citetitle><emphasis>Gut</emphasis></citetitle> <emphasis role="strong">50:</emphasis>285–289.</para>
          </listitem>
          <listitem id="ch0095s000000li0288" role="bibliographyEntry">
            <para>288.<emphasis role="strong">Kim SY, Park JM, Lim CH, Lee HA, Shin GY, Choe Y, Cho YK, Choi MG.</emphasis> 2021. Types of 23S ribosomal RNA point mutations and therapeutic outcomes for <citetitle><emphasis>Helicobacter pylori. Gut Liver</emphasis></citetitle> <emphasis role="strong">15:</emphasis>528–536.</para>
          </listitem>
          <listitem id="ch0095s000000li0289" role="bibliographyEntry">
            <para>289.<emphasis role="strong">Argueta EA, Alsamman MA, Moss SF, D’Agata EMC.</emphasis> 2021. Impact of antimicrobial resistance rates on eradication of <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> in a US population. <citetitle><emphasis>Gastroenterology</emphasis></citetitle> <emphasis role="strong">160:</emphasis>2181–2183.e1.</para>
          </listitem>
          <listitem id="ch0095s000000li0290" role="bibliographyEntry">
            <para>290.<emphasis role="strong">Kim JJ, Kim JG, Kwon DH.</emphasis> 2003. Mixed-infection of antibiotic susceptible and resistant <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> isolates in a single patient and underestimation of antimicrobial susceptibility testing. <citetitle><emphasis>Helicobacter</emphasis></citetitle> <emphasis role="strong">8:</emphasis>202–206.</para>
          </listitem>
          <listitem id="ch0095s000000li0291" role="bibliographyEntry">
            <para>291.<emphasis role="strong">Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY.</emphasis> 2001. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant <citetitle><emphasis>Helicobacter pylori. Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">17:</emphasis>39–44.</para>
          </listitem>
          <listitem id="ch0095s000000li0292" role="bibliographyEntry">
            <para>292.<emphasis role="strong">El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, Crowe SE, Elfant A, Haas T, Hapke RJ, Graham DY.</emphasis> 2018. Houston Consensus Conference on Testing for <citetitle><emphasis>Helicobacter pylori</emphasis></citetitle> Infection in the United States. <citetitle><emphasis>Clin Gastroenterol Hepatol</emphasis></citetitle> <emphasis role="strong">16:</emphasis>992-1002 e1006.</para>
          </listitem>
          <listitem id="ch0095s000000li0293" role="bibliographyEntry">
            <para>293.<emphasis role="strong">Cannon JP, Lee TA, Bolanos JT, Danziger LH.</emphasis> 2005. Pathogenic relevance of <citetitle><emphasis>Lactobacillus</emphasis></citetitle>: a retrospective review of over 200 cases. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>31–40.</para>
          </listitem>
          <listitem id="ch0095s000000li0294" role="bibliographyEntry">
            <para>294.<emphasis role="strong">Delgado S, Flórez AB, Mayo B.</emphasis> 2005. Antibiotic susceptibility of <citetitle><emphasis>Lactobacillus</emphasis></citetitle> and <citetitle><emphasis>Bifidobacterium</emphasis></citetitle> species from the human gastrointestinal tract. <citetitle><emphasis>Curr Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>202–207.</para>
          </listitem>
          <listitem id="ch0095s000000li0295" role="bibliographyEntry">
            <para>295.<emphasis role="strong">Klare I, Konstabel C, Werner G, Huys G, Vankerckhoven V, Kahlmeter G, Hildebrandt B, Müller-Bertling S, Witte W, Goossens H.</emphasis> 2007. Antimicrobial susceptibilities of <citetitle><emphasis>Lactobacillus, Pediococcus</emphasis></citetitle> and <citetitle><emphasis>Lactococcus</emphasis></citetitle> human isolates and cultures intended for probiotic or nutritional use. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">59:</emphasis>900–912.</para>
          </listitem>
          <listitem id="ch0095s000000li0296" role="bibliographyEntry">
            <para>296.<emphasis role="strong">Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, Järvinen A.</emphasis> 2006. <citetitle><emphasis>Lactobacillus</emphasis></citetitle> bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">42:</emphasis>e35–e44.</para>
          </listitem>
          <listitem id="ch0095s000000li0297" role="bibliographyEntry">
            <para>297.<emphasis role="strong">Goldstein EJ, Tyrrell KL, Citron DM.</emphasis> 2015. <citetitle><emphasis>Lactobacillus</emphasis></citetitle> species: taxonomic complexity and controversial susceptibilities. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">60</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>S98–S107.</para>
          </listitem>
          <listitem id="ch0095s000000li0298" role="bibliographyEntry">
            <para>298.<emphasis role="strong">Vay C, Cittadini R, Barberis C, Hernán Rodríguez C, Perez Martínez H, Genero F, Famiglietti A.</emphasis> 2007. Antimicrobial susceptibility of non-enterococcal intrinsic glycopeptide-resistant Gram-positive organisms. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">57:</emphasis>183–188.</para>
          </listitem>
          <listitem id="ch0095s000000li0299" role="bibliographyEntry">
            <para>299.<emphasis role="strong">Swenson JM, Facklam RR, Thornsberry C.</emphasis> 1990. Antimicrobial susceptibility of vancomycin-resistant <citetitle><emphasis>Leuconostoc, Pediococcus</emphasis></citetitle>, and <citetitle><emphasis>Lactobacillus</emphasis></citetitle> species. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">34:</emphasis>543–549.</para>
          </listitem>
          <listitem id="ch0095s000000li0300" role="bibliographyEntry">
            <para>300.<emphasis role="strong">Svec P, Sevcíková A, Sedlácek I, Bednárová J, Snauwaert C, Lefebvre K, Vandamme P, Vancanneyt M.</emphasis> 2007. Identification of lactic acid bacteria isolated from human blood cultures. <citetitle><emphasis>FEMS Immunol Med Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>192–196.</para>
          </listitem>
          <listitem id="ch0095s000000li0301" role="bibliographyEntry">
            <para>301.<emphasis role="strong">Rolston KV, Kapadia M, Tarrand J, Coyle E, Prince RA.</emphasis> 2013. Spectrum of gram-positive bacteraemia and in vitro activities of daptomycin, linezolid and vancomycin against organisms isolated from cancer patients. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">41:</emphasis>516–520.</para>
          </listitem>
          <listitem id="ch0095s000000li0302" role="bibliographyEntry">
            <para>302.<emphasis role="strong">Danielsen M, Simpson PJ, O’Connor EB, Ross RP, Stanton C.</emphasis> 2007. Susceptibility of <citetitle><emphasis>Pediococcus</emphasis></citetitle> spp. to antimicrobial agents. <citetitle><emphasis>J Appl Microbiol</emphasis></citetitle> <emphasis role="strong">102:</emphasis>384–389.</para>
          </listitem>
          <listitem id="ch0095s000000li0303" role="bibliographyEntry">
            <para>303.<emphasis role="strong">Morvan A, Moubareck C, Leclercq A, Hervé-Bazin M, Bremont S, Lecuit M, Courvalin P, Le Monnier A.</emphasis> 2010. Antimicrobial resistance of <citetitle><emphasis>Listeria monocytogenes</emphasis></citetitle> strains isolated from humans in France. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2728–2731.</para>
          </listitem>
          <listitem id="ch0095s000000li0304" role="bibliographyEntry">
            <para>304.<emphasis role="strong">Huang YT, Liao CH, Teng LJ, Hsueh PR.</emphasis> 2007. Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1570–1572.</para>
          </listitem>
          <listitem id="ch0095s000000li0305" role="bibliographyEntry">
            <para>305.<emphasis role="strong">Yan S, Li M, Luque-Sastre L, Wang W, Hu Y, Peng Z, Dong Y, Gan X, Nguyen S, Anes J, Bai Y, Xu J, Fanning S, Li F.</emphasis> 2019. Susceptibility (re)-testing of a large collection of <citetitle><emphasis>Listeria monocytogenes</emphasis></citetitle> from foods in China from 2012 to 2015 and WGS characterization of resistant isolates. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">74:</emphasis>1786–1794.</para>
          </listitem>
          <listitem id="ch0095s000000li0306" role="bibliographyEntry">
            <para>306.<emphasis role="strong">Lungu B, O’Bryan CA, Muthaiyan A, Milillo SR, Johnson MG, Crandall PG, Ricke SC.</emphasis> 2011. <citetitle><emphasis>Listeria monocytogenes</emphasis></citetitle>: antibiotic resistance in food production. <citetitle><emphasis>Foodborne Pathog Dis</emphasis></citetitle> <emphasis role="strong">8:</emphasis>569–578.</para>
          </listitem>
          <listitem id="ch0095s000000li0307" role="bibliographyEntry">
            <para>307.<emphasis role="strong">Rakic-Martinez M, Drevets DA, Dutta V, Katic V, Kathariou S.</emphasis> 2011. <citetitle><emphasis>Listeria monocytogenes</emphasis></citetitle> strains selected on ciprofloxacin or the disinfectant benzalkonium chloride exhibit reduced susceptibility to ciprofloxacin, gentamicin, benzalkonium chloride, and other toxic compounds. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">77:</emphasis>8714–8721.</para>
          </listitem>
          <listitem id="ch0095s000000li0308" role="bibliographyEntry">
            <para>308.<emphasis role="strong">Kremer PH, Lees JA, Koopmans MM, Ferwerda B, Arends AW, Feller MM, Schipper K, Valls Seron M, van der Ende A, Brouwer MC, van de Beek D, Bentley SD.</emphasis> 2017. Benzalkonium tolerance genes and outcome in <citetitle><emphasis>Listeria monocytogenes meningitis. Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">23:</emphasis>265.e1–265.e7.</para>
          </listitem>
          <listitem id="ch0095s000000li0309" role="bibliographyEntry">
            <para>309.<emphasis role="strong">Davis JA, Jackson CR.</emphasis> 2009. Comparative antimicrobial susceptibility of <citetitle><emphasis>Listeria monocytogenes</emphasis></citetitle>, L. innocua, and L. welshimeri. <citetitle><emphasis>Microb Drug Resist</emphasis></citetitle> <emphasis role="strong">15:</emphasis>27–32.</para>
          </listitem>
          <listitem id="ch0095s000000li0310" role="bibliographyEntry">
            <para>310.<emphasis role="strong">von Eiff C, Herrmann M, Peters G.</emphasis> 1995. Antimicrobial susceptibilities of <citetitle><emphasis>Stomatococcus mucilaginosus</emphasis></citetitle> and of <citetitle><emphasis>Micrococcus</emphasis></citetitle> spp. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">39:</emphasis>268–270.</para>
          </listitem>
          <listitem id="ch0095s000000li0311" role="bibliographyEntry">
            <para>311.<emphasis role="strong">von Eiff C, Peters G.</emphasis> 1998. In vitro activity of ciprofloxacin, ofloxacin, and levofloxacin against <citetitle><emphasis>Micrococcus</emphasis></citetitle> species and <citetitle><emphasis>Stomatococcus mucilaginosus</emphasis></citetitle> isolated from healthy subjects and neutropenic patients. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>890–892.</para>
          </listitem>
          <listitem id="ch0095s000000li0312" role="bibliographyEntry">
            <para>312.<emphasis role="strong">Hsu SF, Lin YT, Chen TL, Siu LK, Hsueh PR, Huang ST, Fung CP.</emphasis> 2012. Antimicrobial resistance of <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> isolates in Taiwan. <citetitle><emphasis>J Microbiol Immunol Infect</emphasis></citetitle> <emphasis role="strong">45:</emphasis>134–140.</para>
          </listitem>
          <listitem id="ch0095s000000li0313" role="bibliographyEntry">
            <para>313.<emphasis role="strong">Khan MA, Northwood JB, Levy F, Verhaegh SJ, Farrell DJ, Van Belkum A, Hays JP.</emphasis> 2010. <citetitle><emphasis>bro</emphasis></citetitle> β-lactamase and antibiotic resistances in a global cross-sectional study of <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> from children and adults. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">65:</emphasis>91–97.</para>
          </listitem>
          <listitem id="ch0095s000000li0314" role="bibliographyEntry">
            <para>314.<emphasis role="strong">Yamada K, Arai K, Saito R.</emphasis> 2017. Antimicrobial susceptibility to β-lactam antibiotics and production of BRO β-lactamase in clinical isolates of <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> from a Japanese hospital. <citetitle><emphasis>J Microbiol Immunol Infect</emphasis></citetitle> <emphasis role="strong">50:</emphasis>386–389.</para>
          </listitem>
          <listitem id="ch0095s000000li0315" role="bibliographyEntry">
            <para>315.<emphasis role="strong">Shi W, Wen D, Chen C, Yuan L, Gao W, Tang P, Cheng X, Yao K.</emphasis> 2018. β-Lactamase production and antibiotic susceptibility pattern of <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> isolates collected from two county hospitals in China. <citetitle><emphasis>BMC Microbiol</emphasis></citetitle> <emphasis role="strong">18:</emphasis>77.</para>
          </listitem>
          <listitem id="ch0095s000000li0316" role="bibliographyEntry">
            <para>316.<emphasis role="strong">Flamm RK, Sader HS, Farrell DJ, Jones RN.</emphasis> 2012. Macrolide and tetracycline resistance among <citetitle><emphasis>Moraxella catarrhalis</emphasis></citetitle> isolates from 2009 to 2011. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">74:</emphasis>198–200.</para>
          </listitem>
          <listitem id="ch0095s000000li0317" role="bibliographyEntry">
            <para>317.<emphasis role="strong">Sutton LD, Biedenbach DJ, Yen A, Jones RN.</emphasis> 1995. Development, characterization, and initial evaluations of S1. A new chromogenic cephalosporin for beta-lactamase detection. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>1–8.</para>
          </listitem>
          <listitem id="ch0095s000000li0318" role="bibliographyEntry">
            <anchor id="ch0095s000000a0121"/>
            <para>318.<emphasis role="strong">Citron DM, Warren YA, Fernandez HT, Goldstein MA, Tyrrell KL, Goldstein EJ.</emphasis> 2005. Broth microdilution and disk diffusion tests for susceptibility testing of <citetitle><emphasis>Pasteurella</emphasis></citetitle> species isolated from human clinical specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2485–2488.</para>
          </listitem>
          <listitem id="ch0095s000000li0319" role="bibliographyEntry">
            <para>319.<emphasis role="strong">Mortensen JE, Giger O, Rodgers GL.</emphasis> 1998. In vitro activity of oral antimicrobial agents against clinical isolates of <citetitle><emphasis>Pasteurella multocida. Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">30:</emphasis>99–102.</para>
          </listitem>
          <listitem id="ch0095s000000li0320" role="bibliographyEntry">
            <para>320.<emphasis role="strong">Naas T, Benaoudia F, Lebrun L, Nordmann P.</emphasis> 2001. Molecular identification of TEM-1 beta-lactamase in a <citetitle><emphasis>Pasteurella multocida</emphasis></citetitle> isolate of human origin. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>210–213.</para>
          </listitem>
          <listitem id="ch0095s000000li0321" role="bibliographyEntry">
            <para>321.<emphasis role="strong">Goldstein EJ, Citron DM, Merriam CV, Tyrrell KL.</emphasis> 2012. Ceftaroline versus isolates from animal bite wounds: comparative in vitro activities against 243 isolates, including 156 <citetitle><emphasis>Pasteurella</emphasis></citetitle> species isolates. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>6319–6323.</para>
          </listitem>
          <listitem id="ch0095s000000li0322" role="bibliographyEntry">
            <para>322.<emphasis role="strong">Levin JM, Talan DA.</emphasis> 1990. Erythromycin failure with subsequent <citetitle><emphasis>Pasteurella multocida</emphasis></citetitle> meningitis and septic arthritis in a cat-bite victim. <citetitle><emphasis>Ann Emerg Med</emphasis></citetitle> <emphasis role="strong">19:</emphasis>1458–1461.</para>
          </listitem>
          <listitem id="ch0095s000000li0323" role="bibliographyEntry">
            <para>323.<emphasis role="strong">Ramanan P, Barreto JN, Osmon DR, Tosh PK.</emphasis> 2014. <citetitle><emphasis>Rothia</emphasis></citetitle> bacteremia: a 10-year experience at Mayo Clinic, Rochester, Minnesota. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>3184–3189.</para>
          </listitem>
          <listitem id="ch0095s000000li0324" role="bibliographyEntry">
            <para>324.<emphasis role="strong">Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA.</emphasis> 2007. Growing problem of multidrug-resistant enteric pathogens in Africa. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">13:</emphasis>1640–1646.</para>
          </listitem>
          <listitem id="ch0095s000000li0325" role="bibliographyEntry">
            <para>325.<emphasis role="strong">Das B, Verma J, Kumar P, Ghosh A, Ramamurthy T.</emphasis> 2020. Antibiotic resistance in <citetitle><emphasis>Vibrio cholerae</emphasis></citetitle>: understanding the ecology of resistance genes and mechanisms. <citetitle><emphasis>Vaccine</emphasis></citetitle> <emphasis role="strong">38</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>A83–A92.</para>
          </listitem>
          <listitem id="ch0095s000000li0326" role="bibliographyEntry">
            <para>326.<emphasis role="strong">Pan JC, Ye R, Wang HQ, Xiang HQ, Zhang W, Yu XF, Meng DM, He ZS.</emphasis> 2008. <citetitle><emphasis>Vibrio cholerae</emphasis></citetitle> O139 multiple-drug resistance mediated by <citetitle><emphasis>Yersinia pestis</emphasis></citetitle> pIP1202-like conjugative plasmids. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">52:</emphasis>3829–3836.</para>
          </listitem>
          <listitem id="ch0095s000000li0327" role="bibliographyEntry">
            <para>327.<emphasis role="strong">Igbinosa EO, Okoh AI.</emphasis> 2008. Emerging <citetitle><emphasis>Vibrio</emphasis></citetitle> species: an unending threat to public health in developing countries. <citetitle><emphasis>Res Microbiol</emphasis></citetitle> <emphasis role="strong">159:</emphasis>495–506.</para>
          </listitem>
          <listitem id="ch0095s000000li0328" role="bibliographyEntry">
            <para>328.<emphasis role="strong">Wang R, Lou J, Liu J, Zhang L, Li J, Kan B.</emphasis> 2012. Antibiotic resistance of <citetitle><emphasis>Vibrio cholerae</emphasis></citetitle> O1 El Tor strains from the seventh pandemic in China, 1961-2010. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">40:</emphasis>361–364.</para>
          </listitem>
          <listitem id="ch0095s000000li0329" role="bibliographyEntry">
            <para>329.<emphasis role="strong">Yu L, Zhou Y, Wang R, Lou J, Zhang L, Li J, Bi Z, Kan B.</emphasis> 2012. Multiple antibiotic resistance of <citetitle><emphasis>Vibrio cholerae</emphasis></citetitle> serogroup O139 in China from 1993 to 2009. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e38633.</para>
          </listitem>
          <listitem id="ch0095s000000li0330" role="bibliographyEntry">
            <para>330.<emphasis role="strong">Mandal J, Sangeetha V, Ganesan V, Parveen M, Preethi V, Harish BN, Srinivasan S, Parija SC.</emphasis> 2012. Third-generation cephalosporin-resistant <citetitle><emphasis>Vibrio cholerae</emphasis></citetitle>, India. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">18:</emphasis>1326–1328.</para>
          </listitem>
          <listitem id="ch0095s000000li0331" role="bibliographyEntry">
            <para>331.<emphasis role="strong">Saha D, Karim MM, Khan WA, Ahmed S, Salam MA, Bennish ML.</emphasis> 2006. Single-dose azithromycin for the treatment of cholera in adults. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">354:</emphasis>2452–2462.</para>
          </listitem>
          <listitem id="ch0095s000000li0332" role="bibliographyEntry">
            <para>332.<emphasis role="strong">Sjölund-Karlsson M, Reimer A, Folster JP, Walker M, Dahourou GA, Batra DG, Martin I, Joyce K, Parsons MB, Boncy J, Whichard JM, Gilmour MW.</emphasis> 2011. Drug-resistance mechanisms in <citetitle><emphasis>Vibrio cholerae</emphasis></citetitle> O1 outbreak strain, Haiti, 2010. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>2151–2154.</para>
          </listitem>
        </itemizedlist>
        <para id="ch0095s000000p0171"><emphasis role="strong"><phrase role="figureLabel"><link linkend="ch0095s000000a0002">TABLE 1</link></phrase></emphasis> CLSI and EUCAST disk diffusion and MIC testing conditions and recommended QC strains for more common fastidious bacteria</para>
      </sect2>
    </sect1>
  </chapter>
